US20160257974A1

US20160257974A1 - Methods, Cells & Organisms

Info

Publication number: US20160257974A1
Application number: US15/072,978
Authority: US
Inventors: Allan Bradley; Hanif Ali; E-Chiang Lee
Original assignee: Kymab Ltd
Current assignee: Kymab Ltd
Priority date: 2013-09-18
Filing date: 2016-03-17
Publication date: 2016-09-08
Also published as: EP3418379B1; US20170275611A1; US20160177340A1; US11920128B2; EP3842528A1; EP3418379A2; TW201542816A; EP3988649A1; EP3418379A3; ES2844174T3; US20150079680A1; US20160207983A1; DE202014010413U1; CN105637087A; EP2877571A1; ES2681622T3; EP2877571B1; US20160257948A1; WO2015040402A1; US20190338274A1

Abstract

The invention relates to an approach for introducing one or more desired insertions and/or deletions of known sizes into one or more predefined locations in a nucleic acid (e.g., in a cell or organism genome). They developed techniques to do this either in a sequential fashion or by inserting a discrete DNA fragment of defined size into the genome precisely in a predefined location or carrying out a discrete deletion of a defined size at a precise location. The technique is based on the observation that DNA single-stranded breaks are preferentially repaired through the HDR pathway, and this reduces the chances of indels (e.g., produced by NHEJ) in the present invention and thus is more efficient than prior art techniques. The invention also provides sequential insertion and/or deletions using single- or double-stranded DNA cutting.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application under 35 U.S.C. §120 of co-pending International Application No. PCT/GB2014/052837 filed Sep. 18, 2014, which designated the U.S., and which claims benefit of GB Application No. 1316560.0 filed Sep. 18, 2013, and claims benefit of GB Application No. 1321210.5 filed Dec. 2, 2013 the contents of each of which are incorporated herein by reference in their entireties.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 15, 2016, is named K00016-1-Sequence-Listing-069496-086064.txt and is 1,444,445 bytes in size.
The inventors have devised an approach for introducing one or more desired insertions and/or deletions of known sizes into one or more predefined locations in a nucleic acid (e.g., in a cell or organism genome). They developed techniques to do this either in a sequential fashion or by inserting a discrete DNA fragment of defined size into the genome precisely in a predefined location or carrying out a discrete deletion of a defined size at a precise location. The technique is based on the observation that DNA single-stranded breaks are preferentially repaired through the HDR pathway, and this reduces the chances of indels (e.g., produced by NHEJ) in the present invention and thus is more efficient than prior art techniques.
The inventors have also devised new techniques termed sequential endonuclease-mediated homology directed recombination (sEHDR) and sequential Cas-mediated homology directed recombination (sCHDR).

BACKGROUND

Certain bacterial and archaea strains have been shown to contain highly evolved adaptive immune defence systems, CRISPR/Cas systems, which continually undergo reprogramming to direct degradation of complementary sequences present within invading viral or plasmid DNA. Short segments of foreign DNA, called spacers, are incorporated into the genome between CRISPR repeats, and serve as a ‘memory’ of past exposures. CRISPR spacers are then used to recognize and silence exogenous genetic elements in a manner analogous to RNAi in eukaryotic organisms.
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system including the CRISPR associated (Cas) protein has been reconstituted in vitro by a number of research groups allowing for the DNA cleavage of almost any DNA template without the caveat of searching for the right restriction enzyme cutter. The CRISPR/Cas system also offers a blunt end cleavage creating a dsDNA or, using mutated Cas versions, a selective single strand-specific cleavage (see Cong et al., Wang et al. & Mali et al. cited below).
Through in vitro studies using Streptococcus pyogenes type II CRISPR/Cas system it has been shown that the only components required for efficient CRISPR/Cas-mediated target DNA or genome modification are a Cas nuclease (e.g., a Cas9 nuclease), CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA). The wild-type mechanism of CRISPR/Cas-mediated DNA cleavage occurs via several steps. Transcription of the CRISPR array, containing small fragments (20-30 base-pairs) of the encountered (or target) DNA, into pre-crRNA, which undergoes maturation through the hybridisation with tracrRNA via direct repeats of pre-crRNA. The hybridisation of the pre-crRNA and tracrRNA, known as guide RNA (gRNA or sgRNA), associates with the Cas nuclease forming a ribonucleoprotein complex, which mediates conversion of pre-crRNA into mature crRNA. Mature crRNA:tracrRNA duplex directs Cas9 to the DNA target consisting of the protospacer and the requisite protospacer adjacent motif (CRISPR/cas protospacer-adjacent motif; PAM) via heteroduplex formation between the spacer region of the crRNA and the protospacer DNA on the host genome. The Cas9 nuclease mediates cleavage of the target DNA upstream of PAM to create a double-stranded break within the protospacer or a strand-specific nick using mutated Cas9 nuclease whereby one DNA strand-specific cleavage motif is mutated (for example, Cas9 nickase contains a D10A substitution) (Cong et al.).
It is worth noting that different strains of Streptococcus have been isolated which use PAM sequences that are different from that used by Streptococcus pyogenes Cas9. The latter requires a NGG PAM sequence. CRISPR/Cas systems (for example, the Csy4 endoribonulcease in Pseudomonas aerognosa (see Shah et al.) have been described in other prokaryotic species, which recognise a different PAM sequence (e.g., CCN, TCN, TTC, AWG, CC, NNAGNN, NGG, NGGNG). It is noteworthy that the Csy4 (also known as Cas6f) has no sequence homology to Cas9 but the DNA cleavage occurs through a similar mechanism involving the assembly of a Cas-protein-crRNA complex that facilitates target DNA recognition leading to specific DNA cleavage (Haurwitz et al.).
In vitro-reconstituted type II CRISPR/Cas system has been adapted and applied in a number of different settings. These include creating selective gene disruption in single or multiple genes in ES cells and also single or multiple gene disruption using a one-step approach using zygotes to generate biallelic mutations in mice. The speed, accuracy and the efficiency at which this system could be applied to genome editing in addition to its multiplexing capability makes this system vastly superior to its predecessor genome editing technologies namely zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and engineered homing meganucleases (Gaj et al. & Perez-Pinera et al.). These have been successfully used in various eukaryotic hosts but they all suffer from important limitations; notably off-target mutagenesis leading to nuclease-related toxicity, and also the time and cost of developing such engineered proteins. The CRISPR/Cas system on the other hand is a superior genome editing system by which mutations can be introduced with relative ease, simply by designing a single guided RNA complementary to the protospacer sequence on the target DNA.
The dsDNA break induced by an endonuclease, such as Cas9, is subsequently repaired through non-homologous end joining mechanism (NHEJ), whereby the subsequent DNA repair at the breakpoint junction is stitched together with different and unpredictable inserted or deletions (indels) of varying size. This is highly undesirable when precise nucleic acid or genome editing is required. However a predefined precise mutation can be generated using homology directed repair (HDR), e.g., with the inclusion of a donor oligo or donor DNA fragment. This approach with Cas9 nuclease has been shown to generate precise predefined mutations but the efficiency at which this occurs in both alleles is low and mutation is seen in one of the strands of the dsDNA target (Wang et al.).
The CRISPR/Cas system does therefore have some limitations in its current form. While it may be possible to modify a desired sequence in one strand of dsDNA, the sequence in the other strand is often mutated through undesirable NHEJ.

SUMMARY OF THE INVENTION

A First Configuration of the Present Invention Provides:—

A method of nucleic acid recombination, the method comprising providing dsDNA comprising first and second strands and

- (a) using nucleic acid cleavage to create 5′ and 3′ cut ends in the first strand;
- (b) using homologous recombination to insert a nucleotide sequence between the ends, thereby producing a modified first strand; thereby producing DNA wherein the first strand has been modified by said recombination but the second strand has not been modified; and
- (c) optionally replicating the modified first strand to produce a progeny dsDNA wherein each strand thereof comprises a copy of the inserted nucleotide sequence; and isolating the progeny dsDNA.

A Second Configuration of the Present Invention Provides:—

A method of nucleic acid recombination, the method comprising

- (a) using nucleic acid cleavage to create 5′ and 3′ cut ends in a single nucleic acid strand;
- (b) using homologous recombination to insert a nucleotide sequence between the ends, wherein the insert sequence comprises a regulatory element or encodes all or part of a protein; and
- (c) optionally obtaining the nucleic acid strand modified in step (b) or a progeny nucleic strand comprising the inserted nucleotide sequence.

A Third Configuration of the Present Invention Provides:—

A method of nucleic acid recombination, the method comprising

- (a) using nucleic acid cleavage to create first and second breaks in a nucleic acid strand, thereby creating 5′ and 3′ cut ends and a nucleotide sequence between the ends;
- (b) using homologous recombination to delete the nucleotide sequence; and
- (c) optionally obtaining the nucleic acid strand modified in step (b) or a progeny nucleic strand comprising the deletion.

A Fourth Configuration of the Present Invention Provides:—

- (a) using Cas endonuclease-mediated nucleic acid cleavage to create a cut end in the first strand 3′ of a PAM motif;
- (b) using Cas endonuclease-mediated nucleic acid cleavage to create a cut in the second strand at a position which corresponds to a position 3′ of the cut end of the strand of part (a), which cut is 3′ of the PAM motif;
- (c) providing a first gRNA which hybridises with a sequence 5′ to the PAM motif in the strand of part (a)
- (d) providing a second gRNA which hybridises with a sequence 5′ to the PAM motif in the strand of part (b)

wherein the nucleic acid strands of part (a) and part (b) are repaired to produce a deletion of nucleic acid between the cuts.
In aspects of the configurations of the invention there is provided a method of sequential endonuclease-mediated homology directed recombination (sEHDR) comprising carrying out the method of any preceding configuration a first time and carrying out the method of any preceding configuration a second time. In this way, the invention enables serial nucleic acid modifications, e.g., genome modifications, to be carried out, which may comprise precise sequence deletions, insertions or combinations of these two or more times. For example, it is possible to use this aspect of the invention to “walk along” nucleic acids (e.g., chromosomes in cells) to make relatively large and precise nucleotide sequence deletions or insertions. In an embodiment, one or more Cas endonucleases (e.g., a Cas9 and/or Cys4) is used in a method of sequential Cas-mediated homology directed recombination (sCHDR).
In another aspect, the invention can be described according to the numbered sentences below:
1. A method of nucleic acid recombination, the method comprising providing dsDNA comprising first and second strands and
(a) using nucleic acid cleavage to create 5′ and 3′ cut ends in the first strand;
(b) using homologous recombination to insert a nucleotide sequence between the ends, thereby producing a modified first strand; thereby producing DNA wherein the first strand has been modified by said recombination but the second strand has not been modified; and
(c) optionally replicating the modified first strand to produce a progeny dsDNA wherein each strand thereof comprises a copy of the inserted nucleotide sequence; and isolating the progeny dsDNA.
2. A method of nucleic acid recombination, the method comprising
(a) using nucleic acid cleavage to create 5′ and 3′ cut ends in a single nucleic acid strand;
(b) using homologous recombination to insert a nucleotide sequence between the ends, wherein the insert sequence comprises a regulatory element or encodes all or part of a protein; and
(c) optionally obtaining the nucleic acid strand modified in step (b) or a progeny nucleic strand comprising the inserted nucleotide sequence.
3. The method of any preceding sentence, wherein the insert sequence replaces an orthologous or homologous sequence of the strand.
4. The method of any preceding sentence, wherein the insert nucleotide sequence is at least 10 nucleotides long.
5. The method of any preceding sentence, wherein the insert sequence comprises a site specific recombination site.
6. A method of nucleic acid recombination, the method comprising
(a) using nucleic acid cleavage to create first and second breaks in a nucleic acid strand, thereby creating 5′ and 3′ cut ends and a nucleotide sequence between the ends;
(b) using homologous recombination to delete the nucleotide sequence; and
(c) optionally obtaining the nucleic acid strand modified in step (b) or a progeny nucleic strand comprising the deletion.
7. The method of sentence 6, wherein the deleted sequence comprises a regulatory element or encodes all or part of a protein.
8. The method of any preceding sentence, wherein step (c) is performed by isolating a cell comprising the modified first strand, or by obtaining a non-human vertebrate in which the method has been performed or a progeny thereof.
9. The method of any preceding sentence, wherein the nucleic acid strand or the first strand is a DNA strand.
10. The method of any preceding sentence wherein the product of the method comprises a nucleic acid strand comprising a PAM motif 3′ of the insertion or deletion.
11. The method of any preceding sentence, wherein step (b) is performed by carrying out homologous recombination between an incoming nucleic acid comprising first and second homology arms, wherein the homology arms are substantially homologous respectively to a sequence extending 5′ from the 5′ end and a sequence extending 3′ from the 3′ end.
12. The method of sentence 11, wherein step (b) is performed by carrying out homologous recombination between an incoming nucleic acid comprising an insert nucleotide sequence flanked by the first and second homology arms, wherein the insert nucleotide sequence is inserted between the 5′ and 3′ ends.
13. The method of sentence 12, wherein the insert is as recited in any one of sentences 3 to 5 and there is no further sequence between the homology arms.
14. The method of any one of sentences 11 to 13, wherein each homology arm is at least 20 contiguous nucleotides long.
15. The method of any one of sentences 11 to 14, wherein the first and/or second homology arm comprises a PAM motif.
16. The method of any preceding sentence, wherein Cas endonuclease-mediated cleavage is used in step (a); optionally by recognition of a GG or NGG PAM motif.
17. The method of sentence 16, wherein a nickase is used to cut in step (a).
18. The method of any preceding sentence, wherein the method is carried out in a cell, e.g. a eukaryotic cell.
19. The method of sentence 18, wherein the method is carried out in a mammalian cell.
20. The method of sentence 18, wherein the cell is a rodent (e.g., mouse) ES cell or zygote.
21. The method of any preceding sentence, wherein the method is carried out in a non-human mammal, e.g. a mouse or rat or rabbit.
22. The method of any preceding sentence, wherein each cleavage site is flanked by PAM motif (e.g., a NGG or NGGNG sequence, wherein N is any base and G is a guanine).
23. The method of any preceding sentence, wherein the 3′ end is flanked 3′ by a PAM motif.
24. The method of any preceding sentence, wherein step (a) is carried out by cleavage in one single strand of dsDNA.
25. The method of any preceding sentence, wherein step (a) is carried out by combining in a cell the nucleic acid strand, a Cas endonuclease, a crRNA and a tracrRNA (e.g., provided by one or more gRNAs) for targeting the endonuclease to carry out the cleavage, and optionally an insert sequence for homologous recombination with the nucleic acid strand.
26. The method of any preceding sentence, wherein step (b) is performed by carrying out homologous recombination with an incoming nucleic acid comprising first and second homology arms, wherein the homology arms are substantially homologous respectively to a sequence extending 5′ from the 5′ end and a sequence extending 3′ from the 3′ end, wherein the second homology arm comprises a PAM sequence such that homologous recombination between the second homology arm and the sequence extending 3′ from the 3′ end produces a sequence comprising a PAM motif in the product of the method.
27. A method of sequential endonuclease-mediated homology directed recombination (sEHDR) comprising carrying out the method of any preceding sentence (e.g., when according to sentence 1 using a nickase to cut a single strand of dsDNA; or when dependent from sentence 2 or 5 using a nuclease to cut both strands of dsDNA) a first time and a second time, wherein endonuclease-mediated cleavage is used in each step (a); wherein the product of the first time is used for endonuclease-mediated cleavage the second time, whereby either (i) first and second nucleotide sequences are deleted the first time and the second times respectively; (ii) a first nucleotide sequence is deleted the first time and a second nucleotide sequence is inserted the second time; (iii) a first nucleotide sequence is inserted the first time and a second nucleotide sequence is deleted the second time; or (iv) first and second nucleotide sequences are inserted the first and second times respectively: optionally wherein the nucleic acid strand modification the second time is within 20 or less nucleotides of the nucleic acid strand modification the first time.
28. The method of sentence 27, wherein the first time is carried out according to claim 6, wherein the incoming nucleic acid comprises no sequence between the first and second homology arms, wherein sequence between the 5′ and 3′ ends is deleted by homologous recombination: and/or the second time is carried out according to sentence 6, wherein step (b) is performed by carrying out homologous recombination between an incoming nucleic acid comprising first and second homology arms, wherein the homology arms are substantially homologous respectively to a sequence extending 5′ from the 5′ end and a sequence extending 3′ from the 3′ end, wherein the incoming nucleic acid comprises no sequence between the first and second homology arms such that sequence between the 5′ and 3′ ends is deleted by homologous recombination; optionally wherein the second arm comprises a PAM motif such that the product of the second time comprises a PAM motif for use in a subsequent Cas endonuclease-mediated method according to any one of sentences 1 to 26.
29. The method of sentence 27, wherein the first time is carried out according to sentence 1 or 2, wherein the incoming nucleic acid comprises the insert sequence between the first and second homology arms, wherein the insert sequence is inserted between the 5′ and 3′ ends by homologous recombination; and/or the second time is carried out according to sentence 1 or 2, wherein step (b) is performed by carrying out homologous recombination between an incoming nucleic acid comprising first and second homology arms, wherein the homology arms are substantially homologous respectively to a sequence extending 5′ from the 5′ end and a sequence extending 3′ from the 3′ end, wherein the insert sequence is inserted between the 5′ and 3′ ends by homologous recombination: optionally wherein the second arm comprises a PAM motif such that the product of the second time comprises a PAM motif for use in a subsequent Cas endonuclease-mediated method according to any one of sentences 1 to 26.
30. The method of sentence 27, wherein one of said first and second times is carried out as specified in sentence 28 and the other time is carried out as specified in sentence 29, wherein at least one sequence deletion and at least one sequence insertion is performed.
31. The method of any preceding sentence, wherein step (a) is carried out using Cas endonuclease-mediated cleavage and a gRNA comprising a crRNA and a tracrRNA.
32. The method of sentence 25 or 31, wherein the crRNA has the structure 5′-X-Y-3′, wherein X is an RNA nucleotide sequence (optionally at least 5 nucleotides long) and Y is a crRNA sequence comprising a nucleotide motif that hybridises with a motif comprised by the tracrRNA, wherein X is capable of hybridising with a nucleotide sequence extending 5′ from the desired site of the 5′ cut end.
33. The method of sentence 25, 31 or 32, wherein Y is 5′-N1UUUUAN2N3GCUA-3′ (SEQ ID NO:3), wherein each of N1-3 is a A, U, C or G and/or the tracrRNA comprises the sequence (in 5′ to 3′ orientation) UAGCM1UUAAAAM2 (SEQ ID NO:4), wherein M1 is spacer nucleotide sequence and M2 is a nucleotide.
34. A method of producing a cell or a transgenic non-human organism, the method comprising

- (a) carrying out the method of any preceding claim to (i) knock out a target nucleotide sequence in the genome of a first cell and/or (ii) knock in an insert nucleotide sequence into the genome of a first cell, optionally wherein the insert sequence replaces a target sequence in whole or in part at the endogenous location of the target sequence in the genome; wherein the cell or a progeny thereof can develop into a non-human organism or cell; and
- (b) developing the cell or progeny into a non-human organism or a non-human cell.

35. The method of sentence 34, wherein the organism or cell is homozygous for the modification (i) and/or (ii).
36. The method of sentence 34 or 35, wherein the cell is an ES cell, iPS cell, totipotent cell or pluripotent cell.
37. The method of any one of sentences 34 to 36, wherein the cell is a rodent (e.g., a mouse or rat) cell.
38. The method of any one of sentences 34 to 37, wherein the target sequence is an endogenous sequence comprising all or part of a regulatory element or encoding all or part of a protein.
39. The method of any one of sentences 34 to 38, wherein the insert sequence is a synthetic sequence; or comprises a sequence encoding all or part of a protein from a species other than the species from which the first cell is derived; or comprises a regulatory element from said first species.
40. The method of sentence 39, wherein the insert sequence encodes all or part of a human protein or a human protein subunit or domain.
41. A cell or a non-human organism whose genome comprises a modification comprising a non-endogenous nucleotide sequence flanked by endogenous nucleotide sequences, wherein the cell or organism is obtainable by the method of any one of sentences 24 to 40 and wherein the non-endogenous sequence is flanked 3′ by a Cas PAM motif; wherein the cell is not comprised by a human; and one, more or all of (a) to (d) applies

- (a) the genome is homozygous for the modification; or comprises the modification at one allele and is unmodified by Cas-mediated homologous recombination at the other allele;
- (b) the non-endogenous sequence comprises all or part of a regulatory element or encodes all or part of a protein;
- (c) the non-endogenous sequence is at least 20 nucleotides long;
- (d) the non-endogenous sequence replaces an orthologous or homologous sequence in the genome.

42. The cell or organism of sentence 41, wherein the non-endogenous sequence is a human sequence.
43. The cell or organism of sentence 41 or 42, wherein the PAM motif comprises a sequence selected from CCN, TCN, TTC, AWG, CC, NNAGNN, NGGNG GG, NGG, WGG, CWT, CTT and GAA.
44. The cell or organism of any one of sentences 41 to 43, wherein there is a PAM motif no more than 10 nucleotides (e.g., 3 nucleotides) 3′ of the non-endogenous sequence.
45. The cell or organism of any one of sentences 41 to 44, wherein the PAM motif is recognised by a Streptococcus Cas9.
46. The cell or organism of any one of sentences 41 to 45, which is a non-human vertebrate cell or a non-human vertebrate that expresses one or more human antibody heavy chain variable domains (and optionally no heavy chain variable domains of a non-human vertebrate species).
47. The cell or organism of any one of sentences 41 to 46, which is a non-human vertebrate cell or a non-human vertebrate that expresses one or more human antibody kappa light chain variable domains (and optionally no kappa light chain variable domains of a non-human vertebrate species).
48. The cell or organism of any one of sentences 41 to 47, which is a non-human vertebrate cell or a non-human vertebrate that expresses one or more human antibody lambda light chain variable domains (and optionally no kappa light chain variable domains of a non-human vertebrate species).
49. The cell or organism of any one of sentences 46 to 48, wherein the non-endogenous sequence encodes a human Fc receptor protein or subunit or domain thereof (e.g., a human FcRn or FcΥ receptor protein, subunit or domain).
50. The cell or organism of any one of sentences 41 to 48, wherein the non-endogenous sequence comprises one or more human antibody gene segments, an antibody variable region or an antibody constant region.
51. The cell or organism of any one of sentences 41 to 50, wherein the insert sequence is a human sequence that replaces or supplements an orthologous non-human sequence.
52. A monoclonal or polyclonal antibody prepared by immunisation of a vertebrate (e.g., mouse or rat) according to any one of sentences 41 to 51 with an antigen.
53. A method of isolating an antibody that binds a predetermined antigen, the method comprising
(a) providing a vertebrate (optionally a mouse or rat) according to any one of sentences 41 to 51.
(b) immunising said vertebrate with said antigen;
(c) removing B lymphocytes from the vertebrate and selecting one or more B lymphocytes expressing antibodies that bind to the antigen;
(d) optionally immortalising said selected B lymphocytes or progeny thereof, optionally by producing hybridomas therefrom; and
(e) isolating an antibody (e.g., and IgG-type antibody) expressed by the B lymphocytes.
54. The method of sentence 53, comprising the step of isolating from said B lymphocytes nucleic acid encoding said antibody that binds said antigen; optionally exchanging the heavy chain constant region nucleotide sequence of the antibody with a nucleotide sequence encoding a human or humanised heavy chain constant region and optionally affinity maturing the variable region of said antibody; and optionally inserting said nucleic acid into an expression vector and optionally a host.
55. The method of sentence 53 or 54, further comprising making a mutant or derivative of the antibody produced by the method of claim 53 or 54.
56. The use of an isolated, monoclonal or polyclonal antibody according to sentence 52, or a mutant or derivative antibody thereof that binds said antigen, in the manufacture of a composition for use as a medicament.
57. The use of an isolated, monoclonal or polyclonal antibody according to sentence 52, or a mutant or derivative antibody thereof that binds said antigen for use in medicine.
58. A nucleotide sequence encoding an antibody of sentence 52, optionally wherein the nucleotide sequence is part of a vector.
59. A pharmaceutical composition comprising the antibody or antibodies of sentence 52 and a diluent, excipient or carrier.
60. An ES cell, a eukaryotic cell, a mammalian cell, a non-human animal or a non-human blastocyst comprising an expressible genomically-integrated nucleotide sequence encoding a Cas endonuclease.
61. The cell, animal or blastocyst of sentence 60, wherein the endonuclease sequence is constitutively expressible.
62. The cell, animal or blastocyst of sentence 60, wherein the endonuclease sequence is inducibly expressible.
63. The cell, animal or blastocyst of sentence 60, 61 or 62, wherein the endonuclease sequence is expressible in a tissue-specific or stage-specific manner in the animal or a progeny thereof, or in a non-human animal that is a progeny of the cell or blastocyst.
64. The cell or animal of sentence 63, wherein the cell is a non-human embryo cell or the animal is a non-human embryo, wherein the endonuclease sequence is expressible or expressed in the cell or embryo.
65. The cell of animal sentence 64, wherein the endonuclease is operatively linked to a promoter selected from the group consisting of an embryo-specific promoter (e.g., a Nanog promoter, a Pou5fl promoter or a SoxB promoter).
66. The cell, animal or blastocyst of any one of sentences 60 to 65, wherein the Cas endonuclease is at a Rosa 26 locus.
67. The cell, animal or blastocyst of any one of sentences 60 to 65, wherein the Cas endonuclease is operably linked to a Rosa 26 promoter.
68. The cell, animal or blastocyst of any one of sentences 60 to 63, w5erein the Cas endonuclease sequence is flanked 5′ and 3′ by transposon elements (e.g., inverted piggyBac terminal elements) or site-specific recombination sites (e.g., loxP and/or a mutant lox, e.g., lox2272 or lox511; or frt).
69. The cell, animal or blastocyst of sentence 68, comprising one or more restriction endonuclease sites between the Cas endonuclease sequence and a transposon element.
70. The cell, animal or blastocyst of any one of sentences 60 to 69 comprising one or more gRNAs.
71. The cell, animal or blastocyst of sentence 68, 69 or 70, wherein the gRNA(s) are flanked 5′ and 3′ by transposon elements (e.g., inverted piggyBac terminal elements) or site-specific recombination sites (e.g., loxP and/or a mutant lox, e.g., lox2272 or lox511; or frt).
72. Use of the cell, animal or blastocyst of any one of sentences 60 to 71 in a method according to any one of sentences 1 to 51 or 73.
73. A method of nucleic acid recombination, the method comprising providing dsDNA comprising first and second strands and
(a) using Cas endonuclease-mediated nucleic acid cleavage to create a cut end in the first strand 3′ of a PAM motif;
(b) using Cas endonuclease-mediated nucleic acid cleavage to create a cut in the second strand at a position which corresponds to a position 3′ of the cut end of the strand of part (a), which cut is 3′ of the PAM motif;
(c) providing a first gRNA which hybridises with a sequence 5′ to the PAM motif in the strand of part (a)
(d) providing a second gRNA which hybridises with a sequence 5′ to the PAM motif in the strand of part (b)
wherein the nucleic acid strands of part (a) and part (b) are repaired to produce a deletion of nucleic acid between the cuts.
74. The method of sentence 6, wherein the deleted sequence comprises a regulatory element or encodes all or part of a protein.
75. The method of sentence 73 or 74, wherein Cas endonuclease-mediated cleavage is used in step (a) or in step (b) is by recognition of a GG or NGG PAM motif.
76. The method of sentence 75, wherein a nickase is used to cut in step (a) and/or in step (b).
77. The method of sentence 73 or 74 wherein a nuclease is used to cut in step (a) and/or in step (b).
78. The method of any one of sentences 74 to 77, wherein the method is carried out in a cell, e.g. a eukaryotic cell.
79. The method of sentence 78, wherein the method is carried out in a mammalian cell.
80. The method of sentence 78, wherein the cell is a rodent (e.g., mouse) ES cell or zygote.
81. The method of any one of sentences 74 to 80, wherein the method is carried out in a non-human mammal, e.g. a mouse or rat or rabbit.
82. The method of any one of sentences 74 to 81, wherein each cleavage site is flanked by PAM motif (e.g., a NGG or NGGNG sequence, wherein N is any base and G is a guanine).
83. Use of a first and second gRNA to target a desired part of the nucleic acid, defining the region to be deleted, in a method according to any one of sentences 74 to 82.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A. Precise DNA Insertion in a Predefined Location (KI): gRNA designed against a predefined location can induce DNA nick using Cas9 D10A nickase 5′ of the PAM sequence (shown as solid black box). Alternatively, gRNA can be used together with Cas9 wild-type nuclease to induce double-stranded DNA breaks 5′ of the PAM sequence. The addition of a donor oligo or a donor DNA fragment (single or double stranded) with homology around the breakpoint region containing any form of DNA alterations including addition of endogenous or exogenous DNA can be precisely inserted at the breakpoint junction where the DNA is repaired through HDR.

FIG. 1B. Precise DNA Insertion in a Predefined Location (KI): This figure shows a more detailed description of the mechanism described in FIG. 1A. sgRNA designed against a predefined location can induce DNA nick using Cas9 D10A nickase 5′ of the PAM sequence (shown as solid black box). Alternatively, sgRNA can be used together with Cas9 wild-type nuclease to induce double-stranded DNA breaks 5′ of the PAM sequence. The addition of a donor oligo or a donor DNA fragment (single or double stranded) with homology arms (HA) around the breakpoint region containing any form of DNA alterations including addition of endogenous or exogenous DNA, can be precisely inserted at the breakpoint junction where the DNA is repaired through HDR

FIG. 2A. Precise DNA Deletion (KO): gRNAs targeting flanking region of interest can induce two DNA nicks using Cas9 D10A nickase in predefine locations containing the desired PAM sequences (shown as solid black box). Alternatively, gRNAs can be used with Cas9 wild-type nuclease to induce two DSB flanking the region of interest. Addition of a donor oligo or a donor DNA fragment (single or double stranded) with homology to region 5′ of

PAM

1 and 3′ of PAM 2 sequence will guide DNA repair in a precise manner via HDR. DNA repair via HDR will reduce the risk of indel formation at the breakpoint junctions and avoid DNA repair through NHEJ and in doing so, it will delete out the region flanked by the PAM sequence and carry out DNA repair in a pre-determined and pre-defined manner.

FIG. 2B. Precise DNA Deletion (KO): This figure shows a more detailed description of the mechanism described in FIG. 2A. sgRNAs targeting flanking region of interest can induce two DNA nicks using Cas9 D10A nickase in predefine locations containing the desired PAM sequences (shown as solid black box). Note. The PAMs can be located in opposite DNA strands as suppose to the example depicted in the figure where both PAMs are on the same DNA strand. Alternatively, sgRNAs can be used with Cas9 wild-type nuclease to induce two DSB flanking the region of interest. Addition of a donor oligo or a donor DNA fragment (single or double stranded) with homology to region 5′ of

PAM

FIG. 3A: Precise DNA Deletion and Insertion (KO→KI): gRNAs targeting flanking region of interest can induce two DNA nicks using Cas9 D10A nickase in predefine locations containing the desired PAM sequences (shown as solid black box). Alternatively, gRNAs can be used with Cas9 wild-type nuclease to induce two DSB flanking the region of interest. Addition of a donor oligo or a donor DNA fragment (single or double stranded) with homology to region 5′ of

PAM

1 and 3′ to PAM 2 with inclusion of additional endogenous or exogenous DNA, will guide DNA repair in a precise manner via HDR with the concomitant deletion of the region flanked by DSB or nick and the insertion of DNA of interest.

FIG. 3B: Precise DNA Deletion and Insertion (KO→KI): s This figure shows a more detailed description of the mechanism described in FIG. 3A. gRNAs targeting flanking region of interest can induce two DNA nicks using Cas9 D10A nickase in predefine locations containing the desired PAM sequences (shown as solid black box). Alternatively, sgRNAs can be used with Cas9 wild-type nuclease to induce two DSB flanking the region of interest. Addition of a donor oligo or a donor DNA fragment (single or double stranded) with homology to region 5′ of

PAM

1 and 3′ to PAM 2 with inclusion of additional endogenous or exogenous DNA (DNA insert), will guide DNA repair in a precise manner via HDR with the concomitant deletion of the region flanked by DSB or nick and the insertion of DNA of interest. Note. Once again, the PAMs can be located in opposite DNA strands as suppose to the example depicted in the figure where both PAMs are on the same DNA strand

FIG. 4A: Recycling PAM For Sequential Genome Editing (Deletions): gRNAs targeting flanking region of interest can induce two DNA nicks using Cas9 D10A nickase in predefine locations containing the desired PAM sequences (shown as solid black box). Alternatively, gRNAs can be used with Cas9 wild-type nuclease to induce two DSB flanking the region of interest. Addition of a donor oligo or a donor DNA fragment (single or double stranded) with homology to region 5′ of

PAM

2 and 3′ of PAM 3 will guide DNA repair in a precise manner via HDR and in doing so, it will delete out the region between PAM 2 and PAM3. This deletion will retain PAM 3 and thus acts as a site for carrying out another round of CRISPR/Cas mediated genome editing. Another PAM site (e.g., PAM 1) can be used in conjunction with PAM 3 sequence to carry out another round of deletion as described above. Using this PAM recycling approach, many rounds of deletions can be performed in a stepwise deletion fashion, where PAM 3 is recycled after each round. This approach can be used also for the stepwise addition of endogenous or exogenous DNA.

FIG. 4B: Recycling PAM For Sequential Genome Editing (Deletions): This figure shows a more detailed description of the mechanism described in FIG. 4B. sgRNAs targeting flanking region of interest can induce two DNA nicks using Cas9 D10A nickase in predefine locations containing the desired PAM sequences. Alternatively, sgRNAs can be used with Cas9 wild-type nuclease to induce two DSB flanking the region of interest. Addition of a donor oligo or a donor DNA fragment (single or double stranded) with homology to region 5′ of PAM 1 (clear PAM box) and 3′ of PAM 2 (black PAM box) will guide DNA repair in a precise manner via HDR and in doing so, it will delete out the region between PAM 1 and PAM 2. PAM sequence together with unique gRNA can be included in the intruding DNA and targeted back into the site of editing. In this, PAM 1 sequence for example can be recycled and thus acts as a site for carrying out another round of CRISPR/Cas mediated genome editing. Another PAM site (e.g. PAM 3, grey PAM box) can be used in conjunction with the recycled PAM 1 sequence to carry out another round of editing (i.e. Insertion) as described above. Using this PAM recycling approach, many rounds of genome editing can be performed in a stepwise fashion, where PAM 1 is recycled after each round. This approach can be used also for the stepwise addition of endogenous or exogenous DNA.

FIG. 5A: CRISPR/Cas mediated Lox Insertion to facilitate RMCE: gRNAs targeting flanking region of interest can induce two DNA nicks using Cas9 D10A nickase in predefine locations containing the desired PAM sequences (shown as solid black box). Alternatively, gRNAs can be used with Cas9 wild-type nuclease to induce two DSB flanking the region of interest. Addition of two donor oligos or donor DNA fragments (single or double stranded) with homology to regions 5′ and 3′ of each PAM sequence where the donor DNA contains recombinase recognition sequence (RRS) such as loxP and lox5171 will guide DNA repair in a precise manner via HDR with the inclusion of these RRS. The introduced RRS can be used as a landing pad for inserting any DNA of interest with high efficiency and precisely using recombinase mediated cassette exchange (RMCE). The retained PAM 2 site can be recycled for another round of CRISPR/Cas mediated genome editing for deleting or inserting DNA of interest. Note, the inserted DNA of interest could contain selection marker such as PGK-Puro flanked by PiggyBac LTR to allow for the initial selection and upon successful integration into DNA of interest, the selection marker can be removed conveniently by expressing hyperPbase transposase.

FIG. 5B: CRISPR/Cas mediated Lox Insertion to facilitate RMCE: This figure shows a more detailed description of the mechanism described in FIG. 5A. sgRNAs targeting flanking region of interest can induce two DNA nicks using Cas9 D10A nickase in predefine locations containing the desired PAM sequences (shown as solid black box). Alternatively, sgRNAs can be used with Cas9 wild-type nuclease to induce two DSB flanking the region of interest. Addition of two donor oligos or donor DNA fragments (single or double stranded) with homology to regions 5′ and 3′ of each PAM sequences where the donor DNA contains recombinase recognition sequence (RRS) such as loxP and lox5171 will guide DNA repair in a precise manner via HDR with the inclusion of these RRS. Note. The targeting of the lox sites can be done sequentially or as a pool in a single step process. The introduced RRS can be used as a landing pad for inserting any DNA of interest with high efficiency and precisely using recombinase mediated cassette exchange (RMCE). As detailed in FIG. 4, the PAM sequence can be recycled for another round of CRISPR/Cas mediated genome editing for deleting or inserting DNA of interest. As an option, the inserted DNA of interest could contain selection marker such as PGK-Puro flanked by PiggyBac LTR to allow for the initial selection and upon successful integration into DNA of interest, the selection marker can be removed conveniently by expressing hyperPbase transposase.

FIGS. 6A and 6B: Genome modification to produce transposon-excisable Cas9 and gRNA

FIG. 6C: Single copy Cas9 Expression: A landing pad initially can be targeted into any locus of choice in mouse ES cells or any other eukaryotic cell line. The landing pad will typically contain Piggy Bac 5′ and 3′ LTR, selection marker such as neo for example floxed and a gene less promoter such as PGK in the general configuration shown. Targeting is done by homologous recombination and clones are selected on G418. The next step will involve RMCE to insert Cas9 linked via a T2A sequence to Puro-delta-tk with the option to insert single or multiple guide RNA using the unique restriction sites (RS). The orientation of the lox sites are positioned in a manner that only once the intruding DNA containing the Cas9 is inserted into the landing pad, the PGK promoter on the landing pad can activate the transcription and thus the expression of the puromycin and via the T2A transcribe and expression Cas9 production. Using this approach a single stable expression of Cas9 can be achieved. Following 4-6 days of selection on puromycin, the entire Cas9 and guide RNA floxed cassette can be excised using PiggyBac transposase (Pbase) and individual clones can be analysed for genome editing resulting from the introduced guide RNA. As an option, a stable bank cell line expressing Cas9 can be generated from which multiple engineered cell lines can be generated. To do this, only Cas9-T2A-Puro-delta-tk will be inserted and no gRNA at the stage of RMCE. This will produce a general single copy Cas9 expressing cell line where its genome can be edited by transfecting single or multiple gRNA.

FIG. 7: Schematic representing the gRNA position with respect to gene X, the structure of the targeting vector and the oligo pair used for genotyping the resulting targeted clones.

FIG. 8: A gel image showing the genotyping results following Cas9 nuclease mediated double stranded DNA break and the subsequent DNA targeting. The genotyping shows PCR product (880 bp) specific for the 5′ targeted homology arm using oligo pair HAP341/HAP334. The left hand gels show genotyping data from 96 ES cell clones transfected with gRNA, human Cas9 nuclease and either a circular targeting vector (plate 1) or a linear targeting vector (Plate 2). The right hand side gels shows 96 ES cell clones transfected with gRNA and either a circular targeting vector (plate 3) or a linear targeting vector (Plate 4) but with no human Cas9 nuclease. The percentage of the clones correctly targeted is shown for each transfection.

FIG. 9: Schematic showing the position of the gRNAs on a gene to allow for a define deletion of the region in between the two gRNA. The

oligo pair primer

1 and 2 was used to detect ES clones containing the specific 55 bp deletion.

FIG. 10: A 3% agarose gel containing PCR products amplified from 96 ES clones transfected with

gRNA

1 and 2.

Primers

1 and 2 was used to amplify around the two gRNA and any clones containing the define deletion can be seen as a smaller PCR product, which are highlighted by an asterix.

FIG. 11: PCR genotyping by amplifying the 5′ (top gel) and 3′ (bottom gel) targeted homology arms within the Rosa26 gene located on chromosome 6. Correctly targeted clones yielding PCR product for both 5′ and 3′ junctions are marked with an asterix.

FIG. 12: Genotyping for the correct insertion of the Cas9 DNA cassette by PCR amplifying the 5′ (top gel) and 3′ (bottom gel) arm of the inserted DNA cassette.

FIG. 13: PCR genotyping by amplifying the region around the guide RNA and assessing the PCR product for the presence of indels. Larger indels can be seen directly from the gel as they yielded PCR product shorter than the expected WT DNA suggesting significant deletion. For the positive control, genomic DNA from mouse AB2.1 was used to size the corresponding WT PCR product. The negative control was a no DNA water control.

FIG. 14: PCR amplification of the region flanking the guide RNA using DNA extracted from pups following zygote Cas9/guide mRNA injection for analysing indel formation. Lane 14 shows a gross deletion in that mouse and those lanes marked with an asterix indicate these mice contain smaller indels.

FIG. 15: Summary of the sequencing data from the 8 mice analysed and the details of the indels detected are shown. The number refers to the frequency of that particular indel identified in the clones analysed and the description of the indels are shown in brackets.

DETAILED DESCRIPTION OF THE INVENTION

The inventors addressed the need for improved nucleic acid modification techniques. An example of a technique for nucleic acid modification is the application of the CRISPR/Cas system. This system has been shown thus far to be the most advanced genome editing system available due, inter alia, to its broad application, the relative speed at which genomes can be edited to create mutations and its ease of use. The inventors, however, believed that this technology can be advanced for even broader applications than are apparent from the state of the art.
The inventors realised that an important aspect to achieve this would be to find a way of improving the fidelity of nucleic acid modifications beyond that contemplated by the CRISPR/Cas methods known in the art.
Additionally, the inventors realised that only modest nucleic acid modifications had been reported to date. It would be desirable to effect relatively large predefined and precise DNA deletions or insertions using the CRISPR/Cas system.
The inventors have devised an approach for introducing one or more desired insertions and/or deletions of known sizes into one or more predefined locations in a nucleic acid (e.g., in a cell or organism genome). They developed techniques to do this either in a sequential fashion or by inserting a discrete DNA fragment of defined size into the genome precisely in a predefined location or carrying out a discrete deletion of a defined size at a precise location. The technique is based on the observation that DNA single-stranded breaks are preferentially repaired through the HDR pathway, and this reduces the chances of indels (e.g., produced by NHEJ) in the present invention and thus is more efficient than prior art techniques.
To this end, the invention provides:—
A method of nucleic acid recombination, the method comprising providing double stranded DNA (dsDNA) comprising first and second strands and
(a) using nucleic acid cleavage to create 5′ and 3′ cut ends in the first strand; and
(b) using homologous recombination to insert a nucleotide sequence between the ends, thereby producing a modified first strand; thereby producing DNA wherein the first strand has been modified by said recombination but the second strand has not been modified.
Optionally, the method further comprises replicating the modified first strand to produce a progeny dsDNA wherein each strand thereof comprises a copy of the insert nucleotide sequence. Optionally, the method comprises (c) isolating the progeny dsDNA, e.g., by obtaining a cell containing said progeny dsDNA. Replication can be effected, for example in a cell. For example, steps (a) and (b) are carried out in a cell and the cell is replicated, wherein the machinery of the cell replicates the modified first strand, e.g., to produce a dsDNA progeny in which each strand comprises the modification.
Optionally, in any configuration, aspect, example or embodiment of the invention, the modified DNA strand resulting from step (b) is isolated.
Optionally, in any configuration, aspect, example or embodiment of the invention, the method is carried out in vitro. For example, the method is carried out in a cell or cell population in vitro.
Alternatively, optionally, in any configuration, aspect, example or embodiment of the invention, the method is carried out to modify the genome of a virus.
Alternatively, optionally, in any configuration, aspect, example or embodiment of the invention, the method is carried out in vivo in an organism. In an example, the organism is a non-human organism. In an example, it is a plant or an animal or an insect or a bacterium or a yeast. For example, the method is practised on a vertebrate (e.g., a human patient or a non-human vertebrate (e.g., a bird, e.g., a chicken) or non-human mammal such as a mouse, a rat or a rabbit).
Optionally, in any configuration, aspect, example or embodiment of the invention, the method is a method of cosmetic treatment of a human or a non-therapeutic, non-surgical, non-diagnostic method, e.g., practised on a human or a non-human vertebrate or mammal (e.g., a mouse or a rat).
The Invention Also Provides:—
A method of nucleic acid recombination, the method comprising
(a) using nucleic acid cleavage to create 5′ and 3′ cut ends in a single nucleic acid strand;
(b) using homologous recombination to insert a nucleotide sequence between the ends, wherein the insert sequence comprises a regulatory element or encodes all or part of a protein; and
(c) Optionally obtaining the nucleic acid strand modified in step (b) or a progeny nucleic strand comprising the inserted nucleotide sequence, e.g., by obtaining a cell containing said progeny nucleic acid strand.
In an example the progeny strand is a product of the replication of the strand produced by step (b). The progeny strand is, for example, produced by nucleic acid replication in a cell. For example, steps (a) and (b) are carried out in a cell and the cell is replicated, wherein the machinery of the cell replicates the modified strand produced in step (b), e.g., to produce a dsDNA progeny in which each strand comprises the modification.
In an example, the single nucleic acid strand is a DNA or RNA strand.
In an example, the regulatory element is a promoter or enhancer.
Optionally, in any configuration, aspect, example or embodiment of the invention, the inserted nucleotide sequence is a plant, animal, vertebrate or mammalian sequence, e.g., a human sequence. For example, the sequence encodes a complete protein, polypeptide, peptide, domain or a plurality (e.g. one, two or more) of any one of these. In an example, the inserted sequence confers a resistance property to a cell comprising the modified nucleic acid produced by the method of the invention (e.g., herbicide, viral or bacterial resistance). In an example, the inserted sequence encodes an interleukin, receptor (e.g., a cell surface receptor), growth factor, hormone, antibody (or variable domain or binding site thereof), antagonist, agonist; e.g., a human version of any of these. In an example, the inserted sequence is an exon.
Optionally, in any configuration, aspect, example or embodiment of the invention, the inserted nucleotide sequence replaces an orthologous or homologous sequence of the strand (e.g., the insert is a human sequence that replaces a plant, human or mouse sequence). For example, the method is carried out in a mouse or mouse cell (such as an ES cell) and the insert replaces an orthologous or homologous mouse sequence (e.g., a mouse biological target protein implicated in disease). For example, the method is carried out (e.g., in vitro) in a human cell and the insert replaces an orthologous or homologous human sequence (e.g., a human biological target protein implicated in disease, e.g., a mutated form of a sequence is replaced with a different (e.g., wild-type) human sequence, which may be useful for correcting a gene defect in the cell. In this embodiment, the cell may be a human ES or iPS or totipotent or pluripotent stem cell and may be subsequently introduced into a human patient in a method of gene therapy to treat and/or prevent a medical disease or condition in the patient).
Optionally, in any configuration, aspect, example or embodiment of the invention, the inserted nucleotide sequence is at least 10 nucleotides long, e.g., at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800 or 900 nucleotides, or at least 1, 2, 3, 5, 10, 20, 50 or 100 kb long.
Optionally, in any configuration, aspect, example or embodiment of the invention, the insert sequence comprises a site specific recombination site, e.g., a lox, frt or rox site. For example, the site can be a loxP, lox511 or lox2272 site.
The Invention Also Provides:—
A method of nucleic acid recombination, the method comprising
(a) using nucleic acid cleavage to create first and second breaks in a nucleic acid strand, thereby creating 5′ and 3′ cut ends and a nucleotide sequence between the ends;
(b) using homologous recombination to delete the nucleotide sequence; and
(c) optionally obtaining the nucleic acid strand modified in step (b) or a progeny nucleic strand comprising the deletion.
In an example, the progeny strand is a product of the replication of the strand produced by step (b). The progeny strand is, for example, produced by nucleic acid replication in a cell. For example, steps (a) and (b) are carried out in a cell and the cell is replicated, wherein the machinery of the cell replicates the modified strand produced in step (b), e.g., to produce a dsDNA progeny in which each strand comprises the modification.
In an example, the single nucleic acid strand is a DNA or RNA strand.
In an example, the deleted sequence comprises a regulatory element or encodes all or part of a protein. In an embodiment, the deleted regulatory element is a promoter or enhancer.
Optionally, in any configuration, aspect, example or embodiment of the invention, the deleted nucleotide sequence is a plant, animal, vertebrate or mammalian sequence, e.g., a human sequence. For example, the sequence encodes a complete protein, polypeptide, peptide, domain or a plurality (e.g. one, two or more) of any one of these. In an example, the deleted sequence encodes an interleukin, receptor (e.g., a cell surface receptor), growth factor, hormone, antibody (or variable domain or binding site thereof), antagonist, agonist; e.g., a non-human version of any of these. In an example, the deleted sequence is an exon.
Optionally, in any configuration, aspect, example or embodiment of the invention, the deleted nucleotide sequence is replaced by an orthologous or homologous sequence of a different species or strain (e.g., a human sequence replaces an orthologous or homologous plant, human or mouse sequence). For example, the method is carried out in a mouse or mouse cell and the insert replaces an orthologous or homologous mouse sequence (e.g., a mouse biological target protein implicated in disease). For example, the method is carried out (e.g., in vitro) in a human cell and the insert replaces an orthologous or homologous human sequence (e.g., a human biological target protein implicated in disease, e.g., a mutated form of a sequence is replaced with a different (e.g., wild-type) human sequence, which may be useful for correcting a gene defect in the cell. In this embodiment, the cell may be a human ES or iPS or totipotent or pluripotent stem cell and may be subsequently introduced into a human patient in a method of gene therapy to treat and/or prevent a medical disease or condition in the patient).
Optionally, in any configuration, aspect, example or embodiment of the invention, the deleted nucleotide sequence is at least 10 nucleotides long, e.g., at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800 or 900 nucleotides, or at least 1, 2, 3, 5, 10, 20, 50 or 100 kb long.
Optionally, in any configuration, aspect, example or embodiment of the invention, step (c) is performed by isolating a cell comprising the modified first strand, or by obtaining a non-human vertebrate in which the method has been performed or a progeny thereof.
Optionally, in any configuration, aspect, example or embodiment of the invention, the product of the method comprises a nucleic acid strand comprising a PAM motif 3′ of the insertion or deletion. In an example, the PAM motif is within 10, 9, 8, 7 6, 5, 4 or 3 nucleotides of the insertion or deletion. This is useful to enable serial insertions and/or deletions according to the method as explained further below.
Optionally, in any configuration, aspect, example or embodiment of the invention, the product of the method comprises a nucleic acid strand comprising a PAM motif 5′ of the insertion or deletion. In an example, the PAM motif is within 10, 9, 8, 7 6, 5, 4 or 3 nucleotides of the insertion or deletion. This is useful to enable serial insertions and/or deletions according to the method as explained further below.
Optionally, in any configuration, aspect, example or embodiment of the invention, step (b) is performed by carrying out homologous recombination between an incoming nucleic acid comprising first and second homology arms, wherein the homology arms are substantially homologous respectively to a sequence extending 5′ from the 5′ end and a sequence extending 3′ from the 3′ end. The skilled person will be familiar with constructing vectors and DNA molecules for use in homologous recombination, including considerations such as homology arm size and sequence and the inclusion of selection markers between the arms. For example, the incoming nucleic acid comprises first and second homology arms, and the insert sequence and an optional selection marker sequence (e.g., neo nucleotide sequence). The arms may be at least 20, 30, 40, 50, 100 or 150 nucleotides in length, for example. Where deletion is required, the insert is omitted (although an optional selection marker sequence may or may not be included between the arms).
Thus, in an embodiment of the invention, step (b) is performed by carrying out homologous recombination between an incoming nucleic acid comprising an insert nucleotide sequence flanked by the first and second homology arms, wherein the insert nucleotide sequence is inserted between the 5′ and 3′ ends.
In another embodiment of the invention, the insert is between the homology arms and there is no further sequence between the arms.
In an example, each homology arm is at least 20, 30, 40, 50, 100 or 150 nucleotides long.
Optionally, in any configuration, aspect, example or embodiment of the invention, step (a) is carried out using an endonuclease, e.g., a nickase. Nickases cut in a single strand of dsDNA only. For example, the endonuclease is an endonuclease of a CRISPR/Cas system, e.g., a Cas9 or Cys4 endonuclease (e.g., a Cas9 or Cys4 nickase). In an example, the endonuclease recognises a PAM listed in Table 1 below, for example, the endonuclease is a Cas endonuclease that recognises a PAM selected from CCN, TCN, TTC, AWG, CC, NNAGNN, NGGNG GG, NGG, WGG, CWT, CTT and GAA. In an example, the Cas endonuclease is a S pyogenes endonuclease, e.g., a S pyogenes Cas9 endonuclease. In an example, a S. pyogenes PAM sequence or Streptococcus thermophilus LMD-9 PAM sequence is used.
In an example, the endonuclease is a Group 1 Cas endonuclease. In an example, the endonuclease is a Group 2 Cas endonuclease. In an example, the endonuclease is a Group 3 Cas endonuclease. In an example, the endonuclease is a Group 4 Cas endonuclease. In an example, the endonuclease is a Group 7 Cas endonuclease. In an example, the endonuclease is a Group 10 Cas endonuclease.
In an example, the endonuclease recognises a CRISPR/Cas Group 1 PAM. In an example, the endonuclease recognises a CRISPR/Cas Group 2 PAM. In an example, the endonuclease recognises a CRISPR/Cas Group 3 PAM. In an example, the endonuclease recognises a CRISPR/Cas Group 4 PAM. In an example, the endonuclease recognises a CRISPR/Cas Group 7 PAM. In an example, the endonuclease recognises a CRISPR/Cas Group 10 PAM.
In an example, Cas endonuclease-mediated cleavage is used in step (a); optionally by recognition of a GG or NGG PAM motif.
In an example, the first and/or second homology arm comprises a PAM motif. This is useful to enable serial insertions and/or deletions according to the method as explained further below.
An example of a suitable nickase is S pyogenes Cas9 D10A nickase (see Cong et al. and the Examples section below).
Optionally, in any configuration, aspect, example or embodiment of the invention, steps (a) and (b) of the method is carried out in a cell, e.g. a bacterial, yeast, eukaryotic cell, plant, animal, mammal, vertebrate, non-human animal, rodent, rat, mouse, rabbit, fish, bird or chicken cell. For example, the cell is an E coli cell or CHO or HEK293 or Picchia or Saccharomyes cell. In an example, the cell is a human cell in vitro. In one embodiment, the cell is an embryonic stem cell (ES cell, e.g., a human or non-human ES cell, such as a mouse ES cell) or an induced pluripotent stem cell (iPS cell; e.g., a human, rodent, rat or mouse iPS cell) or a pluripotent or totipotent cell. Optionally, the cell is not an embryonic cell, e.g. wherein the cell is not a human embryonic cell. Optionally, the cell is not a pluripotent or totipotent cell. In an example, the method is used to produce a human stem cell for human therapy (e.g., an iPS cell generated from a cell of a patient for reintroduction into the patient after the method of the invention has been performed on the cell), wherein the stem cell comprises a nucleotide sequence or gene sequence inserted by the method of the invention. The features of the examples in this paragraph can be combined.
In an example, the method is carried out in a mammalian cell. For example, the cell is a human cell in vitro or a non-human mammalian cell. For example, a non-human (e.g., rodent, rat or mouse) zygote. For example, a single-cell non-human zygote.
In an example, the method is carried out in a plant or non-human mammal, e.g. a rodent, mouse or rat or rabbit, or a tissue or organ thereof (e.g., in vitro).
In an example, the 3′ or each cleavage site is flanked 3′ by PAM motif (e.g., a motif disclosed herein, such as NGG or NGGNG sequence, wherein N is any base and G is a guanine). For example, one or more or all cleavage sites are flanked 3′ by the sequence 5′-TGGTG-3′. Unlike dsDNA, the PAM is not absolutely required for ssDNA binding and cleavage: A single-stranded oligodeoxynucleotide containing a protospacer with or without a PAM sequence is bound nearly as well as dsDNA and may be used in the invention wherein a single strand of DNA is modified. Moreover, in the presence of Mg²⁺ ions, Cas9 cuts ssDNA bound to the crRNA using its HNH active site independently of PAM.
Optionally, in any configuration, aspect, example or embodiment of the invention, step (a) is carried out by cleavage in one single strand of dsDNA or in ssDNA.
Optionally, in any configuration, aspect, example or embodiment of the invention, step (a) is carried out by combining in a cell the nucleic acid strand, a Cas endonuclease, a crRNA and a tracrRNA (e.g., provided by one or more gRNAs) for targeting the endonuclease to carry out the cleavage, and optionally an insert sequence for homologous recombination with the nucleic acid strand. Instead of an insert sequence, one can use an incoming sequence containing homology arms but no insert sequence, to effect deletion as described above. In an example, the Cas endonuclease is encoded by a nucleotide sequence that has been introduced into the cell. In an example, the gRNA is encoded by a DNA sequence that has been introduced into the cell.
In an example, the method is carried out in the presence of Mg²⁺.
Optionally, in any configuration, aspect, example or embodiment of the invention, step (b) is performed by carrying out homologous recombination with an incoming nucleic acid comprising first and second homology arms, wherein the homology arms are substantially homologous respectively to a sequence extending 5′ from the 5′ end and a sequence extending 3′ from the 3′ end, wherein the second homology arm comprises a PAM sequence such that homologous recombination between the second homology arm and the sequence extending 3′ from the 3′ end produces a sequence comprising a PAM motif in the product of the method. The PAM can be any PAM sequence disclosed herein, for example. Thus, the method produces a modified nucleic acid strand comprising a PAM that can be used for a subsequent nucleic acid modification according to any configuration, aspect, example or embodiment of the invention, wherein a Cas endonuclease is used to cut the nucleic acid. This is useful, for example, for performing sequential endonuclease-mediated homology directed recombination (sEHDR) according to the invention, more particularly sCHDR described below.
Sequential Endonuclease-Mediated Homology Directed Recombination (sEHDR)

The Invention Further Provides:—

A method of sequential endonuclease-mediated homology directed recombination (sEHDR) comprising carrying out the method of any preceding configuration, aspect, example or embodiment of the invention a first time and a second time, wherein endonuclease-mediated cleavage is used in each step (a); wherein the product of the first time is used for endonuclease-mediated cleavage the second time, whereby either (i) first and second nucleotide sequences are deleted the first time and the second times respectively; (ii) a first nucleotide sequence is deleted the first time and a second nucleotide sequence is inserted the second time; (iii) a first nucleotide sequence is inserted the first time and a second nucleotide sequence is deleted the second time; or (iv) first and second nucleotide sequences are inserted the first and second times respectively; optionally wherein the nucleic acid strand modification the second time is within 20, 10, 5, 4, 3, 2 or 1 or less nucleotides of the nucleic acid strand modification the first time or directly adjacent to the nucleic acid strand modification the first time.
For example, the first and second nucleotide sequences are inserted so that they are contiguous after the insertion the second time. Alternatively, the first and second deletions are such that a contiguous sequence has been deleted after the first and second deletions have been performed.
In an embodiment of sEHDR, the invention uses a Cas endonuclease. Thus, there is provided:—
A method of sequential Cas-mediated homology directed recombination (sCHDR) comprising carrying out the method of any preceding claim a first time and a second time, wherein Cas endonuclease-mediated cleavage is used in each step (a); wherein step (b) of the first time is carried out performing homologous recombination with an incoming nucleic acid comprising first and second homology arms, wherein the homology arms are substantially homologous respectively to a sequence extending 5′ from the 5′ end and a sequence extending 3′ from the 3′ end, wherein the second homology arm comprises a PAM sequence such that homologous recombination between the second homology arm and the sequence extending 3′ from the 3′ end produces a sequence comprising a PAM motif in the product of the method, wherein the PAM motif of the product of the first time is used for Cas endonuclease-mediated cleavage the second time, whereby either (i) first and second nucleotide sequences are deleted the first time and the second times respectively; (ii) a first nucleotide sequence is deleted the first time and a second nucleotide sequence is inserted the second time; (iii) a first nucleotide sequence is inserted the first time and a second nucleotide sequence is deleted the second time; or (iv) first and second nucleotide sequences are inserted the first and second times respectively: optionally wherein the nucleic acid strand modification the second time is within 20, 10, 5, 4, 3, 2 or 1 or less nucleotides of the nucleic acid strand modification the first time or directly adjacent to the nucleic acid strand modification the first time.
For example, the first and second nucleotide sequences are inserted so that they are contiguous after the insertion the second time. Alternatively, the first and second deletions are such that a contiguous sequence has been deleted after the first and second deletions have been performed.
In an embodiment (First Embodiment), the first time is carried out according to the third configuration of the invention, wherein the incoming nucleic acid comprises no sequence between the first and second homology arms, wherein sequence between the 5′ and 3′ ends is deleted by homologous recombination; and/or the second time is carried out according to the third configuration of the invention, wherein step (b) is performed by carrying out homologous recombination between an incoming nucleic acid comprising first and second homology arms, wherein the homology arms are substantially homologous respectively to a sequence extending 5′ from the 5′ end and a sequence extending 3′ from the 3′ end, wherein the incoming nucleic acid comprises no sequence between the first and second homology arms such that sequence between the 5′ and 3′ ends is deleted by homologous recombination; optionally wherein the second arm comprises a PAM motif such that the product of the second time comprises a PAM motif for use in a subsequent Cas endonuclease-mediated method according to any configuration, aspect, example or embodiment of the invention.
In an embodiment (Second Embodiment), the first time is carried out according to the first or second configuration of the invention, wherein the incoming nucleic acid comprises the insert sequence between the first and second homology arms, wherein the insert sequence is inserted between the 5′ and 3′ ends by homologous recombination; and/or the second time is carried out according to the first or second configuration of the invention, wherein step (b) is performed by carrying out homologous recombination between an incoming nucleic acid comprising first and second homology arms, wherein the homology arms are substantially homologous respectively to a sequence extending 5′ from the 5′ end and a sequence extending 3′ from the 3′ end, wherein the insert sequence is inserted between the 5′ and 3′ ends by homologous recombination, optionally wherein the second arm comprises a PAM motif such that the product of the second time comprises a PAM motif for use in a subsequent Cas endonuclease-mediated method according to any configuration, aspect, example or embodiment of the invention.
In an example, one of said first and second times is carried out as specified in the First Embodiment and the other time is carried out as specified in the Second Embodiment, wherein at least one sequence deletion and at least one sequence insertion is performed.
Optionally, in any configuration, aspect, example or embodiment of the invention, step (a) is carried out by Cas endonuclease-mediated cleavage using a Cas endonuclease, one or more crRNAs and a tracrRNA. For example, the method is carried out in a cell and the crRNA and tracrRNA is introduced into the cell as RNA molecules. For example, the method is carried out in a zygote (e.g., a non-human zygote, e.g., a rodent, rat or mouse zygote) and the crRNA and tracrRNA is injected into zygote. In another embodiment, the crRNA and tracrRNA are encoded by DNA within a cell or organism and are transcribed inside the cell (e.g., an ES cell, e.g., a non-human ES cell, e.g., a rodent, rat or mouse ES cell) or organism to produce the crRNA and tracrRNA. The organism is, for example, a non-human animal or plant or bacterium or yeast or insect. In an embodiment, the tracrRNA is in this way encoded by DNA but one or more crRNAs are introduced as RNA nucleic acid into the cell or organism to effect the method of the invention.
Additionally or alternatively to these examples, the endonuclease may be introduced as a protein or a vector encoding the endonuclease may be introduced into the cell or organism to effect the method of the invention. In another example, the endonuclease is encoded by DNA that is genomically integrated into the cell or organism and is transcribed and translated inside the cell or organism.
In an example, the method of the invention is carried out in an ES cell (e.g., a non-human ES cell, e.g., a rodent, rat or mouse ES cell) that has been pre-engineered to comprise an expressible genomically-integrated Cas endonuclease sequence (or a vector carrying this has been include in the cell). It would be possible to introduce (or encode) a tracrRNA. By introducing a crRNA with a guiding oligo sequence to target the desired area of the cell genome, one can then carry out modifications in the cell genome as per the invention. In an example, a gRNA as described herein is introduced into the ES cell. The genomically-integrated expressible Cas endonuclease sequence can, for example, be constitutively expressed or inducibly expressible. Alternatively or additionally, the sequence may be expressible in a tissue-specific manner in a progeny organism (e.g., a rodent) developed using the ES cell.
The initial ES cell comprising a genomically-integrated expressible Cas endonuclease sequence can be used, via standard techniques, to produce a progeny non-human animal that contains the expressible Cas endonuclease sequence. Thus, the invention provides:—
A non-human animal (e.g., a vertebrate, mammal, fish or bird), animal cell, insect, insect cell, plant or plant cell comprising a genomically-integrated expressible Cas endonuclease nucleotide sequence and optionally a tracrRNA and/or a nucleotide sequence encoding a tracrRNA. The Cas endonuclease is, for example, Cas9 or Cys4. In an example, the animal, insect or plant genome comprises a chromosomal DNA sequence flanked by site-specific recombination sites and/or transposon elements (e.g., piggyBac transposon repeat elements), wherein the sequence encodes the endonuclease and optionally one or more gRNAs. As described in the Examples below, recombinase-mediated cassette exchange (RMCE) can be used to insert such a sequence. The transposon elements can be used to excise the sequence from the genome once the endonuclease has been used to perform recombination. The RMCE and/or transposon-mediated excision can be performed in a cell (e.g., an ES cell) that later is used to derive a progeny animal or plant comprising the desired genomic modification.
The invention also provides an ES cell derived or derivable from such an animal, wherein the ES cell comprises a genomically-integrated expressible Cas endonuclease nucleotide sequence. In an example, the ES cell is a rodent, e.g., a mouse or rat ES cell, or is a rabbit, dog, pig, cat, cow, non-human primate, fish, amphibian or bird ES cell.
The invention also provides a method of isolating an ES cell, the method comprising deriving an ES cell from an animal (e.g., a non-human animal, e.g., a rodent, e.g., a rat or a mouse), wherein the animal comprises a genomically-integrated expressible Cas endonuclease nucleotide sequence, as described herein.
In any of these aspects, instead of an ES cell, the cell may be an iPS cell or a totipotent or pluripotent cell. Thus, an iPS or stem cell can be derived from (e.g., a somatic cell of) a human, engineered in vitro to comprise a genomically-integrated expressible Cas endonuclease nucleotide sequence and optionally one or more DNA sequences encoding a tracrRNA or gRNA. The invention, thus, also relates to such a method and to a human iPS or stem cell comprising a genomically-integrated expressible Cas endonuclease nucleotide sequence and optionally one or more DNA sequences encoding a tracrRNA or gRNA. This cell can be used in a method of the invention to carry out genome modification (e.g., to correct a genetic defect, e.g., by replacement of defective sequence with a desired sequence, optionally with subsequent transposon-mediated excision of the endonuclease-encoding sequence). After optional excision of the Cas endonuclease sequence, the iPS cell or stem cell can be introduced into the donor human (or a different human, e.g., a genetic relative thereof) to carry out genetic therapy or prophylaxis. In the alternative, a totipotent or pluripotent human cell is used and then subsequently developed into human tissue or an organ or part thereof. This is useful for providing material for human therapy or prophylaxis or for producing assay materials (e.g., for implantation into model non-human animals) or for use in in vitro testing (e.g., of drugs).
In an example, the method uses a single guided RNA (gRNA or sgRNA) comprising a crRNA and a tracrRNA. The crRNA comprises an oligonucleotide sequence (“X” in the structure 5′-X-Y-3′ mentioned below) that is chosen to target a desired part of the nucleic acid or genome to be modified. The skilled person will be able readily to select appropriate oligo sequence(s). In an example, the sequence is from 3 to 100 nucleotides long, e.g., from 3 to 50, 40, 30, 25, 20, 15 or 10 nucleotides long, e.g., from or 5, 10, 15 or 20 to 100 nucleotides long, e.g., from 5, 10, 15 or 20 to 50 nucleotides long.
For example, the gRNA is a single nucleic acid comprising both the crRNA and the tracrRNA. An example of a gRNA comprises the sequence 5′-[oligo]-[UUUUAGAGCUA (S N1UUUUAN2N3GCUA)]-[LINKER]-[UAGCAAGUUAAAA (SEQ ID NO:2)]-3′, wherein the LINKER comprises a plurality (e.g., 4 or more, e.g., 4, 5 or 6) nucleotides (e.g., 5′-GAAA-3′).
For example, the crRNA has the structure 5′-X-Y-3′, wherein X is an RNA nucleotide sequence (optionally, at least 5 nucleotides long) and Y is a crRNA sequence comprising a nucleotide motif that hybridises with a motif comprised by the tracrRNA, wherein X is capable of hybridising with a nucleotide sequence 5′ of the desired site of the 5′ cut end, e.g., extending 5′ from the desired site of the 5′ cut.
In an example, Y is 5′-N1UUUUAN2N3GCUA-3′ (SEQ ID NO:3), wherein each of N1-3 is a A, U, C or G and/or the tracrRNA comprises the sequence (in 5′ to 3′ orientation) UAGCM1UUAAAAM2 (SEQ ID NO:4), wherein M1 is spacer nucleotide sequence and M2 is a nucleotide; e.g., N1-G, N2=G and N3=A. The spacer sequence is, e.g., 5, 4, 3, 2 or 1 RNA nucleotides in length (e.g., AAG in 5′ to 3′ orientation). M2 is, for example, an A, U, C or G (e.g., M2 is a G). In an embodiment, a chimaeric gRNA is used which comprises a sequence 5′-X-Y-Z-3′, wherein X and Y are as defined above and Z is a tracrRNA comprising the sequence (in 5′ to 3′ orientation) UAGCM1UUAAAAM2 (SEQ ID NO:4), wherein M1 is spacer nucleotide sequence and M2 is a nucleotide. In an example, Z comprises the sequence 5′-UAGCAAGUUAAAA-3′ (SEQ ID NO:2), e.g., Z is 5′-UAGCAAGUUAAAAUAAGGCUAGUCCG-3′ (SEQ ID NO:5). In an example, the gRNA has the sequence:

(SEQ ID NO: 6)

5′-GUUUUAGAGGUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUA

UCAACUUGAAAAAGUGGCACCGAGUCGGUGC-3′

When it is desired to use the present invention to insert an exogenous sequence into the nucleic acid to be modified, the exogenous sequence can be provided on linear or circular nucleic acid (e.g., DNA). Typically, the exogenous sequence is flanked by homology arms that can undergo homologous recombination with sequences 5′ and 3′ respectively of the site where the exogenous sequence is to be inserted. The skilled person is familiar with choosing homology arms for homologous recombination.
The invention can be used in a method of producing a transgenic organism, e.g., any organism recited herein. For example, the organism can be a non-human organism used as an assay model to test a pharmaceutical drug or to express an exogenous protein or a part thereof (e.g., a human protein target knocked-in into a non-human animal assay organism). In another example, the invention has been used to knock-out an endogenous sequence (e.g., a target protein) in an organism, such as a non-human organism. This can be useful to assess the effect (phenotype) of the knock-out and thus to assess potential drug targets or proteins implicated in disease. In one example, the organism is a non-human animal (e.g., a vertebrate, mammal, bird, fish, rodent, mouse, rat or rabbit) in which a human target protein has been knocked-in using the invention. Optionally, the invention has been used to knock out an orthologous or homologous endogenous target of the organism (e.g., an endogenous target sequence has been replaced at the endogenous position by an orthologous or homologous human target sequence). In this way, an assay model can be produced for testing pharmaceutical drugs that act via the human target.
In an embodiment, the organism is a non-human vertebrate that expresses human antibody variable regions whose genome comprises a replacement of an endogenous target with an orthologous or homologous human sequence. In an example, the method of the invention is used to produce an Antibody-Generating Vertebrate or Assay Vertebrate as disclosed in WO2013061078, the disclosure of which, and specifically including the disclosure of such Vertebrates, their composition, manufacture and use, is included specifically herein by reference as though herein reproduced in its entirety and for providing basis for claims herein.
The antibodies described herein can be of any format provided that they comprise human variable regions. For example, the present invention is applicable to of 4-chain antibodies, where the antibodies each contain 2 heavy chains and 2 light chains. Alternatively, the invention can be applied to H2 antibodies (heavy chain antibodies) bearing human V regions and which are devoid of CH1 and light chains (equivalent in respects to Camelid H2 antibodies: see, eg, Nature. 1993 Jun. 3; 363(6428):446-8; Naturally occurring antibodies devoid of light chains, Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E B, Bendahman N, Hamers R). These antibodies function to specifically bind antigen, such antibodies being akin to those found in the blood of Camelidae (eg, llamas, camels, alpacas). Such antibodies with human VH pairs can be synthetically produced to provide therapeutic and prophylactic medicaments (eg, see WO1994004678, WO2004041862, WO2004041863). Transgenic mice also can produce such heavy chain antibodies and the in vivo production of the antibodies allows the mouse's immune system to select for human VH-VH pairings, sometimes selecting for such pairings in which mutations have been introduced in vivo by the mouse to accommodate the pairing (W02010109165A2). Thus, in an embodiment of the present invention, the heavy chain transgene is devoid of a CH1 gene segment and the genome comprises no functional antibody light chain locus. Alternatively, the test antibody is an antibody fragment, eg, Fab or Fab2, which comprises a constant region and human variable regions.
The test antibody is isolated from a first transgenic non-human vertebrate (eg, a mouse or rat) (Antibody-Generating Vertebrate) following immunisation with an antigen bearing said human epitope. The skilled person will be familiar with routine methods and protocols for immunising with antigen, eg, using prime and boost immunisation protocols. A suitable protocol is RIMMS (see Hybridoma 1997 August; 16(4):381-9; “Rapid development of affinity matured monoclonal antibodies using RIMMS”; Kilpatrick et al). The Antibody-Generating Vertebrate comprises one or more transgenic antibody loci encoding said variable regions. Suitable non-human vertebrates (eg, mice or rats) are known in the art, and by way of example reference is made to W02011004192, U57501552, U.S. Pat. No. 6,673,986, U56130364, W02009/076464 and U56586251, the disclosures of which are incorporated herein by reference in their entirety.
The transgenic vertebrate has an immune system comprising proteins encoded by an immune gene repertoire (eg, an endogenous immune gene repertoire), said immune gene repertoire comprising said transgenic antibody loci and genes for immune system function (eg, providing an immune response to immunisation of the Antibody-Generating Vertebrate to the human target epitope). In one embodiment, the immune gene repertoire is an endogenous immune gene repertoire (ie, endogenous to the strain of non-human vertebrate used). For example, when the Antibody-Generating Vertebrate is a mouse having a genetic background of a mouse strain or cell selected from 129, C57B/6N, C57BL/6J, JM8, AB2.1, AB2.2, 12955, 12957 or 1295v, the mouse has an immune gene repertoire provided by said genetic background and said transgenic antibody loci. Thus, the skilled person can choose the appropriate starting strain, cell or species (eg, the same cell line or cells separated by no more than 5, 4, 3, 2 or 1 generation) for generating both the Antibody-Generating Vertebrate and Assay Vertebrate, and in doing so the desired immune gene repertoire is provided for both Vertebrates. In one embodiment, the immune gene repertoire is that of a wild-type 129, C57BL/6, B6 or other mouse strain or mouse cell disclosed herein, with the exception that the mouse genome comprises a transgenic IgH locus (optionally in homozygous state) comprising a human variable region (with human VH, D and JH gene segments) operatively connected upstream of (5′ of) a mouse constant region and optionally endogenous mouse heavy chain expression is inactive. In an example, the genome also comprises a transgenic Igk locus (optionally in homozygous state) comprising a human variable region (with human VK and JK gene segments) operatively connected upstream of (5′ of) a mouse constant region and optionally endogenous mouse kappa chain expression is inactive. In an example, the genome also comprises a transgenic IgX locus (optionally in homozygous state) comprising a human variable region (with human VX and JX gene segments) operatively connected upstream of (5′ of) a mouse constant region and optionally endogenous mouse lambda chain expression is inactive. Thus, in one embodiment, the vertebrate of the invention comprises a wild-type 129, C57BL, B6 or other mouse strain genome with the exception that mouse heavy chain (and kappa and/or lambda chain) expression has been inactivated, the genome comprises said transgenic Ig loci and an endogenous target knock-out (and optionally also a human target knock-in) as per the invention. Thus, endogenous regulatory and control mechanisms and proteins functional to produce and regulate immune responses in the vertebrate are retained for production of chimaeric antibody chains having human variable regions in response to immunisation.
The method of the invention comprises the step of providing a second transgenic non-human vertebrate (eg, mouse or rat) (Assay Vertebrate) that is a modified version of said first transgenic non-human vertebrate (ie, Antibody-Generating Vertebrate), wherein the Assay Vertebrate comprises (i) An immune system comprising substantially the same (or the same) immune gene repertoire as the Antibody-Generating Vertebrate; (ii) A genome comprising a knock-in of said human epitope, so that the Assay Vertebrate is capable of expressing an antigen bearing said human epitope; and (iii) Optionally wherein said genome has a knock-out of an endogenous non-human vertebrate epitope that is an orthologue or homologue of said human epitope, wherein said Assay Vertebrate cannot express an antigen bearing said endogenous epitope.
In one aspect, the Antibody-Generating Vertebrate and Assay Vertebrate genomes comprise said knock-out. This is useful, for example, when the endogenous orthologue/homologue epitope or target protein is structurally or epitopically similar to the human target or epitope. By knocking-out the orthologue/homologue expression, test antibodies of interest are generated only to the human epitope/target that is injected into the Antibody-Generating Vertebrate, and isolation of antibodies that are raised against the rthologue/homologue (ie, wrong target) is avoided. Advantageously, this target expression profile is reproduced in the Assay Vertebrate when the orthologue/homologue is knocked-out in that model too.
Thus, in an embodiment, the Antibody-Generating Vertebrate has a knock-out of the epitope that is an orthologue or homologue of said human epitope. Additionally or alternatively, in an embodiment, the Assay Vertebrate has a knock-out of the epitope that is an orthologue or homologue of said human epitope.
In one example, the Antibody-Generating Vertebrate comprises (a) A heavy chain locus comprising one or more human heavy chain V gene segments, one or more human heavy chain D gene segments and one or more human heavy chain JH gene segments upstream of an endogenous non-human vertebrate (eg, endogenous mouse or rat) constant region (eg, Cmu and/or Cgamma); (b) A kappa light chain locus comprising one or more human kappa chain V gene segments, and one or more human kappa chain Jk gene segments upstream of an endogenous non-human vertebrate (eg, endogenous mouse or rat) kappa constant region; and optionally (c) A lambda light chain locus comprising one or more human lambda chain V gene segments, and one or more human lambda chain JX gene segments upstream of a lambda constant region; and (d) Wherein the Vertebrate is capable of producing chimaeric test antibodies following rearrangement of said loci and immunisation with the human epitope or target.
Techniques for constructing non-human vertebrates and vertebrate cells whose genomes comprise a transgene, eg, a transgenic antibody locus containing human V, J and optionally D regions are well known in the art. For example, reference is made to W02011004192, U.S. Pat. No. 7,501,552, U.S. Pat. No. 6,673,986, U.S. Pat. No. 6,130,364, W02009/076464 and U.S. Pat. No. 6,586,251, the disclosures of which are incorporated herein by reference in their entirety.
In one aspect the transgenic antibody loci comprise human V, D and/or J coding regions placed under control of the host regulatory sequences or other (non-human, non-host) sequences. In one aspect reference to human V, D and/or J coding regions includes both human introns and exons, or in another aspect simply exons and no introns, which may be in the form of cDNA.
The host non-human vertebrate constant region herein is optionally the endogenous host wild-type constant region located at the wild type locus, as appropriate for the heavy or light chain. For example, the human heavy chain DNA is suitably inserted on mouse chromosome 12, suitably adjacent the mouse heavy chain constant region, where the vertebrate is a mouse.
In one optional aspect where the Vertebrate is a mouse, the insertion of the human antibody gene DNA, such as the human VDJ region is targeted to the region between the J4 exon and the Cμ locus in the mouse genome IgH locus, and in one aspect is inserted between coordinates 114,667,1090 and 114,665,190, suitably at coordinate 114,667,091. In one aspect the insertion of the human antibody DNA, such as the human light chain kappa V . . . 1 is targeted into mouse chromosome 6 between coordinates 70,673,899 and 70,675,515, suitably at position 70,674,734, or an equivalent position in the lambda mouse locus on chromosome 16.
In one aspect the host non-human vertebrate constant region for forming the chimaeric antibody may be at a different (non endogenous) chromosomal locus. In this case the inserted human antibody DNA, such as the human variable VDJ or V. Iregion(s) may then be inserted into the non-human genome at a site which is distinct from that of the naturally occurring heavy or light constant region. The native constant region may be inserted into the genome, or duplicated within the genome, at a different chromosomal locus to the native position, such that it is in a functional arrangement with the human variable region such that chimaeric antibodies of the invention can still be produced.
In one aspect the human antibody DNA is inserted at the endogenous host wild-type constant region located at the wild type locus between the host constant region and the host VDJ region.
In one aspect the inserted human IgH VDJ region comprises, in germline configuration, all of the V, D and J regions and intervening sequences from a human. Optionally, non-functional V and/or D and/or J gene segments are omitted. For example, VH which are inverted or are pseudogenes may be omitted.
In one aspect 800-1000 kb of the human IgH VDJ region is inserted into the non-human vertebrate IgH locus, and in one aspect a 940, 950 or 960 kb fragment is inserted. Suitably this includes bases 105,400,051 to 106,368,585 from human chromosome 14 (all coordinates refer to NCBI36 for the human genome, ENSEMBL Release 54 and NCBIM37 for the mouse genome, relating to mouse strain C57BL/6J).
In one aspect the inserted IgH human fragment consists of bases 105,400,051 to 106,368,585 from chromosome 14. In one aspect the inserted human heavy chain DNA, such as DNA consisting of bases 105,400,051 to 106,368,585 from chromosome 14, is inserted into mouse chromosome 12 between the end of the mouse J4 region and the Eli region, suitably between coordinates 114,667,091 and 114,665,190, suitably at coordinate 114,667,091.
In one aspect the inserted human kappa V.1 region comprises, in germline configuration, all of the V and J regions and intervening sequences from a human. Optionally, non-functional V and/or J gene segments are omitted. Suitably this includes bases 88,940,356 to 89,857,000 from human chromosome 2, suitably approximately 917 kb. In a further aspect the light chain VJ insert may comprise only the proximal clusters of V segments and J segments. Such an insert would be of approximately 473 kb.
In one aspect the human light chain kappa DNA, such as the human IgK fragment of bases 88,940,356 to 89,857,000 from human chromosome 2, is suitably inserted into mouse chromosome 6 between coordinates 70,673,899 and 70,675,515, suitably at position 70,674,734.
In one aspect the human lambda V.1 region comprises, in germline configuration, all of the V and J regions and intervening sequences from a human. Suitably this includes analogous bases to those selected for the kappa fragment, from human chromosome 2. Optionally, non-functional V and/or J gene segments are omitted.
All specific human antibody fragments described herein may vary in length, and may for example be longer or shorter than defined as above, such as 500 bases, 1 KB, 2K, 3K, 4K, 5 KB, 10 KB, 20 KB, 30 KB, 40 KB or 50 KB or more, which suitably comprise all or part of the human V(D)J region, whilst preferably retaining the requirement for the final insert to comprise human genetic material encoding the complete heavy chain region and light chain region, as appropriate, as described herein.
In one aspect the 3′ end of the last inserted human antibody sequence, generally the last human J sequence, is inserted less than 2 kb, preferably less than 1 KB from the human/non-human vertebrate (eg, human/mouse or human/rat) join region.
Optionally, the genome is homozygous at one, or both, or all three antibody loci (IgH, IgX and Igk).
In another aspect the genome may be heterozygous at one or more of the antibody loci, such as heterozygous for DNA encoding a chimaeric antibody chain and native (host cell) antibody chain. In one aspect the genome may be heterozygous for DNA capable of encoding 2 different antibody chains encoded by immunoglobulin transgenes of the invention, for example, comprising 2 different chimaeric heavy chains or 2 different chimaeric light chains.
In one embodiment in any configuration of the invention, the genome of the Vertebrate has been modified to prevent or reduce the expression of fully-endogenous antibody. Examples of suitable techniques for doing this can be found in W02011004192, U.S. Pat. No. 7,501,552, U.S. Pat. No. 6,673,986, U.S. Pat. No. 6,130,364, W02009/076464, EP1399559 and U.S. Pat. No. 6,586,251, the disclosures of which are incorporated herein by reference. In one embodiment, the non-human vertebrate VDJ region of the endogenous heavy chain immunoglobulin locus, and optionally VJ region of the endogenous light chain immunoglobulin loci (lambda and/or kappa loci), have been inactivated. For example, all or part of the non-human vertebrate VDJ region is inactivated by inversion in the endogenous heavy chain immunoglobulin locus of the mammal, optionally with the inverted region being moved upstream or downstream of the endogenous Ig locus. For example, all or part of the non-human vertebrate VJ region is inactivated by inversion in the endogenous kappa chain immunoglobulin locus of the mammal, optionally with the inverted region being moved upstream or downstream of the endogenous Ig locus. For example, all or part of the non-human vertebrate VJ region is inactivated by inversion in the endogenous lambda chain immunoglobulin locus of the mammal, optionally with the inverted region being moved upstream or downstream of the endogenous Ig locus. In one embodiment the endogenous heavy chain locus is inactivated in this way as is one or both of the endogenous kappa and lambda loci.
Additionally or alternatively, the Vertebrate has been generated in a genetic background which prevents the production of mature host B and T lymphocytes, optionally a RAG-1-deficient and/or RAG-2 deficient background. See U55859301 for techniques of generating RAG-1 deficient animals.
In one embodiment in any configuration of the invention, the human V, J and optional D regions are provided by all or part of the human IgH locus; optionally wherein said all or part of the IgH locus includes substantially the full human repertoire of IgH V, D and J regions and intervening sequences.
A suitable part of the human IgH locus is disclosed in W02011004192. In one embodiment, the human IgH part includes (or optionally consists of) bases 105,400,051 to 106,368,585 from human chromosome 14 (coordinates from NCBI36). Additionally or alternatively, optionally wherein the vertebrate is a mouse or the cell is a mouse cell, the human V, J and optional D regions are inserted into mouse chromosome 12 at a position corresponding to a position between coordinates 114,667,091 and 114,665,190, optionally at coordinate 114,667,091 (coordinates from NCBIM37, relating to mouse strain C57BL/6J).
In one embodiment of any configuration of a Vertebrate or cell (line) of the invention the lambdaantibody transgene comprises all or part of the human IgX locus including at least one human JX region and at least one human CX region, optionally CA6 and/or CA7. Optionally, the transgene comprises a plurality of human JX regions, optionally two or more of JA1, JA2, JA6 and JA7, optionally all of JA1, JA2, JA6 and JA7. The human lambda immunoglobulin locus comprises a unique gene architecture composed of serial J-C clusters. In order to take advantage of this feature, the invention in optional aspects employs one or more such human J-C clusters inoperable linkage with the constant region in the transgene, eg, where the constant region is endogenous to the non-human vertebrate or non-human vertebrate cell (line). Thus, optionally the transgene comprises at least one human JrCA cluster, optionally at least JA7-CA7. The construction of such transgenes is facilitated by being able to use all or part of the human lambda locus such that the transgene comprises one or more J-C clusters in germline configuration, advantageously also including intervening sequences between clusters and/or between adjacent J and C regions in the human locus. This preserves any regulatory elements within the intervening sequences which may be involved in VJ and/or JC recombination and which may be recognised by AID (activation-induced deaminase) or AID homologues.
Optionally, the lambda transgene comprises a human EX enhancer. Optionally, the kappa transgene comprises a human EK enhancer. Optionally, the heavy chain transgene comprises a heavy chain human enhancer.
In one embodiment of any configuration of the invention the heavy chain transgene comprises a plurality human IgH V regions, a plurality of human D regions and a plurality of human J regions, optionally substantially the full human repertoire of IgH V, D and J regions.
In one embodiment of any configuration of the invention, for the Antibody-Generating Vertebrate and/or Assay Vertebrate:—(i) the heavy chain transgene comprises substantially the full human repertoire of IgH V, D and J regions; and (ii) the vertebrate comprises substantially the full human repertoire of Igk V and J regions and/or substantially the full human repertoire of IgX V and J regions.
In an example, an exogenous regulatory element is knocked-in using the method. For example, it is knocked-in to replace an endogenous regulatory element.
In one aspect, the invention provides a method of producing a cell or a transgenic non-human organism (e.g., any non-human organism recited herein), the method comprising:
(a) carrying out the method of any in any configuration, aspect, example or embodiment of the invention to (i) knock out a target nucleotide sequence in the genome of a first cell and/or (ii) knock in an insert nucleotide sequence into the genome of a first cell, optionally wherein the insert sequence replaces a target sequence in whole or in part at the endogenous location of the target sequence in the genome; wherein the cell or a progeny thereof can develop into a non-human organism or cell; and
(b) developing the cell or progeny into a non-human organism or a non-human cell.
In an example, the organism or cell is homozygous for the modification (i) and/or (ii).
In an example, the cell is an ES cell (such as a mouse ES cell), iPS cell, totipotent cell or pluripotent cell. In an example, the cell is a non-human vertebrate cell or a human cell in vitro. In an example, the cell is a plant, yeast, insect or bacterial cell.
In an example, the cell or organism is a rodent (e.g., a mouse or rat) cell or a rabbit, bird, fish, chicken, non-human primate, monkey, pig, dog, Camelid, shark, sheep, cow or cat cell.
In an example, the target sequence is an endogenous sequence comprising all or part of a regulatory element or encoding all or part of a protein.
In an example, the insert sequence is a synthetic sequence; or comprises a sequence encoding all or part of a protein from a species other than the species from which the first cell is derived; or comprises a regulatory element from said first species. This is useful to combine genes with new regulatory elements.
In an example, the insert sequence encodes all or part of a human protein or a human protein subunit or domain. For example, the insert sequence encodes a cell membrane protein, secreted protein, intracellular protein, cytokine, receptor protein (e.g., Fc receptor protein, such as FcRn or a FcΥ receptor protein), protein of the human immune system or domain thereof (e.g., an Ig protein or domain, such as an antibody or TCR protein or domain, or a MHC protein), a hormone or growth factor.
The Invention Also Provides:—
A cell (e.g., an isolated or purified cell, e.g., a cell in vitro, or any cell disclosed herein) or a non-human organism (e.g., any organism disclosed herein, such as a mouse) whose genome comprises a modification comprising a non-endogenous nucleotide sequence flanked by endogenous nucleotide sequences, wherein the cell or organism is obtainable by the method of any configuration, aspect, example or embodiment of the invention, and wherein the non-endogenous sequence is flanked 3′ and/or 5′ by (e.g., within 20, 10, 5, 4, 3, 2 or 1 or less nucleotides of, or directly adjacent to) a Cas PAM motif; wherein the cell is not comprised by a human; and one, more or all of (a) to (d) applies (for example, (a); (b); (c); (d); (a) and (b); (a) and (c); (a) and (d); (b) and (c); (b) and (d); (c) and (d); (a), (b) and (c); (a), (b) and (d); (a), (c) and (d); (b), (c) and (d) or all of (a), (b), (c) and (d)).
(a) the genome is homozygous for the modification; or comprises the modification at one allele and is unmodified by Cas-mediated homologous recombination at the other allele;
(b) the non-endogenous sequence comprises all or part of a regulatory element or encodes all or part of a protein;
(c) the non-endogenous sequence is at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800 or 900 nucleotides, or at least 1, 2, 3, 5, 10, 20, 50 or 100 kb long:
(d) the non-endogenous sequence replaces an orthologous or homologous sequence in the genome.
The cell can be a human cell, or included in human tissue but not part of a human being. For example, the cell is a human cell in vitro.
In an example, the non-endogenous sequence is a human sequence.
In an example, the PAM motif is any PAM disclosed herein or comprises a sequence selected from CCN, TCN, TTC, AWG, CC, NNAGNN, NGGNG GG, NGG, WGG, CWT, CTT and GAA. For example, the motif is a Cas9 PAM motif. For example, the PAM is NGG. In another example, the PAM is GG.
In an example, there is a PAM motif no more than 10 nucleotides (e.g., 3 nucleotides) 3′ and/or 5′ of the non-endogenous sequence.
In an example, the PAM motif is recognised by a Streptococcus Cas9.
In an example, the cell or organism is a non-human vertebrate cell or a non-human vertebrate that expresses one or more human antibody heavy chain variable domains (and optionally no heavy chain variable domains of a non-human vertebrate species). For example, the organism is an Antibody-Generating Vertebrate or Assay Vertebrate disclosed in WO2013061078.
In an example, the cell or organism is a non-human vertebrate cell or a non-human vertebrate that expresses one or more human antibody kappa light chain variable domains (and optionally no kappa light chain variable domains of a non-human vertebrate species).
In an example, the cell or organism is a non-human vertebrate cell or a non-human vertebrate that expresses one or more human antibody lambda light chain variable domains (and optionally no kappa light chain variable domains of a non-human vertebrate species).
In an example, the non-endogenous sequence encodes a human Fc receptor protein or subunit or domain thereof (e.g., a human FcRn or FcΥ receptor protein, subunit or domain).
In an example, the non-endogenous sequence comprises one or more human antibody gene segments, an antibody variable region or an antibody constant region.
In an example, the insert sequence is a human sequence that replaces or supplements an orthologous non-human sequence.
The Invention Also Provides:—
A monoclonal or polyclonal antibody prepared by immunisation of a vertebrate (e.g., mouse or rat) of the invention (or produced by a method of the invention) with an antigen.
The Invention Also Provides:—
A method of isolating an antibody that binds a predetermined antigen, the method comprising:
(a) providing a vertebrate (optionally a mouse or rat) of the invention (or produced by a method of the invention);
(b) immunising said vertebrate with said antigen;
(c) removing B lymphocytes from the vertebrate and selecting one or more B lymphocytes expressing antibodies that bind to the antigen;
(d) optionally immortalising said selected B lymphocytes or progeny thereof, optionally by producing hybridomas therefrom; and
(e) isolating an antibody (e.g., an IgG-type antibody) expressed by the B lymphocytes.
In an example, the method comprises the step of isolating from said B lymphocytes nucleic acid encoding said antibody that binds said antigen; optionally exchanging the heavy chain constant region nucleotide sequence of the antibody with a nucleotide sequence encoding a human or humanised heavy chain constant region and optionally affinity maturing the variable region of said antibody; and optionally inserting said nucleic acid into an expression vector and optionally a host.
In an example, the method comprises making a mutant or derivative of the antibody produced by the method.
The invention provides the use of an isolated, monoclonal or polyclonal antibody described herein, or a mutant or derivative antibody thereof that binds said antigen, in the manufacture of a composition for use as a medicament.
The invention provides the use of an isolated, monoclonal or polyclonal antibody described herein, or a mutant or derivative antibody thereof that binds said antigen for use in medicine.
The invention provides a method of treating a patient in need thereof (e.g., a human patient), comprising administering a therapeutically effective amount of an isolated, monoclonal or polyclonal antibody described herein, or a mutant or derivative antibody thereof which binds an antigen.
The invention provides a nucleotide sequence encoding an antibody described herein, optionally wherein the nucleotide sequence is part of a vector. The invention also provides a host cell comprising said nucleotide sequence.
The invention provides a pharmaceutical composition comprising the antibody or antibodies described herein and a diluent, excipient or carrier.
The invention provides an ES cell, a non-human animal or a non-human blastocyst comprising an expressible genomically-integrated nucleotide sequence encoding a Cas endonuclease (e.g., a Cas9 or Cys4) and optionally an expressible genomically-integrated nucleotide sequence encoding a tracrRNA or a gRNA. For example, the ES cell is any ES cell type described herein.
In an example of the cell, animal or blastocyst, the endonuclease sequence is constitutively expressible.
In an example of the cell, animal or blastocyst, the endonuclease sequence is inducibly expressible.
In an example of the cell, animal or blastocyst, the endonuclease sequence is expressible in a tissue-specific manner in the animal or a progeny thereof, or in a non-human animal that is a progeny of the cell or blastocyst.
In an example, the cell, animal or blastocyst comprises one or more gRNAs or an expressible nucleotide sequence encoding a gRNA or a plurality of expressible nucleotide sequences each encoding a different gRNA.
The invention provides the use of the cell, animal or blastocyst in a method according to any configuration, aspect, embodiment or example of the invention.
An aspect provides an antibody produced by the method of the invention, optionally for use in medicine, e.g., for treating and/or preventing (such as in a method of treating and/or preventing) a medical condition or disease in a patient, e.g., a human.
An aspect provides a nucleotide sequence encoding the antibody of the invention, optionally wherein the nucleotide sequence is part of a vector. Suitable vectors will be readily apparent to the skilled person, e.g., a conventional antibody expression vector comprising the nucleotide sequence together in operable linkage with one or more expression control elements.
An aspect provides a pharmaceutical composition comprising the antibody of the invention and a diluent, excipient or carrier, optionally wherein the composition is contained in an intravenous (IV) container (e.g., and IV bag) or a container connected to an IV syringe.
An aspect provides the use of the antibody of the invention in the manufacture of a medicament for the treatment and/or prophylaxis of a disease or condition in a patient, e.g. a human.
In a further aspect, the invention relates to humanised antibodies and antibody chains produced according to the present invention, both in chimaeric and fully humanised form, and use of said antibodies in medicine. The invention also relates to a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier or other excipient.
Antibody chains containing human sequences, such as chimaeric human-non human antibody chains, are considered humanised herein by virtue of the presence of the human protein coding regions region. Fully human antibodies may be produced starting from DNA encoding a chimaeric antibody chain of the invention using standard techniques.
Methods for the generation of both monoclonal and polyclonal antibodies are well known in the art, and the present invention relates to both polyclonal and monoclonal antibodies of chimaeric or fully humanised antibodies produced in response to antigen challenge in non-human vertebrates of the present invention.
In a yet further aspect, chimaeric antibodies or antibody chains generated in the present invention may be manipulated, suitably at the DNA level, to generate molecules with antibody-like properties or structure, such as a human variable region from a heavy or light chain absent a constant region, for example a domain antibody; or a human variable region with any constant region from either heavy or light chain from the same or different species; or a human variable region with a non-naturally occurring constant region; or human variable region together with any other fusion partner. The invention relates to all such chimaeric antibody derivatives derived from chimaeric antibodies identified according to the present invention.
In a further aspect, the invention relates to use of animals of the present invention in the analysis of the likely effects of drugs and vaccines in the context of a quasi-human antibody repertoire.
The invention also relates to a method for identification or validation of a drug or vaccine, the method comprising delivering the vaccine or drug to a mammal of the invention and monitoring one or more of: the immune response, the safety profile; the effect on disease.
The invention also relates to a kit comprising an antibody or antibody derivative as disclosed herein and either instructions for use of such antibody or a suitable laboratory reagent, such as a buffer, antibody detection reagent.
It will be understood that particular embodiments described herein are shown by way of illustration and not as limitations of the invention. The principal features of this invention can be employed in various embodiments without departing from the scope of the invention. Those skilled in the art will recognize, or be able to ascertain using no more than routine study, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the claims. All publications and patent applications mentioned in the specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.” Throughout this application, the term “about” is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.
As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps
The term “or combinations thereof” as used herein refers to all permutations and combinations of the listed items preceding the term. For example, “A, B, C, or combinations thereof is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing with this example, expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth. The skilled artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context.
Any part of this disclosure may be read in combination with any other part of the disclosure, unless otherwise apparent from the context.
All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

REFERENCES

1. Cong L, Ran F A, Cox D, Lin S, Barretto R, Habib N, Hsu P D, Wu X, Jiang W, Marrafflini L A et al: Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339(6121):819-823.
2. Wang H, Yang H, Shivalila C S, Dawlaty M M, Cheng A W, Zhang F, Jaenisch R: One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 2013, 153(4):910-918.
3. Mali P, Yang L, Esvelt K M, Aach J, Guell M, DiCarlo J E, Norville J E, Church G M: RNA-guided human genome engineering via Cas9. Science 2013, 339(6121):823-826.
4. Gaj T, Gersbach C A, Barbas C F, 3rd: ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 2013, 31(7):397-405.
5. Perez-Pinera P, Ousterout D G, Gersbach C A: Advances in targeted genome editing. Curr Opin Chem Biol 2012, 16(3-4):268-277.
6. Shah S A, Erdmann S, Mojica F J, Garrett R A: Protospacer recognition motifs: Mixed identities and functional diversity. RNA Biol 2013, 10(5).
7. Haurwitz R E, Sternberg S H, Doudna J A: Csy4 relies on an unusual catalytic dyad to position and cleave CRISPR RNA. EMBO J 2012, 31(12):2824-2832.
8. Yusa K, Zhou L, Li M A, Bradley A, Craig N L: A hyperactive piggyBac transposase for mammalian applications. Proc Natl Acad Sci USA 2011, 108(4):1531-1536.
9. Qiao J, Oumard A, Wegloehner W, Bode J: Novel tag-and-exchange (RMCE) strategies generate master cell clones with predictable and stable transgene expression properties. J Mol Biol 2009, 390(4):579-594.
10. Oumard A. Qiao J. Jostock T, Li J, Bode J: Recommended Method for Chromosome Exploitation: RMCE-based Cassette-exchange Systems in Animal Cell Biotechnology. Cytotechnology 2006, 50(1-3):93-108.

The present invention is described in more detail in the following non limiting exemplification.
Some embodiments of the technology described herein can be defined according to any of the following numbered paragraphs:

1. A method of nucleic acid recombination, the method comprising
- (a) using Cas endonuclease-mediated nucleic acid cleavage to create first and second breaks in a nucleic acid strand, thereby creating 5′ and 3′ cut ends and a nucleotide sequence between the ends;
- (b) using homologous recombination to delete the nucleotide sequence; and
- (c) optionally obtaining the nucleic acid strand modified in step (b) or a progeny nucleic strand comprising the deletion.
2. The method of paragraph 1, wherein the deleted sequence comprises a regulatory element or encodes all or part of a protein.
3. The method of paragraph 2, wherein the deleted sequence comprises a protein subunit or domain.
4. The method of any one of paragraphs 1 to 3, wherein the deletion of step (b) is at least 20 nucleotides long.
5. The method of paragraph 1, further comprising a step of inserting a nucleotide sequence between the cut ends in (a).
6. The method of paragraph 5, wherein the insert nucleotide sequence comprises a PAM motif.
7. The method of paragraph 5 or paragraph 6, wherein the insert sequence is at least 10 nucleotides long.
8. The method of any one of paragraphs 5 to 7, wherein recombinase recognition sequences are used to insert the nucleotide sequence, e.g. loxP and/or a mutant lox, e.g., lox2272 or lox511; or frt.
9. The method of any one of paragraphs 5 to 7, wherein homologous recombination is used to insert the insert nucleotide sequence.
10. The method of any one of paragraphs 5 to 9, wherein the method is carried out in a cell and the insert sequence replaces an orthologous or homologous sequence in the cell.
11. The method of any preceding paragraph, wherein step (c) is performed by isolating a cell comprising the modified first strand, or by obtaining a non-human vertebrate in which the method has been performed or a progeny thereof.
12. The method of any preceding paragraph, wherein the nucleic acid strand or the first strand is a DNA strand.
13. The method of any preceding paragraph wherein the product of the method comprises a nucleic acid strand comprising a PAM motif 3′ of the insertion or deletion.
14. The method of paragraph 13, wherein the PAM motif is no more than 10 nucleotides 3′ of the deletion.
15. The method of any preceding paragraph, wherein step (b) is performed by carrying out homologous recombination between an incoming nucleic acid comprising first and second homology arms, wherein the homology arms are substantially homologous respectively to a sequence extending 5′ from the 5′ end and a sequence extending 3′ from the 3′ end.
16. The method of paragraph 15, wherein step (b) is performed by carrying out homologous recombination between an incoming nucleic acid comprising an insert nucleotide sequence flanked by the first and second homology arms, wherein the insert nucleotide sequence is inserted between the 5′ and 3′ ends.
17. The method of paragraph 15 or paragraph 16, wherein each homology arm is at least 20 contiguous nucleotides long.
18. The method of any one of paragraphs 15 to 17, wherein the first and/or second homology arm comprises a recombinase recognition sequence, such as a PAM motif.
19. The method of any preceding paragraph, wherein Cas endonuclease-mediated cleavage is used in step (a) and is carried out by recognition of a GG or NGG PAM motif.
20. The method of paragraph 19, wherein a nickase is used to cut in step (a), and optionally, wherein the nickase is a Cas nickase.
21. The method of any preceding paragraph, wherein the method is carried out in a cell, e.g. a eukaryotic cell.
22. The method of paragraph 21, wherein the method is carried out in a mammalian cell, e.g. rodent or mouse cell, e.g. a rodent (e.g., mouse) ES cell or zygote.
23. The method of any preceding paragraph, wherein the method is carried out in a non-human mammal, e.g. a mouse or rat or rabbit.
24. The method of any preceding paragraph, wherein each cleavage site is flanked by PAM motif (e.g., a NGG or NGGNG sequence, wherein N is any base and G is a guanine).
25. The method of any preceding paragraph, wherein the 3′ end is flanked 3′ by a PAM motif.
26. The method of any preceding paragraph, wherein step (a) is carried out by cleavage in one single strand of dsDNA.
27. The method of any preceding paragraph, wherein step (a) is carried out by combining in a cell the nucleic acid strand, a Cas endonuclease, a crRNA and a tracrRNA (e.g., provided by one or more gRNAs) for targeting the endonuclease to carry out the cleavage, and optionally an insert sequence for homologous recombination with the nucleic acid strand.
28. The method of any preceding paragraph, wherein step (b) is performed by carrying out homologous recombination with an incoming nucleic acid comprising first and second homology arms, wherein the homology arms are substantially homologous respectively to a sequence extending 5′ from the 5′ end and a sequence extending 3′ from the 3′ end, wherein the second homology arm comprises a PAM sequence such that homologous recombination between the second homology arm and the sequence extending 3′ from the 3′ end produces a sequence comprising a PAM motif in the product of the method.
29. A method of sequential endonuclease-mediated homology directed recombination (sEHDR) comprising carrying out the method of any preceding paragraph a first time and a second time, wherein the product of the first time is used for endonuclease-mediated cleavage the second time, whereby either (i) first and second nucleotide sequences are deleted the first time and the second times respectively; (ii) a first nucleotide sequence is deleted the first time and a second nucleotide sequence is inserted the second time; (iii) a first nucleotide sequence is inserted the first time and a second nucleotide sequence is deleted the second time; or (iv) first and second nucleotide sequences are inserted the first and second times respectively; optionally wherein the nucleic acid strand modification the second time is within 20 or less nucleotides of the nucleic acid strand modification the first time.
30. The method of paragraph 29, wherein the first time is carried out according to paragraph 1, wherein the incoming nucleic acid comprises no sequence between the first and second homology arms, wherein sequence between the 5′ and 3′ ends is deleted by homologous recombination; and/or the second time is carried out according to paragraph 1, wherein step (b) is performed by carrying out homologous recombination between an incoming nucleic acid comprising first and second homology arms, wherein the homology arms are substantially homologous respectively to a sequence extending 5′ from the 5′ end and a sequence extending 3′ from the 3′ end, wherein the incoming nucleic acid comprises no sequence between the first and second homology arms such that sequence between the 5′ and 3′ ends is deleted by homologous recombination; optionally wherein the second arm comprises a PAM motif such that the product of the second time comprises a PAM motif for use in a subsequent Cas endonuclease-mediated method according to any one of paragraphs 1 to 28.
31. The method of any preceding paragraph, wherein step (a) is carried out using Cas endonuclease-mediated cleavage and a gRNA comprising a crRNA and a tracrRNA.
32. The method of paragraph 27 or 31, wherein the crRNA has the structure 5′-X-Y-3′, wherein X is an RNA nucleotide sequence (optionally at least 5 nucleotides long) and Y is an RNA sequence comprising a nucleotide motif that hybridises with a motif comprised by the tracrRNA, wherein X is capable of hybridising with a nucleotide sequence extending 5′ from the desired site of the 5′ cut end.
33. The method of paragraph 27, 31 or 32, wherein Y is 5′-N₁UUUUAN₂N₃GCUA-3′, wherein each of N_1-3is a A, U, C or G and/or the tracrRNA comprises the sequence (in 5′ to 3′ orientation) UAGCM₁UUAAAAM₂, wherein M₁is spacer nucleotide sequence and M₂is a nucleotide.
34. A method of nucleic acid recombination, the method comprising providing dsDNA comprising first and second strands and
- (a) using Cas endonuclease-mediated nucleic acid cleavage to create a cut end in the first strand 3′ of a PAM motif;
- (b) using Cas endonuclease-mediated nucleic acid cleavage to create a cut in the second strand at a position which corresponds to a position 3′ of the cut end of the strand of part (a), which cut is 3′ of the PAM motif;
- (c) providing a first gRNA which hybridises with a sequence 5′ to the PAM motif in the strand of part (a)
- (d) providing a second gRNA which hybridises with a sequence 5′ to the PAM motif in the strand of part (b)
  wherein the nucleic acid strands of part (a) and part (b) are repaired to produce a deletion of nucleic acid between the cuts.
35. A method of producing a cell or a transgenic non-human organism, the method comprising:
- (a) carrying out the method of any preceding paragraph to (i) knock out a target nucleotide sequence in the genome of a first cell and/or (ii) knock in an insert nucleotide sequence into the genome of a first cell, optionally wherein the insert sequence replaces a target sequence in whole or in part at the endogenous location of the target sequence in the genome; wherein the cell or a progeny thereof can develop into a non-human organism or cell; and
- (b) developing the cell or progeny into a non-human organism or a non-human cell.
36. The method of paragraph 35, wherein the organism or cell is homozygous for the modification (i) and/or (ii).
37. The method of paragraph 35 or 36, wherein the cell is an ES cell, iPS cell, totipotent cell or pluripotent cell, optionally a rodent (e.g., a mouse or rat) cell.
38. The method of any one of paragraphs 35 to 37, wherein the target sequence is an endogenous sequence comprising all or part of a regulatory element or encoding all or part of a protein.
39. The method of any one of paragraphs 35 to 38, wherein the insert sequence is a synthetic sequence; or comprises a sequence encoding all or part of a protein from a species other than the species from which the first cell is derived; or comprises a regulatory element from said first species.
40. The method of paragraph 39, wherein the insert sequence encodes all or part of a human protein or a human protein subunit or domain.
41. A cell or a non-human organism whose genome comprises a modification comprising a non-endogenous nucleotide sequence flanked by endogenous nucleotide sequences, wherein the cell or organism is obtainable by the method of any one of paragraphs 26 to 40 and wherein the non-endogenous sequence is flanked 3′ by a Cas PAM motif; wherein the cell is not comprised by a human: and one, more or all of (a) to (d) applies
- (a) the genome is homozygous for the modification; or comprises the modification at one allele and is unmodified by Cas-mediated homologous recombination at the other allele;
- (b) the non-endogenous sequence comprises all or part of a regulatory element or encodes all or part of a protein;
- (c) the non-endogenous sequence is at least 20 nucleotides long;
- (d) the non-endogenous sequence replaces an orthologous or homologous sequence in the genome.
42. The cell or organism of paragraph 41, wherein the non-endogenous sequence is a human sequence.
43. The cell or organism of paragraph 41 or 42, wherein the PAM motif comprises a sequence selected from CCN, TCN, TTC, AWG, CC, NNAGNN, NGGNG GG, NGG, WGG, CWT, CTT and GAA.
44. The cell or organism of any one of paragraphs 41 to 43, wherein there is a PAM motif no more than 10 nucleotides (e.g., 3 nucleotides) 3′ of the non-endogenous sequence.
45. The cell or organism of any one of paragraphs 41 to 44, wherein the PAM motif is recognised by a Streptococcus Cas9.
46. The cell or organism of any one of paragraphs 41 to 45, which is a non-human vertebrate cell or a non-human vertebrate that expresses one or more human antibody heavy chain variable domains (and optionally no heavy chain variable domains of a non-human vertebrate species).
47. The cell or organism of any one of paragraphs 41 to 46, which is a non-human vertebrate cell or a non-human vertebrate that expresses one or more human antibody kappa light chain variable domains (and optionally no kappa light chain variable domains of a non-human vertebrate species) or that expresses one or more human antibody lambda light chain variable domains (and optionally no kappa light chain variable domains of a non-human vertebrate species).
48. The cell or organism of any paragraph 46 or paragraph 47, wherein the non-endogenous sequence encodes a human Fc receptor protein or subunit or domain thereof (e.g., a human FcRn or FcΥ receptor protein, subunit or domain).
49. The cell or organism of any one of paragraphs 41 to 48, wherein the non-endogenous sequence comprises one or more human antibody gene segments, an antibody variable region or an antibody constant region.
50. The cell or organism of any one of paragraphs 41 to 49, wherein the insert sequence is a human sequence that replaces or supplements an orthologous non-human sequence.
51. A monoclonal or polyclonal antibody prepared by immunisation of a vertebrate (e.g., mouse or rat) according to any one of paragraphs 41 to 50 with an antigen.
52. A method of isolating an antibody that binds a predetermined antigen, the method comprising
- (a) providing a vertebrate (optionally a mouse or rat) according to any one of paragraphs 41 to 51;
- (b) immunising said vertebrate with said antigen;
- (c) removing B lymphocytes from the vertebrate and selecting one or more B lymphocytes expressing antibodies that bind to the antigen;
- (d) optionally immortalising said selected B lymphocytes or progeny thereof, optionally by producing hybridomas therefrom; and
- (e) isolating an antibody (e.g., and IgG-type antibody) expressed by the B lymphocytes.
53. The method of paragraph 52, comprising the step of isolating from said B lymphocytes nucleic acid encoding said antibody that binds said antigen; optionally exchanging the heavy chain constant region nucleotide sequence of the antibody with a nucleotide sequence encoding a human or humanised heavy chain constant region and optionally affinity maturing the variable region of said antibody; and optionally inserting said nucleic acid into an expression vector and optionally a host.
54. The method of paragraph 52 or 53, further comprising making a mutant or derivative of the antibody produced by the method of paragraph 52 or 53.
55. The use of an isolated, monoclonal or polyclonal antibody according to paragraph 51, or a mutant or derivative antibody thereof that binds said antigen, in the manufacture of a composition for use as a medicament.
56. The use of an isolated, monoclonal or polyclonal antibody according to paragraph 51, or a mutant or derivative antibody thereof that binds said antigen for use in medicine.
57. A nucleotide sequence encoding an antibody of paragraph 51, optionally wherein the nucleotide sequence is part of a vector.
58. A pharmaceutical composition comprising the antibody or antibodies of paragraph 51 and a diluent, excipient or carrier.
59. An ES cell, a eukaryotic cell, a mammalian cell, a non-human animal or a non-human blastocyst comprising an expressible genomically-integrated nucleotide sequence encoding a Cas endonuclease.
60. The cell, animal or blastocyst of paragraph 59, wherein the endonuclease sequence is constitutively expressible.
61. The cell, animal or blastocyst of paragraph 59, wherein the endonuclease sequence is inducibly expressible.
62. The cell, animal or blastocyst of paragraph 59, 60 or 61, wherein the endonuclease sequence is expressible in a tissue-specific or stage-specific manner in the animal or a progeny thereof, or in a non-human animal that is a progeny of the cell or blastocyst.
63. The cell or animal of paragraph 62, wherein the cell is a non-human embryo cell or the animal is a non-human embryo, wherein the endonuclease sequence is expressible or expressed in the cell or embryo.
64. The cell of animal paragraph 63, wherein the endonuclease is operatively linked to a promoter selected from the group consisting of an embryo-specific promoter (e.g., a Nanog promoter, a Pou5fl promoter or a SoxB promoter).
65. The cell, animal or blastocyst of any one of paragraphs 61 to 64, wherein the Cas endonuclease is at a Rosa 26 locus, and is optionally operably linked to a Rosa 26 promoter.
66. The cell, animal or blastocyst of any one of paragraphs 59 to 62, wherein the Cas endonuclease sequence is flanked 5′ and 3′ by transposon elements (e.g., inverted piggyBac terminal elements) or site-specific recombination sites (e.g., loxP and/or a mutant lox, e.g., lox2272 or lox511; or frt).
67. The cell, animal or blastocyst of paragraph 66, comprising one or more restriction endonuclease sites between the Cas endonuclease sequence and a transposon element.
68. The cell, animal or blastocyst of any one of paragraphs 59 to 67 comprising one or more gRNAs.
69. The cell, animal or blastocyst of paragraph 66, 67 or 68, wherein the gRNA(s) are flanked 5′ and 3′ by transposon elements (e.g., inverted piggyBac terminal elements) or site-specific recombination sites (e.g., loxP and/or a mutant lox, e.g., lox2272 or lox511; or frt).
70. Use of the cell, animal or blastocyst of any one of paragraphs 59 to 69 in a method according to any one of paragraphs 1 to 50.

EXAMPLES

Example 1

Precise DNA Modifications

(a) Use of Nickase for HDR
It has been reported that the Cas9 nuclease can be converted into a nickase through the substitution of an aspartate to alanine (D10A) in the RuvCl domain of SpCas9 (Cong et al.). It is noteworthy that DNA single-stranded breaks are preferentially repaired through the HDR pathway. The Cas9 D10A nickase, when in a complex with mature crRNA:tracrRNA, can specifically induce DNA nicking at a precise location. With this in mind, we propose extending the application of the CRISPR/Cas system by creating a nick in a given location in a genome using Cas9 D10A nickase and then exploiting the HDR pathway for inserting a single-stranded DNA fragment (endogenous or exogenous) which will contain DNA homology (typically for recombineering, 50 bp is enough for efficient recombination) flanking the nicked DNA junction to bring in and insert a given DNA in a precision location; similar size homology will be used with the present example (FIG. 1A). Guide RNA (gRNA) will be design individually per target protospacer sequence or incorporated into a single CRISPR array encoding for 2 or more spacer sequences allowing multiplex genome editing from a single CRSPR array.

(b) Example of Precise DNA Deletion

To demonstrate precise deletion using Cas9 in association with gRNA and no targeting vector or donor DNA, we designed two gRNA within a gene, which were 55 bp apart. The two gRNA were on opposite DNA strands as shown in FIG. 9.
Mouse ES cells were transfected with human Cas9 nuclease and the two gRNAs. The transfection procedure was carried out as detailed above but the resulting clones were not selected. The transfected ES clones were genotyped using oligos pair spanning the two gRNA (Primer 1 & 2) to detect specific 55 bp deletion (FIG. 10).
Most of the clones did not show the specific 55 bp deletion, however, clones were clearly identified which contained the defined deletion. Out of the 384 clones analysed, approximately 4% of the clones were found to contain the specific 55 bp deletion. Note: Not all the genotyping data is shown. The clones containing the specific 55 bp deletion were further analysed by sequencing the PCR products as a final confirmation (data not shown). Furthermore, where we saw the specific deletion, we observed both alleles to contain the specific deletion. These data confirmed that when two gRNAs are used, a precise and specific deletion can be made without the requirement for a targeting vector. However we can assume the efficiency of the define deletion can be greatly enhance using the two gRNA combination together with a targeting vector or a donor DNA fragment containing homology arms flanking the intended deletion region.

(c) Alternative Methodology for Deletion of DNA

In a separate setting, two gRNA or a single CRISPR array encoding multiple spacer sequence can be designed flanking a gene or a region of interest and with the association of Cas9 D10A nickase, two separate single-stranded breaks can be induced. This, in association with a single-stranded DNA fragment containing DNA homology to the 5′ breakpoint junction of the first DNA nick, and DNA homology to the 3′ breakpoint junction of the second nick, the region in between the two single stranded DNA nick can be precisely deleted (FIG. 2A).

(d) Alternative Methodology for Replacement of DNA

In an another setting, two separate gRNA or a multiplex single CRISPR array can be designed flanking a gene or a region of interest and with the association of Cas9 D10A nickase two separate single-stranded breaks can be induced. In this case the intruding single stranded DNA fragment (or double stranded DNA) can contain DNA sequence from either endogenous or exogenous source containing sequence for a known gene, regulatory element promoter etc. This single-stranded DNA fragment (or double stranded DNA) can be brought together to replace the DNA region of interest flanked by DNA nick by arming it with DNA homology from the 5′ region of the first nick and 3′ region from the second nick (FIG. 3A). Due to the high efficiency of the CRISPR/Cas system to cleave DNA, the above proposed strategy will not require introduction of any selection marker, thus creating exact seamless genome editing in a precise and defined manner. As an option, a selection marker can be included flanked by PiggyBac LTRs to allow for the direct selection of correctly modified clones. Once the correct clones have been identified, the selection marker can be removed conveniently through the expression of hyperactive piggyBac transposase (Yusa K., Zhou L., Li M. A., Bradley A., Craig N. L.: A hyperactive piggyBac transposase for mammalian applications., Proc. Natl. Acad. Sci. USA, 2011, 108(4):1531-1536). Furthermore, the above approaches can be applied to ES cells, mammalian cells, yeast cells, bacterial cells, plant cells as well as directly performing in zygotes to expedite the process of homozygeous genome engineering in record time. It would be also possible to multiplex this system to generate multiple simultaneous DNA insertions (KI), deletions (KO) and the sequential deletion and insertion (KO→KI).

(e) Example of DNA Deletion and Insertion in a Predefined Location (KO→KI)

To demonstrate a desired DNA region can be manipulated using Cas9, a single guide RNA (gRNA) was selected at a desired region (Exon 1 of gene X) FIG. 7. A targeting vector was also constructed, which contained approximately 300 bp homology arms (5′ and 3′ HA) flanking the gRNA. The homology arms will hybridise exactly in the defined region and thus delete a 50 bp region, which is intended for deletion. The targeting vector also allows for the insertion of any DNA sequence of interest. In this proof of concept experiment, we included an approximate 1.6 kb PGK-puromycin cassette. The guide RNA (0.5 ug) together with the targeting vector (1 ug) and Cas9 nuclease vector (1 ug) was transfected into ES cells and 96 clones were picked after selection on puromycin using the protocol described above. Note. As a test for targeting efficiency, we compared linear verses circular targeting vector. Also as a negative control, we did the same experiment using no Cas9 vector to compare targeting efficiency via homologous recombination with and without Cas9 expression.
All the selected clones were puromycin resistant and the % clones picked from each of the four transfections were genotyped using the oligo pair HAP341/HAP334. Correctly targeted clones yielded an 880 bp PCR product. The resulting genotyping data is shown in FIG. 8.
From the genotyping data of this experiment, it can be seen that Cas9 mediated double stranded DNA break greatly improves homologous recombination efficiency of the targeting vector as 62% and 49% of the clones using circular or linear targeting vector respectively were correctly targeted verse only a single targeted clone using circular targeting vector when no Cas9 was used. Also it can be seen from this data that the circular targeting vector yielded slightly better targeting efficiency than when linear vector was used but a general conclusion cannot be drawn from this single experiment but to say, both circular and linear targeting vector yielded greatly improved targeting efficiency when associated with Cas9 and a specific guide RNA. This experiment also demonstrated that using Cas9 to create a define DNA breakage can be used to delete out a defined DNA region and subsequently insert any DNA fragment of interest

Example 2

Recycling PAM for Sequential Insertions or Deletions

In certain settings it may be useful to edit a genome by chromosome walking. Using any of the three examples outlined above, it could be possible to carry out sequential genome editing in a stepwise fashion whereby the PAM sequence used in a previous round of CRISPR/Cas mediated genome editing, can be re-used to carry out multiple rounds of genome editing such as deletions, insertions or the simultaneous deletion and insertion. An example of sequential deletion whereby the PAM sequence from the previous genome editing step is recycled is shown in FIG. 4A. Using the PAM recycling approach, it is possible to carry out sequential insertions as well as sequential simultaneous deletion and insertion.
The PAM sequence us recycled through reintroducing it via homologous recombination and as part of the homology arm. The PAM sequence can be optionally accompanied by a unique guide-RNA sequence creating a novel site within the host genome for further round of genome editing

Example 3

Rapid Insertion of Lox Sites Using CRISPR/Cas System

Targeting efficiency using conventional homologous recombination methods in ES cells is low. In a different setting, the CRISPR/Cas system can be used to rapidly and efficiently introduce lox sites or other recombinase recognition sequence such as Frt in a defined location to act as a landing pad for genome editing using recombinase mediated cassette exchange (RMCE) (Qiao J., Oumard A., Wegloehner W., Bode J.: Novel tag-and-exchange (RMCE) strategies generate master cell clones with predictable and stable transgene expression properties., J. Mol. Biol., 2009, 390(4):579-594; and Oumard A., Qiao J., Jostock T., Li J., Bode J.: Recommended Method for Chromosome Exploitation: RMCE-based Cassette-exchange Systems in Animal Cell Biotechnology., Cytotechnology 2006, 50(1-3):93-108). Once the lox sites are introduced into the genome, inversion, deletion or cassette exchange to delete and introduce DNA fragment varying in size at this site can be efficiently conducted via expression of Cre recombinase. An example of CRISPR/Cas mediated lox insertion followed by RMCE is shown in FIG. 5A. The RMCE step can be used to invert the region flanked by lox site or to delete this region as well as to simultaneously delete and insert DNA of interest in this region. Furthermore, the RMCE step can be adapted for carrying out multiple sequential rounds of RMCE (sRMCE).

Example 4A

Reference is made to FIG. 6A. A piggyBac transposon harbouring a PGK promoter-driven loxP/mutant lox-flanked neo^Rgene is targeted into an ES cell genome by standard homologous recombination. The targeted clones can be selected by G418. This provides a landing pad for the following recombinase-mediated cassette exchange (RMCE). Such an ES clone can be used a parental cells for any modification further. A cassette containing the loxP/mutant lox-flanked promoterless PuroΔTK-T2A-Cas9 and U6 polymerase III promoter-driven guide RNA (gRNA) genes are inserted into the landing pad through transient cre expression. The gRNA genes can be one or more than one which target to the same gene or different genes. The inserted clones can be selected with puromycin and confirmed by junction PCRs. During the selection, the expression of Cas9 and gRNAs from the inserted cassette results in more efficient gene targeting or modification than transient expression of the Cas9 and gRNA can achieve. Following 4-6 day selection, the whole modified cassette is excised by the transient expression of piggyBac transposase (PBase). The final ES cell clones would not contain any Cas9 or gRNA sequence. The clones with homozygous modified genes would be confirmed by PCR and sequence.
The main feature of this invention is to control the Cas9 and gRNA expression in certain time to be sufficient to generate efficient targeting rates.

Example 4B

Single Copy Cas9 Expression

As detailed in example 6, to demonstrate the single and stable expression of Cas9 from within the chromosome of a cell, we targeted a landing pad vector into Rosa26 allele on chromosome 6. DNA homology arms were used to target the landing pad vector in between exons 2 and 3 of Rosa26. The landing pad vector was targeted into ES cells using procedure described above. The transfected ES clones were selected on G418 and genotyped for correct targeting (FIG. 11) by PCR amplifying the 5′ and 3′ homology arm junctions.
Targeting of the landing pad yielded many targeted ES clones. A selection of the targeted clones were used to insert a DNA cassette containing Cas9 nuclease linked to Puro-delta-tk via a T2A sequence into the targeted landing pad via RMCE, which involved the expression of Cre recombinase. The corresponding loxP and lo2272 sites within both the landing pad and the incoming vector ensured correct orientation of insertion. Since the landing pad contained a geneless PGK promoter, correct insertion of the incoming vector DNA containing Cas9, activated expression of puromycin and thus clones were positively selected on puromycin. Non-specific targeting of this DNA cassette will not yield puromycin resistant clones due to the absence of a promoter driving the transcription of the promoterless puromycin gene in the inserted DNA cassette. The initial Cas9 vector inserted into the landing pad did not contain any guide RNA sequence. The puromycin resistant ES clones were genotyped by PCR for the correct insertion of Cas9 (FIG. 12).
As expected owing to the positive selection, most of the clones genotyped for insertion of the Cas9 vector were correctly targeted via RMCE based on the PCR genotyping results. Two of the correct clones (KHK1.6 Z2-24-27 and KHK1.10Z2-25-4 referred to as positive Z clones) which now contain the single copy Cas9 integrated into the Rosa26 gene as a single copy were used to test whether the Cas9 expression was sufficient enough to induce Cas9 mediated genome editing. Into the two positive Z clones, guide RNA against a gene referred to as gene Y was transfected using procedure described above. Following transfection and expansion of the resulting ES clones, 36 individual clones were isolated from each transfection and analysed initially by PCR using oligo flanking the guide RNA (FIG. 13).
Most of the clones yielded a PCR product of size equivalent to the positive control PCR where DNA from mouse AB2.1 ES cells was used. However, it can be seen clearly that some clones yielded a PCR product distinctively smaller than that of the positive control suggesting these clones contain a significant deletion via indel. To verify this and to check whether the rest of the PCR products though similar in size to the positive control did not contain indels, all the PCR products were purified using Qiagen gel extraction kit and analysed by sequencing. The sequencing data confirmed significant deletion for those PCR products that yielded shorter products than the positive control. It also highlighted, some of the other clones with similar PCR product size to the positive control to contain indels, which included various combinations of insertion and deletion (Sequencing data not shown). Out of the clones analysed, 18% of them contained an indel. These data clearly demonstrated that a single copy expression of Cas9 can be used to carry out genome editing and these clones can now be used as a Cas9 host cells for carrying out a multitude of genome editing. These ES clones are now being used to generate transgenic mouse lines whereby we can carry out a one-step genome editing by injecting only guide mRNA directly into zygotes without the requirement for transcribing Cas9 mRNA to simplify the one-step genome editing protocol.

Example 5(A)

Methodology

A: Reconstructing CRISPR/Cas Vector System (Nuclease)

The CRISPR/Cas genome editing system has been reconstructed in vitro and exemplified in mouse embryonic stem cells using vector pX330 containing humanised S. pyogenes (hSpCsn1) (Cong et al.). The CRISPR/Cas system can be reconstructed as described in Cong et al using synthetic DNA strings and DNA assembly. In the present example, the entire DNA assembly would constitute a 6006 bp fragment containing 45 bp homology to pBlueScript KS+ vector 5′ to the EcoRV cutting site, Human U6 promoter, two BbsI restriction sites for cloning in the spacer sequence which fuses to a chimeric guided RNA sequence, chicken beta-actin promoter with 3 FLAG, nuclear localisation signal (NLS) followed by hSpCsn1 sequence and another NLS, bGH polyA, inverted terminal repeat sequence and finally another 45 bp homology to pBlueScript KS+ 3′ to the EcoRV cutting site. This 6006 bp stretch of DNA will be synthesized as 7 individual DNA fragments where each fragment will have a 45 bp overlap to the adjacent DNA fragment to allow DNA assembly. The DNA sequence of these fragments is shown below in the order of assembly

Fragment 1A (1340 bp)

(SEQ ID NO: 7)

GGTACCGGGCCCCCCCTCGAGGTCGACGGTATCGATAAGCTTGATGAG

GGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCT

GTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTA

GTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCA

GTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACT

TGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGA

AACACCGGGTCTTCGAGAAGACCTGTTTTAGAGCTAGAAATAGCAAGT

TAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCG

GTGCTTTTTTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAG

TCCGTTTTTAGCGCGTGCGCCAATTCTGCAGACAAATGGCTCTAGAGG

TACCCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCA

ACGACCCCCGCCCATTGACGTCAATAGTAACGCCAATAGGGACTTTCC

ATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAG

TACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATG

ACGGTAAATGGCCCGCCTGGCATTGTGCCCAGTACATGACCTTATGGG

ACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCA

TGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCC

CCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTG

CAGCGATGGGGGCGGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGG

GGCGGGGCGAGGGGCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAG

CCAATCAGAGCGGCGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGC

GGCGGCGGCGGCCCTATAAAAAGCGAAGCGCGCGGCGGGCGGGAGTCG

CTGCGACGCTGCCTTCGCCCCGTGCCCCGCTCCGCCGCCGCCTCGCGC

CGCCCGCCCCGGCTCTGACTGACCGCGTTACTCCCACAGGTGAGCGGG

CGGGACGGCCCTTCTCCTCCGGGCTGTAATTAGCTGAGCAAGAGGTAA

GGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTG

GAGCACCTGCCTGAAATCACTTTTTTTCAGGTTGGACCGGTGCCACCA

TGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATT

Fragment 2 (852 bp)

(SEQ ID NO: 8)

ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGAT

TACAAAGACGATGACGATAAGATGGCCCCAAAGAAGAAGCGGAAGGTC

GGTATCCACGGAGTCCCAGCAGCCGACAAGAAGTACAGCATCGGCCTG

GACATCGGCACCAACTCTGTGGGCTGGGCCGTGATCACCGACGAGTAC

AAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCAC

AGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAA

ACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACC

AGACGGAAGAACCGGATCTCTCTATCTGCAAGAGATCTTCAGCAACGA

GATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGTCCTT

CCTGGTGGAAGAGGATAAGAAGCACGAGCGGCACCCCATCTTCGGCAA

CATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCA

CCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCTGCGGCT

GATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCT

GATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTT

CATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCAT

CAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAG

CAAGAGCAGACGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAA

GAAGAATGGCCTGTTCGGAAACCTGATTGCCCTGAGC

Fragment 3 (920 bp)

(SEQ ID NO: 9)

GGCGAGAAGAAGAATGGCCTGTTCGGAAACCTGATTGCCCTGAGCCTG

GGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCC

AAACTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTG

CTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAG

AACCTGTCCGACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACC

GAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGAC

GAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAG

CTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGC

TACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAG

TTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTC

GTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGAC

AACGGCAGCATCCCCCACCAGATCCACCTGCGAGAGCTGCACGCCATT

CTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAA

AAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCT

CTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAG

GAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCT

TCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTG

CCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTC

ACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATG

AGAAAGCC

Fragment 4 (920 bp)

(SEQ ID NO: 10)

CGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGC

CTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAA

GACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAA

GAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCG

GTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAA

GGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGA

TATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGA

ACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGCA

GCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCT

GATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTT

CCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCA

CGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTC

CGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAG

CCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGA

GCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGA

AATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCG

CGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCA

GATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAA

GCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCA

GGAACTGG

Fragment 5 (920 bp)

(SEQ ID NO: 11)

ACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACA

TCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCT

TTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACA

AGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGA

AGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCC

AGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCG

AACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGC

AGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTA

AGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCC

TGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACA

AAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGA

ACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAA

GCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGA

TCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCT

TCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCA

ACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCG

GGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAG

TGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGA

CAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATA

AGCTGATC

Fragment 6 (789 bp)

(SEQ ID NO: 12)

AGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCC

AGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCC

ACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAG

TCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATG

GAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAG

GGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTAC

TCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCC

GGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTG

AACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCC

GAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTAC

CTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATC

CTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCAC

CGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTT

ACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACC

ACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCC

ACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGAC

CTGTCTCAGCTGGGAGGCGAC

Fragment 7 (535 bp)

(SEQ ID NO: 13)

GGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACAAA

AGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGTAA

GAATTCCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCC

AGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAG

GTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGC

ATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGG

ACAGCAAGGGGGAGGATTGGGAAGAGAATAGCAGGCATGCTGGGGAGC

GGCCGCAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCG

CTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGG

GCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGC

AGGGGCGCCTATCGAATTCCTGCAGCCCGGGGGATCCACTAGTTCTAG

AGCGGCC

To reconstruct the CRISPR/Cas system described in Cong et al the above DNA fragments in addition to EcoRV linearised pBlueScript KS++ vector will be assembled using Gibson Assembly kit (NEB Cat No. E5510S). As an alternative approach, the 6006 bp fragment can be assembled by assembly PCR by mixing molar ratio of the individual DNA fragments together and using the DNA mixture as PCR template. The assembled PCR product can then be cloned directly into pBlueScript vector or a standard cloning vector system such as a TOPO TA cloning kit (Invitrogen).

B: Reconstructing CRISPR/Cas Vector System (D10A Nickase)

The D10A nickase version of the CRISPR/Cas system can be conveniently reconstructed by assembling the above fragments where fragment 2 is replaced with fragment 2A which contains the D10A substitution (See sequence below).

Fragment 2A (852 bp)

(SEQ ID NO: 14)

ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGA

TTACAAAGACGATGACGATAAGATGGCCCCAAAGAAGAAGCGGAAGG

TCGGTATCCACGGAGTCCCAGCAGCCGACAAGAAGTACAGCATCGGC

CTG gcc ATCGGCACCAACTCTGTGGGCTGGGCCGTGATCACCGACGA

GTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACC

GGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGC

GGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAG

ATACACCAGACGGAAGAACCGGATCTGCTATCTGCAAGAGATCTTCA

GCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAA

GAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACGAGCGGCACCCCAT

CTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCA

CCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCC

GACCTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCG

GGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAGCGACG

TGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTC

GAGGAAAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATCCT

GTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGATCGCCC

AGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGAAACCTGATTGCC

CTGAGC

The substituted aspartate to alanine is highlighted in bold and underlined.

C: Target (Spacer) Sequence Cloning

The target spacer sequence can be cloned into the above CRISPR/Cas vector system via the BbsI restriction sites located upstream of the chimeric guided RNA sequence. The spacer sequence can be ordered as oligo pairs and annealed together with overhangs as shown below to allow direct cloning into BbsI linearised CRISPR/Cas vector using standard molecular biology protocols.
Sequence of an example oligo pair with spacer sequence:

	(SEQ ID NO: 15)
	5′-CACCGNNNNNNNNNNNNNNNNNNN-3′

	(SEQ ID NO: 16)
	3′-CNNNNNNNNNNNNNNNNNNNCAAA-5′

The 4 bp overhang sequence underlined is required to be included in the spacer oligos to facilitate cloning into the BbsI restriction site in the CRISPR/Cas vector. Using this approach, any spacer sequence can be conveniently cloned into the CRISPR/Cas vector.

D: Reconstructing CRISPR/Cas System for One-Step Generation of Transgenic Animals

In order to reconstitute a CRISPR/Cas system for one-step generation of transgenic animal as described in Wang et al. (Wang H., Yang H., Shivalila C. S., Dawlaty M. M., Cheng A. W., Zhang F., Jaenisch R.: One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering., Cell, 2013, 153(4):910-918) where direct embryo injection is used, the above detailed CRISPR/Cas vector system needs to be modified to incorporate a T7 polymerase promoter to the Cas9 coding sequence. In addition, the gRNA needs to be removed and synthetised separately by annealing oligos or produced synthetically (See below for an example T7-spacer sequence fused to chimeric guided RNA sequence-T7-gRNA). Note, ideally the spacer sequence will be designed in a unique region of a given chromosome to minimise off-target effect and also the respective protospacer genomic sequence needs to have a PAM at the 3′-end.

Example T7-gRNA Sequence

(SEQ ID NO: 17)

TTAATACGACTCACTATAGG NNNNNNNNNNNNNNNNNNNN GTTTTAG

AGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGA

AAAAGTGGCACCGAGTCGGTGCTTTTTT

The underlined 20 bp of N's depicts the spacer sequence for a given target DNA.
To reconstruct the one-step CRISPR/Cas system, the above detailed DNA fragments ( Fragments 2, 3, 4, 5, 6 & 7) can be assembled together where fragment 1A (containing 45 bp homology to pBlueScript KS+ vector 5′ to the EcoRV restriction site, human U6 promoter. BbsI restriction sites, chimeric guided RNA sequence and chicken b-actin promoter) is replaced with fragment 1, which only contains 45 bp homology to pBlueScript KS+ vector and the DNA sequence for T7 polymerase promoter with 45 bp homology to fragment 2. This will create the nuclease version of the CRISPR/Cas system for one-step generation of transgenic animals. To create the nickase version, fragment 2 can be replaced with fragment 2A as detailed above and then fragments 1, 2A, 3, 4, 5, 6 and 7 can be assembled together either by Gibson assembly or by assembly PCR.

Fragment 1 (111 bp)

(SEQ ID NO: 18)

GGTACCGGGCCCCCCCTCGAGGTCGACGGTATCGATAAGCTTGATAA

TACGACTCACTATAGGGAGAATGGACTATAAGGACCACGACGGAGAC

TACAAGGATCATGATATT

E: Preparation of Oligo/DNA Fragments for HDR-Mediated Repair

DNA oligos ranging from 15 bp and upwards in excess of >125 bp will be synthetised through Sigma Custom Oligo synthesis Service. The oligos can contain any sequence such as a defined mutation, introduced restriction sites or a sequence of interest including recombination recognition sequence such as loxP or derivatives thereof. Frt and derivatives thereof or PiggyBac LTR or any other transposon elements or regulatory elements including enhancers, promoter sequence, reporter gene, selection markets and tags. The oligo design will incorporate DNA homology to the region where Cas9 mediates double-stranded DNA break or DNA nick. The size of the homology will range from a few base pairs (2-5 bp) to upwards and in excess of 80 bp. Larger DNA fragments (>100 bp ranging up to several kilobases) will be prepared either synthetically (GeneArt) or by PCR. The DNA fragment will be synthetised either with or without flanked NLS or only with a single NLS and either with or without a promoter (e.g. T7 polymerase promoter). The DNA can be prepared as a single stranded DNA fragment using either the capture biotinylated target DNA sequence method (Invitrogen: Dynabeads M-270 Streptavidin) or any other standard and established single stranded DNA preparation methodology. The single stranded DNA can be prepared for microinjection by IVT as described above and the mRNA co-injected with Cas9 mRNA and gRNA. The DNA fragment can also be co-injected as a double stranded DNA fragment. The DNA fragment will be flanked by DNA homology to the site where Cas9 mediates double-stranded DNA break or DNA nick. The DNA homology can range from a few base pairs (2-5 bp) and up to or in excess of several kilobases. The DNA fragment can be used to introduce any endogenous or exogenous DNA.
HDR-mediated repair can also be done in ES cells following CRISPR/Cas-mediated DNA cleavage. The above mentioned donor oligo or DNA fragment can be co-transfected into ES cells along with the CRISPR/Cas expression vector.
F: Production of Cas9 mRNA and gRNA
Vector containing the T7 polymerase promoter with the coding region of humanised Cas9 will be PCR amplified using oligos Cas9-F and Cas9-R. The T7-Cas9 PCR product can be gel extracted and the DNA purified using Qiagen gel extraction kit. The purified T7-Cas9 DNA will be used for in vitro transcription (IVT) using mMESSAGE mMACHINE T7 Ultra Kit (Life Technologies Cat No. AM1345). The vector containing the T7-gRNA can be PCR amplified using oligos gRNA-F and gRNA-R and once again the PCR products gel purified. IVT of the T7-gRNA will be carried out using MEGAshortscript T7 Kit (Life Technologies Cat No. AM1354) and the gRNA purified using MEGAclear Kit (Life Technologies Cat No. AM1908) and eluted in RNase-free water.

	Cas9-F:
	(SEQ ID NO: 19)
	TTAATACGACTCACTATAGG

	Cas9-R:
	(SEQ ID NO: 20)
	GCGAGCTCTAGGAATTCTTAC

	gRNA-F:
	(SEQ ID NO: 21)
	TTAATACGACTCACTATAGG

	gRNA-R:
	(SEQ ID NO: 22)
	AAAAAAGCACCGACTCGGTGCCAC

Example 5B

One Step Generation of Transgenic Animals

A: ES Cell Transfection Procedure

Mouse embryonic stem cells AB2.1 and derivatives of this line will be used for transfecting the mammalian codon optimised Cas9 and sgRNA from a single expression vector or from separate vectors if desired. AB2.1 ES cells will be cultured on a PSNL76/7/4 MEF feeder layer in M-15: Knockout DMEM (Gibco, no pyruvate, high glucose, 15% FBS, 1×GPS, 1×BME) with standard ES cell culturing techniques. Transfection of CRISPR/Cas expression vector along with the optional addition of a donor oligo or DNA fragment will be done by electroporation using the Amaxa 4D-Nucleofector® Protocol (Lonza). A plasmid expressing PGK-Puro will also be optionally co-transfected to promote transfection efficiency.
In one method, after transfection ES cells will be plated back onto feeder plates and Puromycin (2 μg/ml) will be added 72 hours post transfection for 7 days after which colonies will be picked and genotyped by PCR. Positive colonies will be further cultured and expanded on feeder layer and selection markers where necessary will be excised using a PiggyBac transposon system. This will be done by electroporation of ES cells with a plasmid containing HyPbase using the Amaxa 4D-Nucleofector® Protocol (Lonza). The ES cell will be plated back onto feeder plates. ES cells will be passaged 2-3 days post transfection and after a further 2-3 days the ES cells will be plated out at different cells densities (1:10, 1:20, 1:100 and 1:300) and FIAU (2 μg/ml) selection will be added 24 hours after replating. Colonies will be picked and analysed by PCR genotyping after 7-10 days on selection media. Positive clones will be further cultured and expanded on feeder layer and sent for zygote (blastocyst) microinjection.
In an alternative method, 8 hours prior to transfection ES cells are seeded at a density of 0.5×106 cells using antibiotic free M-15 Knockout DMEM (Gibco, no pyruvate, high glucose, 15% FBS, 1×L-Glutamine, 1×BME) onto 6w feeder plates. Transient transfection is performed using Lipofectamine® LTX Reagent with PLUS™ Reagent (Invitrogen™) by standard protocol. After incubation time transfection reagents are transferred to feeder plates (cultured in antibiotic free media), media (M-15) will not be changed on these plates for at least 24 hours post transfection. 48 hours post transfection ES cells are trypsinized into a single cell suspension and a cell count is carried out and cells are plated out at different cell densities ranging for 100-5000 cells per 10 cm feeder plate. 24 hours after replating Puro selection at 2 μg/ml (Puromycin dihydrochloride from Streptomyces alboniger powder, P8833 Sigma) is applied to the cells for 4 days, after which cells are cultured again in M-15. Colonies are picked 10-13 days post transfection.

Method 5C: Microinjection of Mouse Zygotes—Method 1

Materials and Reagents:

- M2 (Sigma M7167)
- Embryo Max KSOM (Speciality media MR-020P-F)
- Hyaluronidase (Sigma H4272)
- Mineral Oil (Sigma, M-8410)

Possible Donor Strains:

- S3F/S3F:KF3/KF3
- S3F/S3F:K4/K4
- S7F/S7F
- K5F/K5F

Preparation of Zygotes and Microinjection:

The protocol is as described in: A. Nagy Et al. Manipulating the Mouse Embryo 3rd Edition. Chapter 7, Protocols 7-1, 7-6, 7-10, 7-11. Cold Spring Harbor Laboratory Press.
In brief:

1. Zygotes are harvested from E0.5 dpc (day post-coitum) superovulated female mice.
2. The zygotes are incubated in hyaluronidase to disperse cumulus cells.
3. Zygotes are collected and transferred to several drops of M2 medium to rinse off the hyaluronidase solution and debris. Zygotes are placed into KSOM Media and incubated at 37° C. 5% CO₂until required.
4. Zygote quality is assessed and zygotes with normal morphology are selected for injection, these are placed in KSOM media and incubated at 37° C. 5% CO₂until required.

Microinjection Set Up:

Injection procedures are performed on a Nikon Eclipse Ti inverted microscope with Eppendorf micromanipulators and an Eppendorf femtojet injection system. A slide is prepared by adding a large drop ˜200 microlitres of M2 into the centre.

Microinjection:

Place an appropriate number of zygotes onto the slide. Examine the zygotes and select only those with normal morphology (2 distinct pronuclei are visible). Whilst holding a zygote with a male pronucleus closest to the injection pipette, carefully push the injection pipette through the zona pellucida into the pronucleus, apply injection pressure, the pronucleus should visibly swell, remove the injection pipette quickly. The injected zygote can be placed down while the rest are injected.
At the end of the injection session all viable injected zygotes should be placed into prepared dishes containing drops of KSOM and incubated until ready to surgically implant. They are incubated for 2-3 hours before surgically implanting into pseudo pregnant females. Pups will be born 21 days later.

Method 5C: Microinjection of Mouse Zygotes—Method 2

Materials and Reagents

- PMSG
- hCG
- M2 (Sigma M7167)
- Embryo Max KSOM (Specialty media MR-020P-F)
- Mineral Oil (Sigma, M-8410)
- Hyluronidase (Sigma H 4272)
- 35 mm Falcon Petri dishes (Fisher 08-757-100A)
- Sharp scissors
- Sharp watchmakers forceps

Preparation of Oocytes:

- 1. Day 0: Give PMSG (5 I.U.) to the females by I. P. injection.
- 2. Day 2: Give hCG (5 I.U.) to the females 48 Hours later by I. P. injection. Mate the females to stud males.
- 3. Day 3: Check plugs, sacrifice plugged female mice by CO2 asphyxiation or cervical dislocation at 0.5 dpc at 8.00 am.
- 4. Dissect open the abdomen, locate the ovary and fat pad, dissect out the oviduct leaving the ovary and fat, trimming the uterine horn to ˜1 cm, place into a 35 mm Petri dish containing M2 at room temp.
- 5. Place one ovary at a time into a dish containing hyaluronidase solution in M2 (˜0.3 mg/ml) at room temp. View through a stereoscope at 20× or 40× magnification.
- 6. Use one pair of forceps to grasp the oviduct and hold it on the bottom of the dish. Use the second pair of forceps or a 26 g needle to tear the oviduct close to where the zygotes are located (the ampulla), releasing the clutch of cumulus cells.
- 7. The zygotes should be left in the hyaluronidase for a few minutes only, after which time the zygotes may become damaged. If necessary pipette them up and down a few times to help the release of the zygotes from the cumulus cells.
- 8. Use a mouth pipette to pick up the zygotes and transfer them to a fresh dish of M2, then transfer through several drops of M2 to rinse off the hyaluronidase, cumulus cells and debris. Sort through the zygotes removing any obviously bad ones (fragmented, misshapen, not fertilized), and place the good ones (two polar bodies should be visible and any with polar bodies) into equilibrated drops of KSOM+ AA at 37° c. and 5% CO₂, keep incubated until needed. Place about 50 eggs per drop.

Pronuclear Microinjection

- 1. Microinjection set up: Injection procedures are performed on a Nikon Eclipse Ti inverted microscope with Eppendorf micromanipulators. Prepare a 60 mm petri dish to place injected zygotes into. Pipette four-six 40 μl drops of KSOM+AA. cover with oil and place in a 5% CO₂incubator to equilibrate. Prepare a cavity slide by making a large (˜200 μl) drop of M2 media onto the center of the well, add a small drop of medium on the left side of the slide, for the holding pipette.
- 2. Microinjection: Ensure that the pressurized injector has been switched on and is ready to use. Place an appropriate number of zygotes onto the slide, do not add more zygotes than can be injected within 20-30 mins. Place the holding pipette into the drop of M2 on the left of the slide; it will fill using capillary action, once filled to about the shoulder attach to the manipulator. Carefully examine the zygotes, making sure that two pronuclei are visible and morphology is good, discard any that appear abnormal. To test if the injection needle is open, place the tip near to but not touching a zygote in the same focal plane. Apply pressure using the pressurized system, if the zygote moves the needle is open, if it doesn't the needle is closed. In this case apply pressure using the “clear’ feature, if the tip is still not open manually break the tip. Carefully “knock” the tip on the holding pipette and repeat the above test, make sure the tip does not become too large, if this happens replace the needle and start again. Place the tip of the holding pipette next to a zygote and suck it onto the end of the pipette by applying negative pressure. Focus the microscope to locate the pronuclei, the zygote should be positioned in such a way that allows injection into the zygote without hitting the pronuclei, preferably with a gap between the zona pellucida and the oolema. Bring the tip of the injection needle into the same focal plane as the zona pellucida. Bring the injection pipette to the same y-axis position as the zona pellucida, adjust the height of the needle so the tip appears completely sharp, without changing the focus. This ensures the needle will target the zygote exactly. Push the injection pipette through the zona pellucida, through the cytoplasm towards the back of the zygote. The needle will create a “bubble” through the oolema, this needs to be broken, you will see it snap back at which point remove the needle quickly, you will see the cytoplasm moving to indicate RNA is flowing from the needle. Cytoplasmic granules flowing out of the oocytes after removal of the injection pipette is a clear sign that the zygote will soon lyse. In this case, or if nuclear/cytoplasmic components are sticking to the injection pipette, the oocytes should be discarded after injection. If the zygote appears to be intact and successfully injected, sort this into a good group. Pick a new zygote for injection. The same injection pipette can be used as long as it continues to inject successfully. Switch to a new injection pipette if (a) you cannot see any cytoplasmic distortion (b) zygotes are lysing one after the other; (c) the tip of the pipette becomes visibly “dirty” or nuclear contents stick to the pipette. Once all the zygotes have been injected, remove them and place them into the equilibrated KSOM+AA and place them into the incubator at 37° C. overnight. Only transfer those zygotes that have survived injection, and cultured to the 2 cell stage. Leave any lysed ones, and zygotes that have not developed.
- 3. Count the total number injected and record the numbers transferred per recipient

Results

To demonstrate the efficient of the one-step generation of transgenic mice, we used our T7-Cas9 nuclease vector to generate mRNA via in vitro transcription detailed above. mRNA from the guide RNA was also produced using in vitro transcription described above. Before injecting the mRNA mixture into the cytoplasm, oocytes were prepared from female mice using the protocol detailed above. An mRNA mixture containing 100 ng/ul Cas9 nuclease mRNA and 50 ng/ul guide mRNA was injected by microinjection into the cytoplasm as detailed above. The microinjection is done at the single-cell stage. Zygotes that survived the injection were cultured to 2 cell stage, which were then transferred to recipient mice.
In total, 107 zygotes were injected from which 49 survived and went to 2 cell stage. These were then transferred to two recipient female mice. This resulted in 19 pups from 2 litters. Litter 1 yielded 3 males and 6 females. Litter 2 yielded 4 males and 6 females. The pups were ear clipped 3 weeks after birth and DNA was extracted. PCR was carried out using oligos flanking the gRNA to detect possible indels (FIG. 14).
PCR amplifying around the guide RNA and separating out the PCR products on an agarose gel highlighted at least one mouse contained a large indel in the form of a deletion, whereas other mice appeared to have smaller indels judging by the sharpness of the PCR product on the gel. As an initial crude analysis, all the PCR products were sent for sequencing and those marked with an asterix (7 mice in total, FIG. 14) yielded mix sequences around the gRNA further confirming they contain indels. To confirm this, the PCR products from these 7 mice together with the PCR product from another mouse which did not yield a mix sequence (PCR product from lane 19, FIG. 14) were individually cloned into a general cloning vector. From each individual cloning, 28 clones were picked and analysed by sequencing. The sequencing confirmed all 7 mice contain indels and the mice that did not contain any mix sequence contained no indels. The sequencing data is summarised in FIG. 15.
The sequencing data confirmed all of the mice analysed contained indels. It also suggests that using our zygote injection protocol detailed above and our method for preparing mRNA for Cas9 and guide RNA, Cas9 works efficiently at an early stage and until the point where cells starts to divide beyond the 2 cell stage judging by the fact that in all of the mice analysed, no more than 3 types of indels were identified. Out of the 7 mice containing indels, 3 of them had no detectable WT sequence. The female mouse (KMKY6.1j) that did not show mix sequence from the initial sequencing analysis indeed did not contain any indels so it validates our initial sequencing analysis of the PCR products.
The male mouse (KMKY5.1c) that showed no WT sequence was used as a mating partner for the two female mice (KMKY5.1e & KMKY6.1e) that showed no WT sequence too. The resulting pups from the two matings yielded 14 pups in total from the first litter. Following similar sequencing analysis whereby PCR products amplified from the region around the guide RNA were cloned individual and several clones were then analysed for the presence of indels. For each mouse, 24 clones were analysed by sequencing. The sequencing data from all 14 pups confirmed only two indel sequences reflecting the two alleles arising from the parental male and female mouse. This data unequivocally demonstrates that our one-step genome editing protocol works very efficiently at an early stage and not beyond the 2 cell stage thus avoiding complex mosaic indel formation. Using our established protocol, we can carry out define deletions directly in zygotes or carry out define deletion followed by insertion to expedite the process of generating transgenic mice to homozygosity in record time.

Example 6

Single Copy Cas9 Expression in ES Cells

Reference is made to FIG. 6B.

1. A landing pad consisting of a PiggyBac transposon element with the following features will be targeted into mouse ES cells (e.g., 129-derived ES cells, such as AB2.1 ES cells: Baylor College of Medicine, Tex., USA) and selected for on G418. The PiggyBac transposon element will contain neomycin resistance gene flanked by loxP and lox2272. It will also have a geneless PGK promoter. In this example, the landing pad will be targeted into the introgenic region of Rosa26 gene located on chromosome 6, but it could be targeted elsewhere. Targeting this landing pad in the Rosa26 gene will provide a universal ES cell line for precisely inserting any desired DNA fragment including DNA fragments containing Cas9, mutant Cas9 or any other gene of interest via RMCE with high efficiency. Targeting Rosa26 is beneficial since the targeted construct will be inserted as a single copy (unlike random integration elsewhere) and is unlikely to produce an unwanted phenotypic effect.

Note. This landing pad can be inserted into any gene in any chromosome or indeed in any eukaryotic or mammalian cell line, e.g., a human, insect, plant, yeast, mouse, rat, rabbit, rodent, pig, dog, cat, fish, chicken or bird cell line, followed by generation of the respective transgenic organism expressing Cas9.

Rosa 26 Locus

Ubiquitous expression of transgene in mouse embryonic stem cell can be achieved by gene targeting to the ROSA26 locus (also known as: gene trap ROSA 26 or Gt(ROSA)26) by homologous recombination (Ref. (a) and (b) below). The genomic coordinates for mouse C57BL/6J Rosa26 gene based on Ensemble release 73—September 2013 is: Chromosome 6: 113,067,428-113,077,333; reverse strand.
The Rosa26 locus can also be used to as a recipient location to knock-in a transgene. In our example we have use the Rosa26 locus to knock-in the landing pad vector by targeting through homologous recombination into the intronic region located between exons 2 and 3 of mouse strain 129-derived embryonic stem cells using approx. 3.1 kb homology arms. The homology arms were retrieved by recombineering from a BAC Clone generated from mouse strain 129. The sequence of the Rosa26 homology arms used for targeting is given below.

Sequence of Rosa26 5′ homology arm

(SEQ ID NO: 23)

CACATTTGGTCCTGCTTGAACATTGCCATGGCTCTTAAAGTCTTAAT

TAAGAATATTAATTGTGTAATTATTGTTTTTCCTCCTTTAGATCATT

CCTTGAGGACAGGACAGTGCTTGTTTAAGGCTATATTTCTGCTGTCT

GAGCAGCAACAGGTCTTCGAGATCAACATGATGTTCATAATCCCAAG

ATGTTGCCATTTATGTTCTCAGAAGCAAGCAGAGGCATGATGGTCAG

TGACAGTAATGTCACTGTGTTAAATGTTGCTATGCAGTTTGGATTTT

TCTAATGTAGTGTAGGTAGAACATATGTGTTCTGTATGAATTAAACT

CTTAAGTTACACCTTGTATAATCCATGCAATGTGTTATGCAATTACC

ATTTTAAGTATTGTAGCTTTCTTTGTATGTGAGGATAAAGGTGTTTG

TCATAAAATGTTTTGAACATTTCCCCAAAGTTCCAAATTATAAAACC

ACAACGTTAGAACTTATTTATGAACAATGGTTGTAGTTTCATGCTTT

TAAAATGCTTAATTATTCAATTAACACCGTTTGTGTTATAATATATA

TAAAACTGACATGTAGAAGTGTTTGTCCAGAACATTTCTTAAATGTA

TACTGTCTTTAGAGAGTTTAATATAGCATGTCTTTTGCAACATACTA

ACTTTTGTGTTGGTGCGAGCAATATTGTGTAGTCATTTTGAAAGGAG

TCATTTCAATGAGTGTCAGATTGTTTTGAATGTTATTGAACATTTTA

AATGCAGACTTGTTCGTGTTTTAGAAAGCAAAACTGTCAGAAGCTTT

GAACTAGAAATTAAAAAGCTGAAGTATTTCAGAAGGGAAATAAGCTA

CTTGCTGTATTAGTTGAAGGAAAGTGTAATAGCTTAGAAAATTTAAA

ACCATATAGTTGTCATTGCTGAATATCTGGCAGATGAAAAGAAATAC

TCAGTGGTTCTTTTGAGCAATATAACAGCTTGTTATATTAAAAATTT

TCCCCACAGATATAAACTCTAATCTATAACTCATAAATGTTACAAAT

GGATGAAGCTTACAAATGTGGCTTGACTTGTCACTGTGCTTGTTTTA

GTTATGTGAAAGTTTGGCAATAAACCTATGTCCTAAATAGTCAAACT

GTGGAATGACTTTTTAATCTATTGGTTTGTCTAGAACAGTTATGTTG

CCATTTGCCCTAATGGTGAAAGAAAAAGTGGGGAGTGCCTTGGCACT

GTTCATTTGTGGTGTGAACCAAAGAGGGGGGCATGCACTTACACTTC

AAACATCCTTTTGAAAGACTGACAAGTTTGGGTCTTCACAGTTGGAA

TTGGGCATCCCTTTTGTCAGGGAGGGAGGGAGGGAGGGAGGCTGGCT

TGTTATGCTGACAAGTGTGATTAAATTCAAACTTTGAGGTAAGTTGG

AGGAACTTGTACATTGTTAGGAGTGTGACAATTTGGACTCTTAATGA

TTTGGTCATACAAAATGAACCTAGACCAACTTCTGGAAGATGTATAT

AATAACTCCATGTTACATTGATTTCACCTGACTAATACTTATCCCTT

ATCAATTAAATACAGAAGATGCCAGCCATCTGGGCCTTTTAACCCAG

AAATTTAGTTTCAAACTCCTAGGTTAGTGTTCTCACTGAGCTACATC

CTGATCTAGTCCTGAAAATAGGACCACCATCACCCCCAAAAAAATCT

CAAATAAGATTTATGCTAGTGTTTCAAAATTTTAGGAATAGGTAAGA

TTAGAAAGTTTTAAATTTTGAGAAATGGCTTCTCTAGAAAGATGTAC

ATAGTGAACACTGAATGGCTCCTAAAGAGCCTAGAAAACTGGTACTG

AGCACACAGGACTGAGAGGTCTTTCTTGAAAAGCATGTATTGCTTTA

CGTGGGTCACAGAAGGCAGGCAGGAAGAACTTGGGCTGAAACTGGTG

TCTTAAGTGGCTAACATCTTCACAACTGATGAGCAAGAACTTTATCC

TGATGCAAAAACCATCCAAACAAACTAAGTGAAAGGTGGCAATGGAT

CCCAGGCTGCTCTAGAGGAGGACTTGACTTCTCATCCCATCACCCAC

ACCAGATAGCTCATAGACTGCCAATTAACACCAGCTTCTAGCCTCCA

CAGGCACCTGCACTGGTACACATAATTTCACACAAACACAGTAAGAA

GCCTTCCACCTGGCATGGTATTGCTTATCTTTAGTTCCCAACACTTG

GGAGGCAGAGGCCAGCCAGGGCTATGTGACAAAAACCTTGTCTAGAG

GAGAAACTTCATAGCTTATTTCCTATTCACGTAACCAGGTTAGCAAA

ATTTACCAGCCAGAGATGAAGCTAACAGTGTCCACTATATTTGTAGT

GTTTTAAGTCAATTTTTTAAATATACTTAATAGAATTAAAGCTATGG

TGAACCAAGTACAAACCTGGTGTATTAACTTGAGAACTTAGCATAAA

AAGTAGTTCATTTGTTCAGTAAATATTAAATGCTTACTGGCAAAGAT

TATGTCAGGAACTTGGTAAATGGTGATGAAACAATCATAGTTGTACA

TCTTGGTTCTGTGATCACCTTGGTTTGAGGTAAAAGTGGTTCCTTTG

ATCAAGGATGGAATTTTAAGTTTATATTCAATCAATAATGTATTATT

TTGTGATTGCAAAATTGCCTATCTAGGGTATAAAACCTTTAAAAATT

TCATAATACCAGTTCATTCTCCAGTTGATCAAGGATGGAATTTTAAG

TTTATATTCAATCAATAATGTATTATTTTGTGATTGCAAAATTGCCT

ATCTAGGGTATAAAACCTTTAAAAATTTCATAATACCAGTTCATTCT

CCAGTTACTAATTCCAAAAAGCCACTGACTATGGTGCCAATGTGGAT

TCTGTTCTCAAAGGAAGGATTGTCTGTGCCCTTTATTCTAATAGAAA

CATCACACTGAAAATCTAAGCTGAAAGAAGCCAGACTTTCCTAAATA

AATAACTTTCCATAAAGCTCAAACAAGGATTACTTTTAGGAGGCACT

GTTAAGGAACTGATAAGTAATGAGGTTACTTATATAATGATAGTCCC

ACAAGACTATCTGAGGAAAAATCAGTACAACTCGAAAACAGAACAAC

CAGCTAGGCAGGAATAACAGGGCTCCCAAGTCAGGAGGTCTATCCAA

CACCCTTTTCTGTTGAGGGCCCCAGACCTACATATTGTATACAAACA

GGGAGGTGGGTGATTTTAACTCTCCTGAGGTAC

Sequence of Rosa26 3′ homology arm

(SEQ ID NO: 24)

CTTGGTAAATCTTTGTCCTGAGTAAGCAGTACAGTGTACAGTTTACA

TTTTCATTTAAAGATACATTAGCTCCCTCTACCCCCTAAGACTGACA

GGCACTTTGGGGGTGGGGAGGGCTTTGGAAAATAACGCTTCCATACA

CTAAAAGAGAAATTTCTTTAATTAGGCTTGTTGGTTCCATACATCTA

CTGGTGTTTCTACTACTTAGTAATATTATAATAGTCACACAAGCATC

TTTGCTCTGTTTAGGTTGTATATTTATTTTAAGGCAGATGATAAAAC

TGTAGATCTTAAGGGATGCTTCTGCTTCTGAGATGATACAAAGAATT

TAGACCATAAAACAGTAGGTTGCACAAGCAATAGAATATGGCCTAAA

GTGTTCTGACACTTAGAAGCCAAGCAGTGTAGGCTTCTTAAGAAATA

CCATTACAATCACCTTGCTAGAAATCAAGCATTCTGGAGTGGTCAAG

CAGTGTAACCTGTACTGTAAGTTACTTTTCTGCTATTTTTCTCCCAA

AGCAAGTTCTTTATGCTGATATTTCCAGTGTTAGGAACTACAAATAT

TAATAAGTTGTCTTCACTCTTTTCTTTACCAAGGAGGGTCTCTTCCT

TCATCTTGATCTGAAGGATGAACAAAGGCTTGAGCAGTGCGCTTTAG

AAGATAAACTGCAGCATGAAGGCCCCCGATGTTCACCCAGACTACAT

GGACCTTTCGCCACACATGTCCCATTCCAGATAAGGCCTGGCACACA

CAAAAAACATAAGTCATTAGGCTACCAGTCTGATTCTAAAACAACCT

AAAATCTTCCCACTTAAATGCTATGGGTGGTGGGTTGGAAAGTTGAC

TCAGAAAATCACTTGCTGTTTTTAGAGAGGATCTGGGTTCAGTTTCT

GATACATTGTGGCTTACAACTATAACTCCAGTTCTAGGGGGTCCATC

CAACATCCTCTTCTGTTGAGGGCACCAAATAAATGTATTGTGTACAA

ACAGGGAGGTGAGTGATTTAACTCTCGTGTATAGTACCTTGGTAAAA

CATTTCTTGTCCTGAGTAAGCAGTACAGCTCTGCCTGTCCCTGGTCT

ACAGACACGGCTCATTTCCCGAAGGCAAGCTGGATAGAGATTCCAAT

TTCTCTTCTTGGATCCCATCCTATAAAAGAAGGTCAAGTTTAATCTA

TTGCAAAAGGTAAATAGGTAGTTTCTTACATGAGACAAGAACAAATC

TTAGGTGTGAAGCAGTCATCTTTTACAGGCCAGAGCCTCTATTCTAT

GCCAATGAAGGAAACTGTTAGTCCAGTGTTATAGAGTTAGTCCAGTG

TATAGTTTTCTATCAGAACACTTTTTTTTTAAACAACTGCAACTTAG

CTTATTGAAGACAAACCACGAGTAGAAATCTGTCCAAGAAGCAAGTG

CTTCTCAGCCTACAATGTGGAATAGGACCATGTAATGGTACAGTGAG

TGAAATGAATTATGGCATGTTTTTCTGACTGAGAAGACAGTACAATA

AAAGGTAAACTCATGGTATTTATTTAAAAAGAATCCAATTTCTACCT

TTTTCCAAATGGCATATCTGTTACAATAATATCCACAGAAGCAGTTC

TCAGTGGGAGGTTGCAGATATCCCACTGAACAGCATCAATGGGCAAA

CCCCAGGTTGTTTTTCTGTGGAGACAAAGGTAAGATATTTCAATATA

TTTTCCCAAGCTAATGAGATGGCTCAGCAAATAATGGTACTGGCCAT

TAAGTCTCATGACCTGAGCTTGATCCTCAGGGACCATGTGGTACAAG

GAGAGACCTAAATCCTTCAGTTGGACTTCAATCTTCTACCCTCATGT

CCACACACAAATAAATACAATAAAAAACATTCTGCAGTCTGAATTTC

TAAAGGTTGTTTTTCTAAAAAGAAATGTTAAAGTAACATAGGAAGAA

ATATGTCCATAACTGAAATACAAGTTTTTTAAATGGTTAAGACTGGT

TTTCAAAGGATGTATGGTTAAGAAAATACCAGGGAAAATGAGCTTAC

ATGTAAAAAAGTGTCTAAAAGGCCAGAGAAATGACCCAGCTGGCAAA

GGTGTCTGCCCTAAGCCAGACAAAAGGAATTTGATTCACAGGAAGAA

GAGACCCAACTCTCACTAGTTATCCTCTGACTTCCACACCATGACAC

AGCTCCATGGCACTCTCAGGCCCCCACACATATACAGATATAAACAG

AAACCTAATCCACCAGCCTTCAGAAGCAAAGCAATTGGAGGATTTAA

ACAGGCCATGGCTACTAATAGAGATAACTGGTAGTTTAAAAGTTATG

GTAATGACTTTCATGCTTCTTTCAACTCATATTGTTCTAAATAATTA

ATTTGGTTTTTCAAGGCAGGGTTTCTCTGTGTAGTTCTGGCTGTCCT

GGAACTCACTCTGTAGACCAGGCTGGCCTTGAACTCAGATCCATCTG

CCTCTGGAATAAGGGCACGTGCGTGCCTTTTCTACATAACAAAACCT

ATACTATAACAAAACCTATACCATACTGTACCGTTTTGGGAAAAGAC

AAAAAATAATGAACAAAAAAGGAGAAATAACATTCCAATAAAGTATG

GAAATGGTAGTTAAATTAATTACAAATGTTTTTCAGTAAATTAGATG

TGACTTCTCATACTGTTCATTTGGCTATAATGATACCACAAAGCACT

GGGGGTGAATAATAATTCCAAGTCAGTAGGGAGAGAGACTTGAAAAG

ATGCAATGCAATCATTGAAGTTAAACTTACCCATCTTTAATCTGGCT

CTTAGTCAATAGAGATGAGATGTTATTTGCTGCTCTGTTCACTGCCA

GTGGGTTATTGTCCCCAGCAATATGGTAACAGTGAGACCACTCAGTA

GCCCCCTATGAGACAGGAGTGTTGGTTAAACATGCCACAAGAGAAAA

GGGAAAAGTCACTATGGCCAACTCTCAGTAACATGGCAATCCGTGCC

ATTCATTTCCTTGCCAGAAATGTCTTCCCTGTTCTTCTGCCTACTGA

ACTTTCACCCACTAGAAATGTGGCTCCAATGTCATCCACTATGACAT

CAATGTCAGCGCTAGAAGCACTTTGCACACCTCTGTTGCTGACTTAG

REFERENCE

a) Pablo Perez-Pinera, David G. Ousterout, Matthew T. Brown and Charles A. Gersbach (2012) Gene targeting to the ROSA26 locus directed by engineered zinc finger nucleases. Nucleic Acids Research, 2012, Vol. 40, No. 8 3741-3752
b) Peter Hohenstein, Joan Slight, Derya Deniz Ozdemir, Sally F Burn, Rachel Berry and Nicholas D Hastie (2008) High-efficiency Rosa26 knock-in vector construction for Cre-regulated overexpression and RNAi. Patho Genelics 2008, 1:3
2. A recombinase mediated cassette exchange (RMCE)-enabled vector containing a promoterless puromycin-delta-tk with in-frame fusion of T2A at the C-terminus following by either Cas9 or mutant Cas9 nucleotide sequence and a series of unique restriction sites flanked by loxP and lox2272 will allow for the direct targeting of this vector into the landing pad by Cre-mediated RMCE. As is known, T2A allows ribosomal skipping during translation. The insertion of the coding sequence of T2A between two genes results in two products (one gene, one transcript but two proteins expressed, in this case the Cas9 and selection marker). ES clones containing the correctly inserted DNA fragment can be directly selected on puromycin. This approach also advantageously ensures single copy expression of Cas9 as suppose to a random integration or transient expression approach. Insertion of the RMCE enabled vector into the desired locus containing the landing pad can be selected directly as the PGK promoter in the landing pad will drive the transcription of the promoterless Puro-Delta-Tk and Cas9. Since the Puro-delta-Tk is in the same transcriptional unit as Cas9, ES clones selected on puromycin will ensure expression of Cas9.
3. The above strategy allows for three separate approaches to express the sgRNA designed for disrupting (mutation through indel formation, deletion or deletion followed by insertion) gene of interest.
- a. The above ES cell line containing Cas9 can be used for generating transgenic mice with either constitutively expressed Cas9 or modified for inducible Cas9 expression or indeed tissue specific Cas9 expression for example expression of Cas9 at an embryo stage using Nanog-, Pou5fl- or SoxB promoter-specific Cas9 expression. Such derived mouse line expressing Cas9 can be used for genome editing in a streamline fashion whereby in vitro transcribed sgRNA can be easily injected into embryos obtained from such transgenic mice. This will enhance the efficiency of generating mouse lines with the desired homozygous genotype and thus will dramatically reduce the number of animals required.
- b. sgRNA can be transfected directly into the ES cells expressing Cas9 and thus avoids the requirement for cloning into the RMCE enabled vector single or multiple sgRNA. This approach will allow multiple sgRNA to be inserted into the ES cells simultaneously very rapidly.
- c. Multiple sgRNA can be cloned directly into the multiple cloning site of the RMCE enabled vector (ie, using a plurality of different restriction endonuclease sites) to allow single copy expression of the guide-RNA. This approach may be useful for limiting off-target effects particularly relevant for those genes with high sequence homology within the genome.
4. ES cells expressing Cas9 and sgRNA can be selected for directly on medium containing puromycin. Selection on puromycin for 4-6 days will allow for the desired location to be mutated or disrupted and the advantage of manipulating ES cells is that individual clones can be analysed by PCR followed by sequencing for the desired mutation. Only correctly mutated ES cell clones can be processed further whereby inserted DNA element introduced through insertion of the landing pad and the subsequent insertion of the RMCE vector can be completely removed leaving the ES cell devoid of any alteration other than the intended mutation induced by the action of Cas9 and the sgRNA. This can be done through transiently expressing PBase transposon followed by selection on FIAU. Removal of the constitutively expressed Cas9 with only the minimal length of time required to induce mutation in the presence of sgRNA will reduce or eliminate the possibility of Cas9 inducing unwanted mutations.
5. ES Clones containing the desired mutation can be injected into blastocyst to generate transgenic mice.

TABLE 1

PAM conservation in repeats and leaders for
various CRISPR types (reproduced from Short
motif sequences determine the targets of
the prokaryotic CRISPR defence system
F. J. M. Mojica, C. Diez-Villasenor,
J. Garcia-Martinez, C. Almendros Microbiology
(2009), 155, 733-740)

			CRISPR
	Genomes{circumflex over ( )}	PAM	Consensus^†	Leaders^‡

Group 1	Mth	NGG	ATTTCAATCC	AGGGCGGATT
			CATTTTGGTC	ATGGCCAATT
			TGATTTTAAC
	Lmo	WGG	ATTTACATTT	CCACTAACTT
			CAHAATAAGT	CC GCTCTATT
			ARYTAAAAC

Group
2	Eco	CWT	CGGTTTATCC	TCTAAACATA
			CCGCTGGCGC	TCTAAAAGTA
			GGGGAACWC
	Pae	CTT	CGGTTCATCC	ACTTACCGTA
			CCACRCMYGT	CCTTACCGTA
			GGGGAACAC

Group
3	Spy	GAA	ATTTCAATCC	TGCGCCAAAT
			ACTCACCCAT
			GAAGGGTGAG
			AC
	Xan	GAA	GTTTCAATCC	CCCCCCTTAG
			ACGCGCCCGT	GCCGCCAGCA
			GAGGRCGCGA
			C

Group
4	She	GG	TTTCTAAGCC	AATAGCTTAT
			GCCTGTGCGG	TGTAGAATAA
			CGGTGAAC
	Pae	GG	TTTCTTAGCT	TAGCTCCGAA
			GCCTATACGG	TAGACCAAAA
			CAGTGAAC
	Ype	GG	TTTCTAAGCT	GTAAGATAAT
			GCCTGTGCGG
			CAGTGAAC

Group
7	Sso	NGG	CTTTCAATTC	TGAGGGTTTA
			TATAAGAGAT
			TATC
	Mse	NGG	CTTTCAACTC	TGATACCTTT
			TATAGGAGAT	TGAAACTTTT
			TAAC	TGACACTCTT

Group
10	Str	NGG	GTTTTAGAGC	CTCGTAGACT
			TATGCTGTTT	CTCGTAGAAA
			TGAATGGTCC
			CAAAAC
	Lis	NGG	GTTTTAGAGC	CTCGCAGAAT
			TATGTTATTT	CTCGTAGAAT
			TGAATGCTAM
			CAAAAC

* Genomes are abbreviated according to the denominations of the species or genera carrying the corresponding CRISPR arrays:
Mth, M. thermautrophicus;
Lmo, L. monocytogenes;
Eco, E. coli;
Pae, P. aeruginosa;
Spy, S. pyogenes;
Xan, Xanthomonas spp.;
She, Shewanella spp.;
Ype, Y. pestis;
Sso, S. solfataricus;
Mse, M. sedular;
Str, Streptococcus spp.;
Lis, Listeria spp.
^†Sequences matching the PAM are underlined.
^‡Representative CRISPR array proximal Leader sequences.
Nucleotides matching the PAM are underlined.

SEQ ID NOs for the sequences in Table 1 are set out in the table below.


			CRISPR	SEQ		SEQ
	Genomes*	PAM	Consens^†	ID NO.	Leaders^‡	ID NO.

Group 1	Mth	NGG	ATTTCAATCC		25	AGGGCGGATT	38
			CATTTTGGTC		ATGGCCAATT	39
			TGATTTTAAC
	Lmo	WGG	ATTTACATTT	26	CCACTAACTT	40
			CAHAATAAGT		CCGCTCTATT	41
			ARYTAAAAC

Group
2	Eco	CWT	CGGTTTATCC	27	TCTAAACATA	42
			CCGCTGGCGC		TCTAAAAGTA	43
			GGGGAACWC
	Pac	CTT	CGGTTCATCC	28	ACTTACCGTA	44
			CCACRCMYGT		CCTTACCGTA	45
			GGGGAACAC

Group
3	Spy	GAA	ATTTCAATCC	29	TGCGCCAAAT	46
			ACTCACCCAT
			GAAGGGTGAG
			AC
	Xan	GAA	GTTTCAATCC	30	CCCCCCTTAG	47
			ACGCGCCCGT		GCCGCCAGCA	48
			GAGGRCGCGA
			C

Group
4	She	GG	TTTCTAAGCC	31	AATAGCTTAT	49
			GCCTGTGCGG		TGTAGAATAA		50
			CGGTGAAC
	Pae	GG	TTTCTTAGCT	32	TAGCTCCGAA	51
			GCCTATACGG		TAGACCAAAA	52
			CAGTGAAC
	Ype	NGG	TTTCTAAGCT	33	GTAAGATAAT	53
			GCCTGTGCGG
			CAGTGAAC

Group
7	Sso	NGG	CTTTCAATTC	34	TGAGGGTTTA	54
			TATAAGAGAT
			TATC
	Mse	NGG	CTTTCAACTC	35	TGATACCTTT	55
			TATAGGAGAT		TGAAACTTTT	56
			TAAC		TGACACTCTT	57

Group 10	Str	NGG	GTTTTAGAGC	36	CTCGTAGACT	58
			TATGCTGTTT		CTCGTAGAAA	59
			TGAATGGTCC
			CAAAAC
	Lis	NGG	GTTTTAGAGC	37	CTCGCAGAAT	60
			TATGTTATTT		CTCGTAGAAT	61
			TGAATGCTAM
			CAAAAC

Table 2: CRISPR-Associated Endonucleases

[Gene ID numbers refer to genes in the NCBI Gene Database as at September 2013; all sequence information relating to the gene IDs below is incorporated herein by reference for possible use in the present invention]

1. Plav_0099

CRISPR-associated endonuclease Csn1 family protein [Parvibaculum lavamentivorans DS-1]

Other Aliases: Plav_0099

Genomic context: Chromosome
Annotation: NC_009719.1 (105795 . . . 108908, complement)

ID: 5454634

SEQ ID NO: 62

2. FTN_0757

membrane protein [Francisella novicida U112]

Other Aliases: FTN_0757

Genomic context: Chromosome

Annotation: NC_008601.1 (810052 . . . 814941)

ID: 4548251

SEQ ID NO: 63

3. Cj1523c

CRISPR-associated protein [Campylobacter jejuni subsp. jejuni NCTC 11168=ATCC 700819]

Other Aliases: Cj1523c

Genomic context: Chromosome
Annotation: NC_002163.1 (1456880 . . . 1459834, complement)

ID: 905809

SEQ ID NO: 64

4. mcrA
restriction endonuclease [Bifidobacterium longum DJO10A]

Other Aliases: BLD_1902

Genomic context: Chromosome

Annotation: NC_010816.1 (2257993 . . . 2261556)

ID: 6362834

SEQ ID NO: 65

5. MGA_0519

Csn1 family CRISPR-associated protein [Mycoplasma gallisepticum str. R(low)]

Other Aliases: MGA_0519

Genomic context: Chromosome

Annotation: NC_004829.2 (919248 . . . 923060)

ID: 1089911

SEQ ID NO: 66

6. Emin_0243

CRISPR-associated endonuclease Csn1 family protein [Elusimicrobium minutum Pei191]

Other Aliases: Emin_0243

Genomic context: Chromosome

Annotation: NC_010644.1 (261119 . . . 264706)

ID: 6263045

SEQ ID NO: 67

7. FTW_1427

CRISPR-associated large protein [Francisella tularensis subsp. tularensis WY96-3418]

Other Aliases: FTW_1427

Genomic context: Chromosome
Annotation: NC_009257.1 (1332426 . . . 1335803, complement)

ID: 4958852

SEQ ID NO: 68

8. SMA_1444

CRISPR-associated protein, Csn1 family [Streptococcus macedonicus ACA-DC 198]

Other Aliases: SMA_1444

Annotation: NC_016749.1 (1418337 . . . 1421729, complement)

ID: 11601419

SEQ ID NO: 69

9. SSUST3_1318

CRISPR-associated protein, Csn1 family [Streptococcus suis ST3]

Other Aliases: SSUST3_1318

Genomic context: Chromosome
Annotation: NC_015433.1 (1323872 . . . 1327240, complement)

ID: 10491484

SEQ ID NO: 70

10. cas5
CRISPR-associated protein, Csn1 family [Streptococcus gallolyticus UCN34]

Other Aliases: GALLO_1439

Genomic context: Chromosome
Annotation: NC_013798.1 (1511433 . . . 1514825, complement)

ID: 8776949

SEQ ID NO: 71

11. GALLO_1446

CRISPR-associated protein [Streptococcus gallolyticus UCN34]

Other Aliases: GALLO_1446

Genomic context: Chromosome
Annotation: NC_013798.1 (1518984 . . . 1523110, complement)

ID: 8776185

SEQ ID NO: 72

12. csn1
CRISPR-associated endonuclease Csn1 [Bifidobacterium dentium Bd1]

Other Aliases: BDP_1254

Genomic context: Chromosome
Annotation: NC_013714.1 (1400576 . . . 1403992, complement)

ID: 8692053

SEQ ID NO: 73

13. NMO_0348

putative CRISPR-associated protein [Neisseria meningitidis alpha14]

Other Aliases: NMO_0348

Genomic context: Chromosome
Annotation: NC_013016.1 (369547 . . . 372795, complement)

ID: 8221228

SEQ ID NO: 74

14. csn1
CRISPR-Associated Protein Csn1 [Streptococcus equi subsp. zooepidemicus MGCS10565]

Other Aliases: Sez_1330

Genomic context: Chromosome
Annotation: NC_011134.1 (1369339 . . . 1373385, complement)

ID: 6762114

SEQ ID NO: 75

15. csn1
CRISPR-associated endonuclease Csn1 family protein [Streptococcus gordonii str. Challis substr. CH1]

Other Aliases: SGO_1381

Genomic context: Chromosome
Annotation: NC_009785.1 (1426750 . . . 1430160, complement)

ID: 5599802

SEQ ID NO: 76

16. M28_Spy0748

cytoplasmic protein [Streptococcus pyogenes MGAS6180]

Other Aliases: M28_Spy0748

Genomic context: Chromosome

Annotation: NC_007296.1 (771231 . . . 775337)

ID: 3573516

SEQ ID NO: 77

17. SGGBAA2069_c14690
CRISPR-associated protein [Streptococcus gallolyticus subsp. gallolyticus ATCC BAA-2069]
Other Aliases: SGGBAA2069_c14690
Genomic context: Chromosome
Annotation: NC_015215.1 (1520905 . . . 1525017, complement)

ID: 10295470

SEQ ID NO: 78

18. SAR116_2544

CRISPR-associated protein, Csn1 family [Candidatus Puniceispirillum marinum IMCC1322]

Other Aliases: SAR116_2544

Genomic context: Chromosome

Annotation: NC_014010.1 (2748992 . . . 2752099)

ID: 8962895

SEQ ID NO: 79

19. TDE0327

CRISPR-associated Cas5e [Treponema denticola ATCC 35405]

Other Aliases: TDE0327

Genomic context: Chromosome

Annotation: NC_002967.9 (361021 . . . 365208)

ID: 2741543

SEQ ID NO: 80

20. csn1
CRISPR-associated protein [Streptococcus pasteurianus ATCC 43144]

Other Aliases: SGPB_1342

Genomic context: Chromosome
Annotation: NC_015600.1 (1400035 . . . 1403427, complement)

ID: 10753339

SEQ ID NO: 81

21. cas9
CRISPR-associated protein [Corynebacterium ulcerans BR-AD22]

Other Aliases: CULC22_00031

Genomic context: Chromosome
Annotation: NC_015683.1 (30419 . . . 33112, complement)

ID: 10842578

SEQ ID NO: 82

22. MGAS2096_Spy0843

putative cytoplasmic protein [Streptococcus pyogenes MGAS2096]

Other Aliases: MGAS2096_Spy0843

Genomic context: Chromosome

Annotation: NC_008023.1 (813084 . . . 817190)

ID: 4066021

SEQ ID NO: 83

23. MGAS9429_Spy0885

cytoplasmic protein [Streptococcus pyogenes MGAS9429]

Other Aliases: MGAS9429_Spy0885

Genomic context: Chromosome

Annotation: NC_008021.1 (852508 . . . 856614)

ID: 4061575

SEQ ID NO: 84

24. AZL_009000

CRISPR-associated protein, Csn1 family [Azospirillum sp. B510]

Other Aliases: AZL_009000

Genomic context: Chromosome
Annotation: NC_013854.1 (1019522 . . . 1023028, complement)

ID: 8789261

SEQ ID NO: 85

25. EUBREC_1713

contains RuvC-like nuclease and HNH-nuclease domains [Eubacterium rectale ATCC 33656]

Other Aliases: EUBREC 1713

Other Designations: CRISPR-system related protein
Genomic context: Chromosome

Annotation: NC_012781.1 (1591112 . . . 1594456)

ID: 7963668

SEQ ID NO: 86

26. Alide2_0194

CRISPR-associated protein, Csn1 family [Alicycliphilus denitrificans K601]

Other Aliases: Alide2_0194

Genomic context: Chromosome

Annotation: NC_015422.1 (218107 . . . 221196)

ID: 10481210

SEQ ID NO: 87

27. Alide_0205

crispr-associated protein, csn1 family [Alicycliphilus denitrificans BC]

Other Aliases: Alide_0205

Genomic context: Chromosome

Annotation: NC_014910.1 (228371 . . . 231460)

ID: 10102228

SEQ ID NO: 88

28. STER_1477

CRISPR-system-like protein [Streptococcus thermophilus LMD-9]

Other Aliases: STER_1477

Genomic context: Chromosome
Annotation: NC_008532.1 (1379975 . . . 1384141, complement)

ID: 4437923

SEQ ID NO: 89

29. STER_0709

CRISPR-system-like protein [Streptococcus thermophilus LMD-9]

Other Aliases: STER_0709

Genomic context: Chromosome

Annotation: NC_008532.1 (643235 . . . 646600)

ID: 4437391

SEQ ID NO: 90

30. cas9
CRISPR-associated protein [Corynebacterium diphtheriae 241]

Other Aliases: CD241_2102

Genomic context: Chromosome

Annotation: NC_016782.1 (2245769 . . . 2248399)

ID: 11674395

SEQ ID NO: 91

31. cas3
CRISPR-associated endonuclease [Corynebacterium diphtheriae 241]

Other Aliases: CD241_0034

Genomic context: Chromosome

Annotation: NC_016782.1 (35063 . . . 38317)

ID: 11672999

SEQ ID NO: 92

32. Corgl_1738

CRISPR-associated protein, Csn1 family [Coriobacterium glomerans PW2]

Other Aliases: Corgl_1738

Genomic context: Chromosome

Annotation: NC_015389.1 (2036091 . . . 2040245)

ID: 10439994

SEQ ID NO: 93

33. Fluta_3147

CRISPR-associated protein, Csn1 family [Fluviicola taffensis DSM 16823]

Other Aliases: Fluta_3147

Genomic context: Chromosome
Annotation: NC_015321.1 (3610221 . . . 3614597, complement)

ID: 10398516

SEQ ID NO: 94

34. Acav_0267

CRISPR-associated protein, Csn1 family [Acidovorax avenae subsp. avenae ATCC 19860]

Other Aliases: Acav_0267

Genomic context: Chromosome

Annotation: NC_015138.1 (295839 . . . 298976)

ID: 10305168

SEQ ID NO: 95

35. NAL212_2952

CRISPR-associated protein, Csn1 family [Nitrosomonas sp. AL212]

Other Aliases: NAL212_2952

Genomic context: Chromosome
Annotation: NC_015222.1 (2941806 . . . 2944940, complement)

ID: 10299493

SEQ ID NO: 96

36. SpiBuddy_2181

CRISPR-associated protein, Csn1 family [Sphaerochaeta globosa str. Buddy]

Other Aliases: SpiBuddy_2181

Genomic context: Chromosome
Annotation: NC_015152.1 (2367952 . . . 2371491, complement)

ID: 10292274

SEQ ID NO: 97

37. Tmz1t_2411

HNH endonuclease [Thaucra sp. MZ1T]

Other Aliases: Tmzlt_2411

Genomic context: Plasmid pTha01
Annotation: NC_011667.1 (75253 . . . 76200, complement)

ID: 7094333

SEQ ID NO: 98

38. Gdia_0342

Csn1 family CRISPR-associated protein [Gluconacetobacter diazotrophicus PA51]

Other Aliases: Gdia_0342

Genomic context: Chromosome

Annotation: NC_011365.1 (382737 . . . 385748)

ID: 6973736

SEQ ID NO: 99

39. JJD26997_1875

CRISPR-associated Cas5e family protein [Campylobacter jejuni subsp. doylei 269.97]

Other Aliases: JJD26997_1875

Genomic context: Chromosome
Annotation: NC_009707.1 (1656109 . . . 1659063, complement)

ID: 5389688

SEQ ID NO: 100

40. Asuc_0376

CRISPR-associated endonuclease Csn1 family protein [Actinobacillus succinogenes 130Z]

Other Aliases: Asuc_0376

Genomic context: Chromosome

Annotation: NC_009655.1 (431928 . . . 435116)

ID: 5348478

SEQ ID NO: 101

41. Veis_1230

CRISPR-associated endonuclease Csn1 family protein [Verminephrobacter eiseniae EF01-2]

Other Aliases: Veis_1230

Genomic context: Chromosome

Annotation: NC_008786.1 (1365979 . . . 1369185)

ID: 4695198

SEQ ID NO: 102

42. MGAS10270_Spy0886

putative cytoplasmic protein [Streptococcus pyogenes MGAS10270]

Other Aliases: MGAS10270_Spy0886

Genomic context: Chromosome

Annotation: NC_008022.1 (844446 . . . 848552)

ID: 4063984

SEQ ID NO: 103

43. gbs0911
hypothetical protein [Streptococcus agalactiae NEM316]
Other Aliases: gbs0911
Genomic context: Chromosome

Annotation: NC_004368.1 (945801 . . . 949946)

ID: 1029893

SEQ ID NO: 104

44. NMA0631

hypothetical protein [Neisseria meningitidis Z2491]

Other Aliases: NMA0631

Genomic context: Chromosome
Annotation: NC_003116.1 (610868 . . . 614116, complement)

ID: 906626

SEQ ID NO: 105

45. Ccan_14650

hypothetical protein [Capnocytophaga canimorsus Cc5]

Other Aliases: Ccan_14650

Genomic context: Chromosome
Annotation: NC_015846.1 (1579873 . . . 1584165, complement)

ID: 10980451

SEQ ID NO: 106

46. Ipp0160

hypothetical protein [Legionella pneumophila str. Paris]
Other Aliases: lpp0160
Genomic context: Chromosome

Annotation: NC_006368.1 (183831 . . . 187949)

ID: 3118625

SEQ ID NO: 107

47. Cbei_2080

hypothetical protein [Clostridium beijerinckii NCIMB 8052]

Other Aliases: Cbei_2080

Genomic context: Chromosome

Annotation: NC_009617.1 (2422056 . . . 2423096)

ID: 5296367

SEQ ID NO: 108

48. MMOB0330

hypothetical protein [Mycoplasma mobile 163K]

Other Aliases: MMOB0330

Genomic context: Chromosome
Annotation: NC_006908.1 (45652 . . . 49362, complement)

ID: 2807677

SEQ ID NO: 109

49. MGF_5203

Csn1 family CRISPR-associated protein [Mycoplasma gallisepticum str. F]

Other Aliases: MGF_5203

Genomic context: Chromosome

Annotation: NC_017503.1 (888602 . . . 892411)

ID: 12397088

SEQ ID NO: 110

50. MGAH_0519

Csn1 family CRISPR-associated protein [Mycoplasma gallisepticum str. R(high)]

Other Aliases: MGAH_0519

Genomic context: Chromosome

Annotation: NC_017502.1 (918476 . . . 922288)

ID: 12395725

SEQ ID NO: 111

51. Smon_1063

CRISPR-associated protein. Csn1 family [Streptobacillus moniliformis DSM 12112]

Other Aliases: Smon_1063

Genomic context: Chromosome
Annotation: NC_013515.1 (1159048 . . . 1162827, complement)

ID: 8600791

SEQ ID NO: 112

52. Spy49_0823

hypothetical protein [Streptococcus pyogenes NZ131]

Other Aliases: Spy49_0823

Genomic context: Chromosome

Annotation: NC_011375.1 (821210 . . . 825316)

ID: 6985827

SEQ ID NO: 113

53. CSJ_1425

hypothetical protein [Campylobacter jejuni subsp. jejuni 81116]

Other Aliases: C8J_1425

Genomic context: Chromosome
Annotation: NC_009839.1 (1442672 . . . 1445626, complement)

ID: 5618449

SEQ ID NO: 114

54. FTF0584

hypothetical protein [Francisella tularensis subsp. tularensis FSC198]

Other Aliases: FTF0584

Genomic context: Chromosome

Annotation: NC_008245.1 (601115 . . . 604486)

ID: 4200457

SEQ ID NO: 115

55. FTT_0584

hypothetical protein [Francisella tularensis subsp. tularensis SCHU S4]

Other Aliases: FTT_0584

Genomic context: Chromosome

Annotation: NC_006570.2 (601162 . . . 604533)

ID: 3191177

SEQ ID NO: 116

56. csn1
CRISPR-associated protein [Streptococcus dysgalactiae subsp. equisimilis RE378]

Other Aliases: GGS_1116

Annotation: NC_018712.1 (1169559 . . . 1173674, complement)

ID: 13799322

SEQ ID NO: 117

57. SMUGS5_06270

CRISPR-associated protein csn1 [Streptococcus mutans GS-5]

Other Aliases: SMUGS5_06270

Genomic context: Chromosome
Annotation: NC_018089.1 (1320641 . . . 1324678, complement)

ID: 13299050

SEQ ID NO: 118

58. Y1U_C1412

Csn1 [Streptococcus thermophilus MN-ZLW-002]

Other Aliases: Y1U_C1412

Genomic context: Chromosome
Annotation: NC_017927.1 (1376653 . . . 1380819, complement)

ID: 12977193

SEQ ID NO: 119

59. Y1U_C0633

CRISPR-system-like protein [Streptococcus thermophilus MN-ZLW-002]

Other Aliases: Y1U_C0633

Genomic context: Chromosome

Annotation: NC_017927.1 (624274 . . . 627639)

ID: 12975630

SEQ ID NO: 120

60. SALIVA_0715

CRISPR-associated endonuclease. Csn1 family [Streptococcus salivarius JIM8777]

Other Aliases: SALIVA 0715

Annotation: NC_017595.1 (708034 . . . 711417)

ID: 12910728

SEQ ID NO: 121

61. csn1
CRISPR-associated protein csn1 [Streptococcus mutans LJ23]

Other Aliases: SMULJ23_0701

Annotation: NC_017768.1 (751695 . . . 755732)

ID: 12898085

SEQ ID NO: 122

62. RIA_1455

CRISPR-associated protein, SAG0894 [Riemerella anatipestifer RA-GD]

Other Aliases: RIA_1455

Genomic context: Chromosome

Annotation: NC_017569.1 (1443996 . . . 1448198)

ID: 12613647

SEQ ID NO: 123

63. STND_0658

CRISPR-associated endonuclease, Csn1 family [Streptococcus thermophilus ND03]

Other Aliases: STND_0658

Genomic context: Chromosome

Annotation: NC_017563.1 (633621 . . . 636986)

ID: 12590813

SEQ ID NO: 124

64. RA0C_1034

putative BCR [Riemerella anatipestifer ATCC 11845=DSM 15868]

Other Aliases: RA0C_1034

Genomic context: Chromosome
Annotation: NC_017045.1 (1023494 . . . 1026931, complement)

ID: 11996006

SEQ ID NO: 125

65. Sinf_1255

CRISPR-associated protein. SAG0894 family [Streptococcus infantarius subsp. infantarius CJ18]

Other Aliases: Sinf_1255

Genomic context: Chromosome
Annotation: NC_016826.1 (1276484 . . . 1280611, complement)

ID: 11877786

SEQ ID NO: 126

66. Nitsa_1472

CRISPR-associated protein, csn1 family [Nitratifractor salsuginis DSM 16511]

Other Aliases: Nitsa_1472

Genomic context: Chromosome

Annotation: NC_014935.1 (1477331 . . . 1480729)

ID: 10148263

SEQ ID NO: 127

67. NLA_17660

hypothetical protein [Neisseria lactamica 020-06]

Other Aliases: NLA_17660

Genomic context: Chromosome

Annotation: NC_014752.1 (1890078 . . . 1893326)

ID: 10006697

SEQ ID NO: 128

68. SmuNN2025_0694

hypothetical protein [Streptococcus mutans NN2025]

Other Aliases: SmuNN2025_0694

Genomic context: Chromosome

Annotation: NC_013928.1 (737258 . . . 741295)

ID: 8834629

SEQ ID NO: 129

69. SDEG_1231

hypothetical protein [Streptococcus dysgalactiae subsp. equisimilis GGS_124]

Other Aliases: SDEG_1231

Chromosome: 1

Annotation: Chromosome 1NC_012891.1 (1176755 . . . 1180870, complement)

ID: 8111553

SEQ ID NO: 130

70. NMCC_0397

hypothetical protein [Neisseria meningitidis 053442]

Other Aliases: NMCC_0397

Genomic context: Chromosome
Annotation: NC_010120.1 (402733 . . . 405981, complement)

ID: 5796426

SEQ ID NO: 131

71. SAK_1017

hypothetical protein [Streptococcus agalactiae A909]

Other Aliases: SAK_1

Genomic context: Chromosome

Annotation: NC_007432.1 (980303 . . . 984415)

ID: 3686185

SEQ ID NO: 132

72. M5005_Spy_0769
hypothetical protein [Streptococcus pyogenes MGAS5005]
Other Aliases: M5005_Spy_0769
Genomic context: Chromosome

Annotation: NC_007297.1 (773340 . . . 777446)

ID: 3572134

SEQ ID NO: 133

73. MS53_0582

hypothetical protein [Mycoplasma synoviae 53]

Other Aliases: MS53_0582

Genomic context: Chromosome

Annotation: NC_007294.1 (684155 . . . 688099)

ID: 3564051

SEQ ID NO: 134

74. DIP0036

hypothetical protein [Corynebacterium diphtheriae NCTC 13129]

Other Aliases: DIP0036

Genomic context: Chromosome

Annotation: NC_002935.2 (34478 . . . 37732)

ID: 2650188

SEQ ID NO: 135

75. WS1613

hypothetical protein [Wolinella succinogenes DSM 1740]

Other Aliases: WS1613

Genomic context: Chromosome

Annotation: NC_005090.1 (1525628 . . . 1529857)

ID: 2553552

SEQ ID NO: 136

76. PM1127

hypothetical protein [Pasteurella multocida subsp. multocida str. Pm70]

Other Aliases: PM1127

Genomic context: Chromosome
Annotation: NC_002663.1 (1324015 . . . 1327185, complement)

ID: 1244474

SEQ ID NO: 137

77. SPs1176

hypothetical protein [Streptococcus pyogenes SSI-1]

Other Aliases: SPs1176

Genomic context: Chromosome
Annotation: NC_004606.1 (1149610 . . . 1153716, complement)

ID: 1065374

SEQ ID NO: 138

78. SMU_1405c

hypothetical protein [Streptococcus mutans UA159]

Other Aliases: SMU_1405c, SMU.1405c

Genomic context: Chromosome
Annotation: NC_004350.2 (1330942 . . . 1334979, complement)

ID: 1028661

SEQ ID NO: 139

79. lin2744
hypothetical protein [Listeria innocua Clip11262]
Other Aliases: lin2744
Genomic context: Chromosome
Annotation: NC_003212.1 (2770707 . . . 2774711, complement)

ID: 1131597

SEQ ID NO: 140

80. csn1B
CRISPR-associated protein [Streptococcus gallolyticus subsp. gallolyticus ATCC 43143]

Other Aliases: SGGB_1441

Annotation: NC_017576.1 (1489111 . . . 1493226, complement)

ID: 12630646

SEQ ID NO: 141

81. csn1A
CRISPR-associated protein [Streptococcus gallolyticus subsp. gallolyticus ATCC 43143]

Other Aliases: SGGB_1431

Annotation: NC_017576.1 (1480439 . . . 1483831, complement)

ID: 12630636

SEQ ID NO: 142

82. cas9
CRISPR-associated protein [Corynebacterium ulcerans 809]

Other Aliases: CULC809_00033

Genomic context: Chromosome
Annotation: NC_017317.1 (30370 . . . 33063, complement)

ID: 12286148

SEQ ID NO: 143

83. GDI_2123

hypothetical protein [Gluconacetobacter diazotrophicus PA15]

Other Aliases: GDI_2123

Genomic context: Chromosome

Annotation: NC_010125.1 (2177083 . . . 2180235)

ID: 5792482

SEQ ID NO: 144

84. Nham_4054

hypothetical protein [Nitrobacter hamburgensis X14]

Other Aliases: Nham_4054

Genomic context: Plasmid 1
Annotation: NC_007959.1 (13284 . . . 16784, complement)

ID: 4025380

SEQ ID NO: 145

85. str0657
hypothetical protein [Streptococcus thermophilus CNRZ1066]
Other Aliases: str0657
Genomic context: Chromosome

Annotation: NC_006449.1 (619189 . . . 622575)

ID: 3165636

SEQ ID NO: 146

86. stu0657
hypothetical protein [Streptococcus thermophilus LMG 18311]
Other Aliases: stu0657
Genomic context: Chromosome

Annotation: NC_006448.1 (624007 . . . 627375)

ID: 3165000

SEQ ID NO: 147

87. SpyM3_0677

hypothetical protein [Streptococcus pyogenes MGAS315]

Other Aliases: SpyM3_0677

Genomic context: Chromosome

Annotation: NC_004070.1 (743040 . . . 747146)

ID: 1008991

SEQ ID NO: 148

88. HFMG06CAA_5227

Csn1 family CRISPR-associated protein [Mycoplasma gallisepticum CA06_2006.052-5-2P]

Other Aliases: HFMG06CAA_5227

Genomic context: Chromosome

Annotation: NC_018412.1 (895338 . . . 899147)

ID: 13464859

SEQ ID NO: 149

89. HFMG01WIA_5025

Csn1 family CRISPR-associated protein [Mycoplasma gallisepticum WI01_2001.043-13-2P]

Other Aliases: HFMG01WIA_5025

Genomic context: Chromosome

Annotation: NC_018410.1 (857648 . . . 861457)

ID: 13463863

SEQ ID NO: 150

90. HFMG01NYA_5169

Csn1 family CRISPR-associated protein [Mycoplasma gallisepticum NY01_2001.047-5-1P]

Other Aliases: HFMG01NYA_5169

Genomic context: Chromosome

Annotation: NC_018409.1 (883511 . . . 887185)

ID: 13462600

SEQ ID NO: 151

91. HFMG96NC SEQ ID NO: 127

A_5295

Csn1 family CRISPR-associated protein [Mycoplasma gallisepticum NC96_1596-4-2P]

Other Aliases: HFMG96NCA_5295

Genomic context: Chromosome

Annotation: NC_018408.1 (904664 . . . 908473)

ID: 13462279

SEQ ID NO: 152

92. HFMG95NCA_5107

Csn1 family CRISPR-associated protein [Mycoplasma gallisepticum NC95_13295-2-2P]

Other Aliases: HFMG95NCA_5107

Genomic context: Chromosome

Annotation: NC_018407.1 (871783 . . . 875592)

ID: 13461469

SEQ ID NO: 153

93. MGAS10750_Spy0921

hypothetical protein [Streptococcus pyogenes MGAS10750]

Other Aliases: MGAS10750_Spy0921

Genomic context: Chromosome

Annotation: NC_008024.1 (875719 . . . 879834)

ID: 4066656

SEQ ID NO: 154

94. XAC3262

hypothetical protein [Xanthomonas axonopodis pv. citri str. 306]

Other Aliases: XAC3262

Genomic context: Chromosome

Annotation: NC_003919.1 (3842310 . . . 3842765)

ID: 1157333

SEQ ID NO: 155

95. SSUST1_1305

CRISPR-system-like protein [Streptococcus suis ST1]

Other Aliases: SSUST1_1305

Genomic context: Chromosome
Annotation: NC_017950.1 (1293105 . . . 1297250, complement)

ID: 13017849

SEQ ID NO: 156

96. SSUD9_1467

CRISPR-associated protein, Csn1 family [Streptococcus suis D9]

Other Aliases: SSUD9_1467

Genomic context: Chromosome
Annotation: NC_017620.1 (1456318 . . . 1459686, complement)

ID: 12718289

SEQ ID NO: 157

97. BBta_3952

hypothetical protein [Bradyrhizobium sp. BTAi1]

Other Aliases: BBta_3952

Genomic context: Chromosome
Annotation: NC_009485.1 (4149455 . . . 4152649, complement)

ID: 5151538

SEQ ID NO: 158

98. CIY_03670

CRISPR-associated protein, Csn1 family [Butyrivibrio fibrisolvens 16/4]

Other Aliases: CIY_03670

Annotation: NC_021031.1 (309663 . . . 311960, complement)

ID: 15213189

SEQ ID NO: 159

99. A11Q_912

CRISPR-associated protein, Csn1 family [Bdellovibrio exovorus JSS]

Other Aliases: A11Q_912

Genomic context: Chromosome
Annotation: NC_020813.1 (904781 . . . 907864, complement)

ID: 14861475

SEQ ID NO: 160

100. MCYN0850

Csn1 family CRISPR-associated protein [Mycoplasma cynos C142]

Other Aliases: MCYN_0850

Annotation: NC_019949.1 (951497 . . . 955216, complement)

ID: 14356531

SEQ ID NO: 161

101. SaSA20_0769

CRISPR-associated protein [Streptococcus agalactiae SA20-06]

Other Aliases: SaSA20_0769

Genomic context: Chromosome

Annotation: NC_019048.1 (803597 . . . 807709)

ID: 13908026

SEQ ID NO: 162

102. csn1
CRISPR-associated protein, Csn1 family [Streptococcus pyogenes A20]

Other Aliases: A20_0810

Genomic context: Chromosome

Annotation: NC_018936.1 (772038 . . . 776144)

ID: 13864445

SEQ ID NO: 163

103. P700755_000291

CRISPR-associated protein Cas9/Csn1, subtype II [Psychroflexus torquis ATCC 700755]

Other Aliases: P700755_000291

Genomic context: Chromosome

Annotation: NC_018721.1 (312899 . . . 317428)

ID: 13804571

SEQ ID NO: 164

104. A911_07335

CRISPR-associated protein [Campylobacter jejuni subsp. jejuni PT14]

Other Aliases: A911_07335

Genomic context: Chromosome
Annotation: NC_018709.2 (1450217 . . . 1453180, complement)

ID: 13791138

SEQ ID NO: 165

105. ASU2_02495

CRISPR-associated endonuclease Csn1 family protein [Actinobacillus suis H91-0380]

Other Aliases: ASU2_02495

Genomic context: Chromosome

Annotation: NC_018690.1 (552318 . . . 555482)

ID: 13751600

SEQ ID NO: 166

106. csn1
CRISPR-associated protein [Listeria monocytogenes SLCC2540]

Other Aliases: LMOSLCC2540_2635

Annotation: NC_018586.1 (2700744 . . . 2704748, complement)

ID: 13647248

SEQ ID NO: 167

107. csn1
CRISPR-associated protein [Listeria monocytogenes SLCC5850]

Other Aliases: LMOSLCC5850_2605

Annotation: NC_018592.1 (2646023 . . . 2650027, complement)

ID: 13626042

SEQ ID NO: 168

108. csn1
CRISPR-associated protein [ Listeria monocytogenes serotype 7 str. SLCC2482]

Other Aliases: LMOSLCC2482_2606

Annotation: NC_018591.1 (2665393 . . . 2669397, complement)

ID: 13605045

SEQ ID NO: 169

109. csn1
CRISPR-associated protein [Listeria monocytogenes SLCC2755]

Other Aliases: LMOSLCC2755_2607

Annotation: NC_018587.1 (2694850 . . . 2698854, complement)

ID: 13599053

SEQ ID NO: 170

110. BN148_1523c

CRISPR-associated protein [Campylobacter jejuni subsp. jejuni NCTC 11168-BN148]

Other Aliases: BN148_1523c

Annotation: NC_018521.1 (1456880 . . . 1459834, complement)

ID: 13530688

SEQ ID NO: 171

111. Belba_3201

CRISPR-associated protein Cas9/Csn1, subtype II/NMEMI [Belliella baltica DSM 15883]

Other Aliases: Belba_3201

Genomic context: Chromosome
Annotation: NC_018010.1 (3445311 . . . 3449369, complement)

ID: 13056967

SEQ ID NO: 172

112. FN3523_1121

membrane protein [Francisella cf. novicida 3523]

Other Aliases: FN3523_1121

Genomic context: Chromosome
Annotation: NC_017449.1 (1129528 . . . 1134468, complement)

ID: 12924881

SEQ ID NO: 173

113. cas9
CRISPR-associated protein Cas9/Csn1, subtype II/NMEMI [Prevotella intermedia 17]

Other Aliases: PIN17_A0201

Chromosome: II

Annotation: Chromosome IINC_017861.1 (240722 . . . 244864)

ID: 12849954

SEQ ID NO: 174

114. csn1
CRISPR-associated protein, Csn1 family [Streptococcus thermophilus JIM 8232]

Other Aliases: STH8232_0853

Annotation: NC_017581.1 (706443 . . . 709808)

ID: 12637306

SEQ ID NO: 175

115. LMOG_01918

CRISPR-associated protein [Listeria monocytogenes J0161]

Other Aliases: LMOG_01918

Genomic context: Chromosome
Annotation: NC_017545.1 (2735374 . . . 2739378, complement)

ID: 12557915

SEQ ID NO: 176

116. LMRG_02138

CRISPR-associated protein [Listeria monocytogenes 10403S]

Other Aliases: LMRG_02138

Genomic context: Chromosome
Annotation: NC_017544.1 (2641981 . . . 2645985, complement)

ID: 12554876

SEQ ID NO: 177

117. CJSA_1443

putative CRISPR-associated protein [Campylobacter jejuni subsp. jejuni IA3902]

Other Aliases: CJSA_1443

Genomic context: Chromosome
Annotation: NC_017279.1 (1454273 . . . 1457227, complement)

ID: 12250720

SEQ ID NO: 178

118. csn1
CRISPR-associated protein Csn1 [Streptococcus pyogenes MGAS1882]

Other Aliases: MGAS1882_0792

Genomic context: Chromosome

Annotation: NC_017053.1 (775696 . . . 779799)

ID: 12014080

SEQ ID NO: 179

119. csn1
CRISPR-associated protein Csn1 [Streptococcus pyogenes MGAS15252]

Other Aliases: MGAS15252_0796

Genomic context: Chromosome

Annotation: NC_017040.1 (778271 . . . 782374)

ID: 11991096

SEQ ID NO: 180

120. cas3
CRISPR-associated endonuclease [Corynebacterium diphtheriae HC02]

Other Aliases: CDHC02_0036

Genomic context: Chromosome

Annotation: NC_016802.1 (37125 . . . 40379)

ID: 11739116

SEQ ID NO: 181

121. cas3
CRISPR-associated endonuclease [Corynebacterium diphtheriae C7 (beta)]

Other Aliases: CDC7B_0035

Genomic context: Chromosome

Annotation: NC_016801.1 (36309 . . . 39563)

ID: 11737358

SEQ ID NO: 182

122. cas3
CRISPR-associated endonuclease [Corynebacterium diphtheriae BH8]

Other Aliases: CDBH8_0038

Genomic context: Chromosome

Annotation: NC_016800.1 (37261 . . . 40515)

ID: 11735325

SEQ ID NO: 183

123. cas3
CRISPR-associated endonuclease [Corynebacterium diphtheriae 31A]

Other Aliases: CD31A_0036

Genomic context: Chromosome

Annotation: NC_016799.1 (34597 . . . 37851)

ID: 11731168

SEQ ID NO: 184

124. cas3
CRISPR-associated endonuclease [Corynebacterium diphtheriae VA01]

Other Aliases: CDVA01_0033

Genomic context: Chromosome

Annotation: NC_016790.1 (34795 . . . 38049)

ID: 11717708

SEQ ID NO: 185

125. cas3
CRISPR-associated endonuclease [Corynebacterium diphtheriae HC01]

Other Aliases: CDHC01_0034

Genomic context: Chromosome

Annotation: NC_016786.1 (35060 . . . 38314)

ID: 11708318

SEQ ID NO: 186

126. cas9
CRISPR-associated protein [Corynebacterium diphtheriae HC01]

Other Aliases: CDHC01_2103

Genomic context: Chromosome

Annotation: NC_016786.1 (2246368 . . . 2248998)

ID: 11708126

SEQ ID NO: 187

127. PARA_18570

hypothetical protein [Haemophilus parainfluenzae T3T1]

Other Aliases: PARA_18570

Genomic context: Chromosome

Annotation: NC_015964.1 (1913335 . . . 1916493)

ID: 11115627

SEQ ID NO: 188

128. HDN1F_34120

hypothetical protein [gamma proteobacterium HdN1]

Other Aliases: HDN1F_34120

Genomic context: Chromosome
Annotation: NC_014366.1 (4143336 . . . 4146413, complement)

ID: 9702142

SEQ ID NO: 189

129. SPy_1046

hypothetical protein [Streptococcus pyogenes M1 GAS]

Other Aliases: SPy_1046

Genomic context: Chromosome

Annotation: NC_002737.1 (854757 . . . 858863)

ID: 901176

SEQ ID NO: 190

130. GBS222_0765

Hypothetical protein [Streptococcus agalactiae]

Other Aliases: GBS222_0765

Annotation: NC_021195.1 (810875 . . . 814987)

ID: 15484689

SEQ ID NO: 191

131. NE061598_03330

hypothetical protein [Francisella tularensis subsp. tularensis NE061598]

Other Aliases: NE061598_03330

Genomic context: Chromosome

Annotation: NC_017453.1 (601219 . . . 604590)

ID: 12437259

SEQ ID NO: 192

132. NMV_1993

hypothetical protein [Neisseria meningitidis 8013]

Other Aliases: NMV_1993

Annotation: NC_017501.1 (1917073 . . . 1920321)

ID: 12393700

SEQ ID NO: 193

133. csn1
hypothetical protein [Campylobacter jejuni subsp. jejuni M1]

Other Aliases: CJM1_1467

Genomic context: Chromosome
Annotation: NC_017280.1 (1433667 . . . 1436252, complement)

ID: 12249021

SEQ ID NO: 194

134. FTU_0629

hypothetical protein [Francisella tularensis subsp. tularensis TIGB03]

Other Aliases: FTU_0629

Genomic context: Chromosome

Annotation: NC_016933.1 (677092 . . . 680463)

ID: 11890131

SEQ ID NO: 195

135. NMAA_0315

hypothetical protein [Neisseria meningitidis WUE 2594]

Other Aliases: NMAA_0315

Annotation: NC_017512.1 (377010 . . . 380258, complement)

ID: 12407849

SEQ ID NO: 1%

136. WS1445

hypothetical protein [Wolinella succinogenes DSM 1740]

Other Aliases: WS1445

Genomic context: Chromosome
Annotation: NC_005090.1 (1388202 . . . 1391381, complement)

ID: 2554690

SEQ ID NO: 197

137. THITE_2123823

hypothetical protein [Thielavia terrestris NRRL 8126]

Other Aliases: THITE_2123823

Chromosome: 6

Annotation: Chromosome 6NC_016462.1 (1725696 . . . 1725928)

ID: 11523019

SEQ ID NO: 198

138. XAC29_16635

hypothetical protein [Xanthomonas axonopodis Xac29-1]

Other Aliases: XAC29_16635

Genomic context: Chromosome

Annotation: NC_020800.1 (3849847 . . . 3850302)

ID: 14853997

SEQ ID NO: 199

139. M1GAS476_0830

hypothetical protein [Streptococcus pyogenes M1 476]

Other Aliases: M1GAS476_0830

Chromosome: 1

Annotation: NC_020540.1 (792119 . . . 796225)

ID: 14819166

SEQ ID NO: 200

140. Piso0_000203

Piso0_000203[Millerozyma farinosa CBS 7064]

Other Aliases: GNLVRS01_PISO0A04202g

Other Designations: hypothetical protein

Chromosome: A

Annotation: NC_020226.1 (343553 . . . 343774, complement)

ID: 14528449

SEQ ID NO: 201

141. G148_0828

hypothetical protein [Riemerella anatipestifer RA-CH-2]

Other Aliases: G148_0828

Genomic context: Chromosome

Annotation: NC_020125.1 (865673 . . . 869875)

ID: 14447195

SEQ ID NO: 202

142. csn1
hypothetical protein [Streptococcus dysgalactiae subsp. equisimilis AC-2713]

Other Aliases: SDSE_1207

Annotation: NC_019042.1 (1134173 . . . 1138288, complement)

ID: 13901498

SEQ ID NO: 203

143. A964_0899

hypothetical protein [Streptococcus agalactiae GD201008-001]

Other Aliases: A964_0899

Genomic context: Chromosome

Annotation: NC_018646.1 (935164 . . . 939276)

ID: 13681619

SEQ ID NO: 204

144. FNFX1_0762

hypothetical protein [Francisella cf. novicida Fx1]

Other Aliases: FNFX1_0762

Genomic context: Chromosome

Annotation: NC_017450.1 (781484 . . . 786373)

ID: 12435564

SEQ ID NO: 205

145. FTV_0545

hypothetical protein [Francisella tularensis subsp. tularensis TI0902]

Other Aliases: FTV_0545

Genomic context: Chromosome

Annotation: NC_016937.1 (601185 . . . 604556)

ID: 11880693

SEQ ID NO: 206

146. FTL_1327

hypothetical protein [Francisella tularensis subsp. holarctica LVS]

Other Aliases: FTL_1327

Genomic context: Chromosome
Annotation: NC_007880.1 (1262508 . . . 1263689, complement)

ID: 3952607

SEQ ID NO: 207

147. FTL_1326

hypothetical protein [Francisella tularensis subsp. holarctica LVS]

Other Aliases: FTL_1326

Genomic context: Chromosome
Annotation: NC_007880.1 (1261927 . . . 1262403, complement)

ID: 3952606

SEQ ID NO: 208

Claims

1. An in vitro method for modifying a genome at a genomic locus of interest in a mouse ES cell, the method comprising:

contacting the mouse ES cell with:

a Cas9 protein;

a CRISPR RNA that hybridizes to a CRISPR target sequence at the genomic locus of interest;

a tracrRNA; and

an incoming nucleic acid sequence that is flanked by:

(i) a 5′ homology arm that is homologous to a 5′ target sequence at the genomic locus of interest; and

(ii) a 3′ homolog arm that is homologous to a 3′ target sequence at the genomic locus of interest;

wherein the incoming nucleic acid sequence is at least 20 kb in size;

wherein following the contacting step, the genome of the mouse ES cell is modified to comprise a targeted genetic modification comprising:

deletion of a region of the genomic locus of interest wherein the deletion is at least 20 kb; and/or

insertion of the insert nucleic acid at the genomic locus of interest wherein the insertion is at least 20 kb.

wherein the targeted genomic modification comprises insertion of:

a. One or more human antibody heavy chain variable domains;

b. One or more human antibody kappa light chain variable domains; or

c. One or more human antibody lambda light chain variable domains;

2. The method of claim 1, wherein the targeted genomic modification comprises deletion of one or more mouse antibody heavy chain variable domains and insertion of one or more human antibody heavy chain variable domains.

3. The method of claim 1, wherein the targeted genomic modification comprises deletion of one or more mouse antibody kappa light chain variable domains and insertion of one or more human antibody kappa light chain variable domains.

4. The method of claim 1, wherein the targeted genomic modification comprises deletion of one or more mouse antibody lambda light chain variable domains and insertion of one or more human antibody lambda light chain variable domains.

5. The method of claim 1, wherein the targeted genomic modification comprises an insertion of a transgenic IgH locus comprising a human variable region comprising human VH, D and JH gene segments.

6. The method of claim 5, wherein the transgenic IgH locus is targeted to the region between the J4 exon and the Cμ locus in the mouse genome IgH locus.

7. The method of claim 5, wherein the transgenic IgH locus is targeted to the region between the J4 exon and the Cμ locus in the mouse genome IgH locus, and wherein the inserted transgenic human IgH locus comprises, in germline configuration, all of the V, D and J regions and intervening sequences from a human.

8. The method of claim 5, wherein the transgenic IgH locus is targeted into mouse chromosome 12 between the end of the mouse J4 region and the Eμ region.

9. The method of claim 5, wherein the 3′ end of the last human J sequence of the transgenic IgH locus is less than 2 kb from 3′ end of the inserted transgenic IgH locus.

10. The method of claim 5, wherein the 3′ end of the last human J sequence of the transgenic IgH locus is less than 1 kb from 3′ end of the inserted transgenic IgH locus.

11. The method of claim 5, wherein the inserted IgH locus is operatively connected upstream of (5′ of) a mouse constant region.

12. The method of claim 1, wherein the targeted genomic modification comprises an insertion of a transgenic Igκ locus comprising a human variable region comprising human Vκ and Jκ gene segments.

13. The method of claim 12, wherein the human light chain kappa V and J gene segments are targeted into mouse chromosome 6.

14. The method of claim 12, wherein the human light chain kappa V and J gene segments are targeted into mouse chromosome 6, and wherein the inserted human kappa V and J gene segments comprise, in germline configuration, all of the V and J regions and intervening sequences from a human.

15. The method of claim 12, wherein the inserted Igκ locus is operatively connected upstream of a mouse constant region.

16. The method of claim 1, wherein the targeted genomic modification comprises an insertion of a transgenic Igλ locus comprising a human variable region comprising human Vλ and Jλ gene segments.

17. The method of claim 16, wherein the human light chain lambda V and J gene segments are targeted into mouse chromosome 16.

18. The method of claim 16, wherein the human light chain lambda V and J gene segments are targeted into mouse chromosome 16, and wherein the inserted human lambda V and J gene segments comprise, in germline configuration, all of the V and J regions and intervening sequences from a human.

19. The method of claim 16, wherein the inserted Igλ locus is operatively connected upstream of a mouse constant region.

20. The method of claim 16, wherein the transgenic Igλ locus further comprises at least one human Cλ region.

21. The method of claim 1 wherein the mouse ES cell is a wild-type 129, C57BL/6N, C57BL/6J, JMS, AB2.1, AB2.2, 129S5, 129S7 or 129Sv strain.

22. The method of claim 1, wherein the mouse ES cell or its progeny is developed into a mouse.

23. A mouse obtained by the method of claim 1 or progeny thereof.

24. A mouse obtained by the method of claim 5 or progeny thereof.

25. The mouse of claim 24 which is heterozygous for the targeted genomic modification.

26. The mouse of claim 24 which is homozygous for the targeted genomic modification.

27. The mouse of claim 24, which further comprises a targeted modification to insert one or more human antibody kappa light chain variable domains.

28. The mouse of claim 24, which further comprises a homozygous targeted modification to insert one or more human antibody kappa light chain variable domains.

29. An antibody produced by the mouse of claim 23 or its clone or progeny.

30. A method for producing an antibody comprising immunizing the mouse of claim 23 or its clone or progeny with an antigen, and isolating an antibody produced by the mouse.

31. The method of claim 30 further comprising a step of making the mouse by modifying an ES cell according to claim 1.